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Abstract 
Not only is there a high prevalence of cannabis use in schizophrenia, but long-term or 
heavy cannabis users are also considered to demonstrate deficits similar to the cognitive 
endophenotypes of the illness itself. The specific neurocognitive domain of executive 
function has particular clinical relevance as executive dysfunction has been found to be 
significantly associated with the functional outcomes of schizophrenia patients. The 
current study sought to examine the pattern of executive functioning in schizophrenia 
patients with cannabis use and its functional outcome correlates. Eleven measures 
guided by a hierarchical model of executive function were administered to 28 
schizophrenic outpatients with cannabis use and 28 matched-controls with a similar 
cannabis use history. Premorbid IQ and ‘real-world’ functional outcome were also 
assessed. A series of ANCOVA’s revealed that patients with cannabis use demonstrated 
poorer performances on a number of executive function measures relative to controls. 
However, further analysis indicated that a significantly larger proportion of this sample 
showed performances that did not fall in the range of clinical impairment. Using 
multiple regression analyses, a retrospective memory and an interference control task 
were found to significantly contribute to ‘real-world’ functional outcome. A lack of 
clinical impairment in the executive functioning of a representative sample of 
schizophrenia patients with cannabis use may be suggestive of differential and subtle 
deficits in this subgroup. Retrospective memory and interference control abilities may 
also present as potential targets helping to better inform rehabilitation planning efforts 
for such patients. Evaluating different subgroups of schizophrenia from a 
neurocognitive viewpoint should be an important consideration for treating clinicians 
particularly when attempting to achieve more successful functional outcomes.   
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Thinking Matters: The Profile of Executive Functioning Associated with Cannabis 
Use in Schizophrenia and its Functional Outcome Correlates 
  Substance use and its misuse have been associated with detrimental effects on 
cognition (Beatty, Katzung, Moreland, & Nixon, 1995; O’Malley, Adamse, Heaton, & 
Gawin, 1993). Cognitive impairment is also considered to be a core feature of the illness 
of schizophrenia (Bleuler, 1911, 1950; Green, 1996; Herman, 2004; Hoff, Riordan, 
O'Donnell, Morris, & DeLisi, 1992; Kraeplin, 1919, 1971; Saykin, Gur, Gur, Mozley, 
Mozley, Resnick, & Stafniak, 1991; Sharma & Antonova, 2003), and executive 
dysfunction is found to be particularly implicated (Pantelis, Barnes, Nelson, Tanner, 
Weatherley, Owen, & Robbins, 1997; Reichenberg & Harvey, 2007; Shallice, Burgess, 
& Frith, 1999). Executive function is considered an important cognitive domain as it has 
been strongly linked to the functional outcomes of patients (Greenwood, Landau, & 
Wykes, 2005; McClure, Bowie, Patterson, Heaton, Weaver, Anderson, & Harvey, 2007; 
Penadés, Boget, Catalán, Bernardo, Gastó, & Salamero 2003; Simon, Giacomini, 
Ferrero, & Mohr, 2012; Williams, Whitford, Flynn, Wong, Liddell, Silverstein et al., 
2008). Not only are there high rates of substance abuse in patients with schizophrenia 
(Drake, Osher, & Wallach, 1991; Mueser, Yarnold, Levinson, Singh, Bellack, Kee et 
al., 1990; Regier, Farmer, Rae, Locke, Keith, Judd, & Goldwin, 1990), but cannabis is 
the most commonly used illicit drug among patients with the illness (Barnes, Mutsatsa, 
Hutton, Watt, & Joyce, 2006). Impaired cognitive function has also been found in 
cannabis abusers alone (Pope, Gruber, & Yurgelun-Todd, 1995). In addition, the 
widespread use of cannabis amongst individuals with schizophrenia has been found to 
be strongly related to the severity of symptoms, the course of their illness, and poor 
outcome (Caspari, 1999; Grech, Van Os, Jones, Lewis, & Murray, 2005; Linszen, 
Dingemans, & Lenior, 1994). Therefore, examining the relative differences in the 
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executive functioning of schizophrenia patients with cannabis use has important clinical 
significance when considering treatment targets for comorbid patients and ultimately 
more successful functional outcomes. Considering the high rates of cannabis use in this 
particular clinical population, both the neuropsychological and functional outcome 
correlates of cannabis use and schizophrenia will be specifically examined. 
Part A 
The Issue of Comorbid Substance Use and Schizophrenia 
 There is a high prevalence of substance use and misuse in individuals with first-
episode psychosis (Cantwell, Brewin, Glazebrook, Dalkin, Fox, Medley, & Harrison, 
1999). In addition, amongst those with psychotic disorders approximately 52% of 
patients are not only found to have comorbid diagnoses, but the most common of these 
diagnoses is substance use disorder (Stratowski, Maurico, Stoll, Faedda, Mayer, 
Kolbrener et al., 1993). Substance abuse is also the most prevalent comorbid condition 
associated with the illness of schizophrenia (Cuffel, Heithoff, & Lawson, 1993). 
Evidence from community studies suggests that schizophrenia patients in particular, are 
more prone to comorbid substance use disorders than the general population and that the 
rate of substance abuse has been found to be 4.6 times higher than those without the 
illness (Regier et al., 1990). The estimated lifetime prevalence rates of substance abuse 
in this clinical population are reported to approximate 50% and the prevalence rates 
relating to recent or current substance use range from 20% to 40% (Drake et al., 1991; 
Mueser et al., 1990). Not only are substance abuse prevalence rates high in this 
population, but substance use in schizophrenia is associated with the greater utilisation 
of services as well as higher service costs (Bartels, Teague, Drake, Clark, Bush, & 
Noordsy, 1993).  
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In comparison to other types of psychiatric patients or healthy individuals, it has 
been found that schizophrenia patients in particular are more likely to use cannabis than 
other drugs of abuse (Degenhardt, Hall, & Lynskey, 2003; Warner, Taylor, Wright, 
Sloat, Springett, Arnold, & Weinberg, 1994). With lifetime use reported to be as high as 
64.4%, cannabis is the most commonly used illicit drug reported among patients with 
schizophrenia (Barnes et al., 2006). More specific to the Australian population, 
approximately 25% of a nationally represented sample of individuals with psychotic 
disorders in contact with services, were found to have reported a lifetime history of 
cannabis abuse (Hall, Teesson, Lynskey, & Degenhardt, 1999). Twenty-four percent of 
these patients were reported to be daily or near-daily users. Data from an Australian 
survey also showed that cannabis dependence was associated with an 11-fold higher 
odds of screening positively for schizophrenia or schizoaffective disorders (Degenhardt 
et al., 2003). Green and colleagues (2005) have considered that the variation in 
prevalence findings across studies is contributed to by a number of factors. These 
include age, the percentage of male representation in studies, the methods used as well 
as the clinical experience of researchers in applying diagnostic criteria to individuals 
with psychoses, the variation in specificity of diagnostic inclusion criteria, and the 
variance in the nature of the interviews used to collect information and the method of 
data collection (e.g., self-report versus sample analysis). Such variability in factors 
across studies makes prevalence rates more difficult to precisely define. However, the 
general consensus suggests that cannabis use and its misuse is a commonality amongst 
this particular clinical population.   
In a meta-analysis of studies examining cannabis use in schizophrenia occurring 
between 1996 and 2008, a median current prevalence rate of 16.0% was reported and a 
median lifetime prevalence rate was estimated to be 27.1% (Koskinen, Löhönen, 
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Koponen, Isohanni, & Miettunen, 2010). It was found that the median rate of cannabis 
use disorders (CUD’s) was higher in first-episode patients compared to long-term 
patients, with rates for current CUD’s being 28.6% and 22.0% respectively, and lifetime 
prevalence rates being 44.4% and 12.2% respectively. The overall findings of the meta-
analysis indicated that approximately 1 in 4 schizophrenia patients in the included 
studies had a diagnosis of CUD. The reviewed studies also suggest that countries such 
as Australia are an example of a country that evidences a high consumption of cannabis 
not only in schizophrenia patients, but also in the general population. Data from the 
Low Prevalence arm of the Australian National Survey of Mental Health and Wellbeing 
which targeted a sample of 970 individuals diagnosed with psychosis, showed that 
26.5% of schizoprenia patients had a comorbid lifetime diagnosis of cannabis abuse or 
dependence (Kavanagh, Waghorn, Jenner, Chant, Carr, Evans, et al., 2004). Cannabis 
was also found to be the most frequently used drug with 40.9% of the overall sample 
using this particular illicit substance. In a review of population-based studies, it has 
been reported that cannabis use appears to overall be associated with a two-fold increase 
in the relative risk for later schizophrenia or schizophreniform disorders when compared 
to the general population (Arseneault, Cannon, Witton, & Murray, 2004).  
It is considered that many young people in Australia use cannabis and that this 
use usually occurs during late adolescence and early adulthood, which is a period of 
development considered to be where the risk of psychoses is at its peak (Hall, 
Degenhardt, & Teesson, 2004). Australian survey data suggests that the age of cannabis 
use initiation now occurs at an earlier age in young people, compared to the age of 
cannabis use onset reported in the 1980’s (Degenhardt, Lynskey, & Hall, 2000). It is 
reasonable to consider that if the onset of psychosis symptoms occurs around this time 
in development; consequently, so does a diagnosis of the illness. However, research 
CANNABIS USE, SCHIZOPHRENIA & EXECUTIVE FUNCTION  5 
 
findings have suggested a more direct link between earlier age of cannabis use onset and 
increased risk of the development of psychosis. Arsenault and colleagues (2002) 
examined the relationship between cannabis use in adolescence and psychosis in young 
adulthood. Results of their study not only demonstrated a significant relationship 
between cannabis use by the age of 15 and an increased risk of reported psychotic 
symptoms by the age of 26, but also the specificity of effects of this particular substance 
on such symptoms. In other words, no significant relationship was found between 
psychotic disorders and other drugs of abuse. In addition to this, no relationship was 
demonstrated between depression and cannabis use. An interaction between age of 
cannabis use onset and psychosis risk was also found, showing earlier cannabis use 
onset being significantly related to psychosis. In line with these findings, results from a 
meta-analysis indicated that the age of psychoses onset in cannabis users is 2.7 years 
earlier in comparison to non-cannabis using individuals (Large, Sharma, Compton, 
Slade, & Nielssen, 2011). It has also been shown that earlier initiation of cannabis abuse 
is associated with the onset of high-risk symptoms for psychosis at a younger age 
(Dragt, Nieman, Becker, van de Fliert, Dingemans, de Haan et al., 2010). In light of the 
research evidence, it appears that earlier age of cannabis use onset has a significant 
association with earlier age of illness onset. In addition, not only is cannabis use in 
schizophrenia highly prevalent around the world, as well as within Australia, but that 
the age of cannabis use onset has become younger over the years which places such 
individuals at greater risk considering the abovementioned relationships.  
Studies investigating the subjective effects of substances based on the self-report 
of users, suggest that patients with schizophrenia use drugs such as cannabis to help 
self-medicate. Cannabis has been reported to be used in order to relieve negative affect, 
‘to increase pleasure’ , ‘to get high’,  ‘to relax,’, ‘to satisfy curiosity’, ‘to give more 
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interests’, as well as  to ‘get along with the group’ (Addington & Duchak, 1997; 
Goswami, Mattoo, Basu, & Singh, 2004). However, despite the many reported reasons 
for using cannabis by individuals with schizophrenia, extensive research has 
demonstrated that there are also many detrimental consequences that are associated with 
cannabis use in this particular patient population. While it has been proposed that 
cannabis may help to relieve negative symptoms (Dixon, Haas, Weiden, Sweeney, & 
Frances, 1991; Peralta & Cuesta, 1992), it has been also reported to have a negative 
impact on the symptom dimensions of the illness and its course (Linszen et al., 1994). 
More specifically, the research examining substance abuse and outcome in 
schizophrenia has suggested that cannabis use is associated with an increase in positive 
symptoms and significantly more and earlier psychotic relapses (Linszen et al., 1994). 
This association is also found to be stronger among heavy cannabis users. Those with a 
history of cannabis use have significantly more rehospitalisations, poorer psychosocial 
functioning, as well as increased ratings of thought disorder and hostility (Caspari, 
1999). Moreover, not only is there is a significant association between increased 
cannabis use and increased severity of positive symptoms, but also a more continuous 
course of the illness itself (Grech et al., 2005). While substance use in schizophrenia has 
been found to be associated with generally fewer negative symptoms, more social 
contacts and better functioning in social-leisure areas, issues in relation to interpersonal 
relationships and family dynamics are still reported to be associated with cannabis use 
in schizophrenia (Salyers & Mueser, 2001). Therefore, given the high rates of 
comorbidity between schizophrenia and substance abuse, as well as considering the vast 
detrimental clinical effects that can be associated with the misuse of substances in 
psychotic disorders, further insight into the implications of substance abuse in 
schizophrenia are of particular relevance when considering the management of such 
CANNABIS USE, SCHIZOPHRENIA & EXECUTIVE FUNCTION  7 
 
individuals. The following section provides an overview of the literature examining the 
individual relationships between cannabis use and cognition, and schizophrenia and 
cognition. More specifically, the relationships between cannabis use, schizophrenia and 
the neurocognitive domain of executive function. The role of this neurocognitive 
domain and its clinical relevance to patients with schizophrenia will then be outlined, 
particularly in relation to the functional outcome of such individuals. Lastly, the 
challenges associated with the assessment of executive function and the ecological 
validity of traditional psychometric measures will be discussed.   
The Relationship Between Cannabis Use, Schizophrenia and Cognition  
In addition to the many clinical implications associated with cannabis use in 
schizophrenia, cognitive functioning has also been found to be significantly affected. 
Cognition involves mental processes that enable day-to-day functioning in humans 
spanning over a range of personal, social and/or occupational domains (Sharma & 
Antonova, 2003). Research has found deleterious cognitive impairments associated with 
cannabis abuse (for review, see Pope, Gruber, & Yurgelun-Todd, 1995), as well as 
substantial cognitive impairments have also been demonstrated in schizophrenia 
patients without a substance abuse history (Hoff et al., 1992; Saykin, Shtasel, Gur, 
Kester, Mozley, Stafiniak, & Gur, 1994). Therefore, given the high rates of cannabis use 
in schizophrenia and its association with poor outcome, a better understanding of the 
relationship between cannabis use, schizophrenia and cognition is warranted. In order to 
be able to fully evaluate the clinical significance of the relationship between dual-
diagnosis and cognition, it is important to firstly review the individual relationships 
between cannabis use, schizophrenia and cognition separately. 
Cognitive impairments associated with cannabis use. Cannabis consumption 
in otherwise healthy subjects has been demonstrated to be accompanied by cognitive 
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deficits similar to the cognitive endophenotypes found in schizophrenia patients (for 
review, see Solowij & Michie, 2007). It has been found that early onset, higher dose, 
higher frequency of use and duration of use are considered as risk factors when 
examining the relationship between patterns of cannabis use and the extent of cognitive 
impairment (Bolla, Brown, Eldreth, Tate, & Cadet, 2002; Harvey, Sellman, Porter, & 
Frampton, 2007; Pope, Gruber, Hudson, Cohane, Huestis, & Yurgelun-Todd, 2003). 
Evidence has also suggested that the cognitive impairments associated with cannabis 
use not only persist beyond the acute intoxication state, but that worse cognitive 
performance has been found to be specifically associated with cumulative years of use 
(Solowij, Stephens, Roffman, Babor, Kadden, Miller et al., 2002). While there has been 
an increase in the empirical evidence suggesting that the deficits demonstrated in 
cannabis users have been shown to persist beyond the acute effects of intoxication, the 
findings related to the recovery of such functions following cannabis use abstinence is 
inconsistent (Solowij & Battisti, 2008; Solowij & Michie, 2007).  
Frontal lobe function, particularly prefrontal, superiorfrontal and central areas, 
have been found to be negatively affected by long-term cannabis use (Lundqvist, 
Jönsson, & Warkentin, 2001). The frontal lobe of the brain is a structure thought to be 
associated with attentional abilities, the facilitation of memory functions and retrieval 
strategies, and the support of higher-level cognitive functions (Lezak, Howieson, & 
Loring, 2004). Such higher-level cognitive abilities, otherwise known as the executive 
functions, are considered to be crucial in decision-making processes where one is faced 
with novel or unfamiliar situations (Crean, Crane, & Mason, 2011). Patients with 
prefrontal cortex (PFC) lesions in the ventromedial sector and individuals with 
substance dependence have been found to show similar behaviours where they not only 
have reduced awareness of their difficulties, but also demonstrate a tendency to choose 
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a course of action that presents themselves with rewards of an immediate nature and 
ignore the risk of future negative consequences (Bechara, 2001; Bechara, Dolan, 
Denburg, Hindes, Anderson, & Nathan, 2001; DiClemente, 1993). In a study conducted 
by Bechara and Martin (2004), it was found that individuals with substance dependence 
who demonstrated decision-making impairments also showed severe deficits in working 
memory performance. However, the pattern of results found were suggestive of deficits 
in the ‘executive’ process of working memory (i.e., switching and response inhibition 
components) in comparison to the memory storage aspect of the task. While it was 
found that overall as a group, individuals with substance dependence showed poor 
performance on measures of decision-making and working memory, not every subject 
demonstrated impaired performances. The authors concluded that the different pattern 
of deficits across individuals with substance dependence may be a result of such 
individuals demonstrating any one, or a combination, of a number of different 
mechanisms which are thought to be involved in decision-making processes and 
inhibitory control supported by the PFC region. As executive dysfunction can result in 
self-monitoring difficulties, reduced ability to modify or control inappropriate 
behaviours, as well as impact rational decision-making processes, it is also considered 
that executive dysfunction may result in the perpetuation of addictive behaviour (Bolla, 
Cadet, & London, 1998). It is postulated that such decision-making deficits could be 
potentially attributable to the cumulative effects of heavy substance use, but may also 
result in the continuation of substance use and unsuccessful abstinence attempts (Bolla, 
Eldreth, London, Kiehl, Mouratidis, Contoreggi et al., 2003; Paulus, Tapert, & 
Schuckit, 2005). In addition, reduced decision-making abilities may make an individual 
more susceptible to the commencement of substance use and further, becoming a 
substance abuser. Therefore, it appears that executive functions may play an important 
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role in the engagement as well as maintenance of substance abuse; consequently, the 
following discussion will specifically focus on the effects of cannabis use in relation to 
this particular neurocognitive domain.  
The role of executive function. Due to previous neuroanatomical research 
findings suggesting associations between impairments in executive function and frontal 
lobe pathology, the use of the term ‘executive function’ was traditionally equated with 
the term ‘frontal lobe function’ (Benton & Hamsher, 1976; Fuster, 1989; Katz, Tadmor, 
Felzen, & Hartman-Maeir, 2007; Luria, 1973; Milner, 1963; Roberts, Robbins, & 
Weiskrantz, 1998; Stuss & Benson,1986). However, the use of the functional definition 
of ‘executive function(s)’ over the more anatomical-based definition of ‘frontal 
functions’ became increasingly more emphasised over the years. This was largely due to 
the number of regions in the brain that were postulated to be implicated in such 
cognitive processes which included those falling outside of the frontal lobes alone 
(Baddeley, 1996). Executive functions are conceptualised as higher-order cognitive 
processes which are considered pertinent to forming intentions, planning and 
organisation, the translation of a plan into purposive action, and self-monitoring and 
self-regulation (Lezak et al., 2004). The term ‘executive function’ is an umbrella term 
that has been used to describe, ‘capacities that enable a person to engage successfully in 
independent, purposive and self-serving behaviour’ (Lezak et al., 2004, p. 35). 
While it is agreed that executive functions are considered to be complex, as well 
as highly important to adaptive human behaviour, there are an array of definitions for 
this particular neurocognitive construct (Jurado & Rosselli, 2007; Lyon & Krasnegor, 
2001). Executive function is considered to be a multidimensional construct referring to 
a number of ‘higher-order cognitive processes including initiation, planning, hypothesis 
generation, cognitive flexibility, decision making, regulation, judgement, feedback 
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utilization, and self-perception that are necessary for effective and contextually 
appropriate behavior’ (Spreen & Strauss, 1998, p. 171). Such functions have been 
considered to be supported by the dorsolateral prefrontal cortex (DLPFC) and referred 
to as the ‘cold’ components of executive functioning due to their corresponding 
processes involving relatively ‘mechanistic’ or logically-driven abilities (Grafman & 
Litvan, 1999). Those executive functions thought to be supported by the ventromedial 
prefrontal cortex (VPFC) are considered to reflect those cognitive processes that are 
more emotionally-driven. These include the experience of reward and punishment, 
decision-making processes related to interpersonal and social behaviour, and the 
interpretation of complex emotions, and are often referred to as ‘hot’ components of 
executive functioning (Bechara, Damasio, Damasio, & Lee, 1999; Bechara, Tranel, 
Damasio, & Damasio, 1996; Damasio, 1995; Grafman & Litvan, 1999).  
Executive functions are also thought to act as those cognitive processes which 
are considered vital for success in the ‘Instrumental Activities of Daily Living’ (IADLs) 
(Chevignard, Taillefer, Picq, Poncet, Noulhiane, & Pradat-Diel, 2008; Shallice & 
Burgess, 1991). Such activities may involve a range of domestic and community 
activities, occupational activities, interpersonal and social behaviours, and the temporal 
organisation of daily activities as a whole (Chevignard et al., 2008). Research 
investigating the effects of executive function impairments have found that such deficits 
may have a negative impact on an individual’s activities of everyday life such as ‘real-
world’ planning abilities (e.g., financial management), the ability to attend to 
educational and work pursuits, independent living, or even the development and/or 
maintenance of social relationships and understanding of social rules (Goel, Grafman, 
Tajik, Gana, & Danto, 1997; Grafman, Schwab, Warden, Pridgen, Brown, & Salazar, 
1996; Green, 1996; Green, Kern, Braff, & Mintz, 2000). 
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Executive function deficits associated with cannabis use. When considering the 
more long-term effects of cannabis use in the literature, tasks that employ executive 
control abilities have at least in some way been shown to be affected (Grant, Gonzalez, 
Carey, Natarajan, & Wolfson, 2003; Pope, Gruber, Hudson, Huestis, & Yurgelun-Todd, 
2001). The impact of cannabis use on executive functioning can be evaluated by its 
acute, residual and long-term effects. However, it is acknowledged that any 
neurocognitive deficits observed following a relatively minimal period of abstinence 
may be associated with drug residues in the brain or even the effects of drug 
withdrawal, therefore it is considered that the interpretation of such results would be 
difficult. With this in mind, the residual (7 hours to 20 days after last use) and longer-
term (over 21 days after last use) effects are of greater interest and will be the focus of 
the following section. In addition, studies examining adolescent subjects were not 
included in the following review due to the consideration that the effects of cumulative 
cannabis use/longer lifetime-use potentially not being fully achieved in such samples. In 
relation to the specific effects of cannabis use on executive processes, the areas of 
attentional processing, working memory, inhibition and impulsivity, verbal fluency and 
decision-making will be discussed.       
Attention. In relation to attentional abilities, no significant differences were 
found between current heavy cannabis users (i.e., those that used at least 5000 times in 
their lifetime and were daily users), individuals with a history of past heavy use (i.e., 
those that used at least 5000 times in their lifetime, but less than 12 times in the last 3 
months), and control subjects with limited cannabis use experience (Pope et al., 2001, 
2002). Subjects were assessed following 0, 1, 7 and 28 days of abstinence. Jager and 
colleagues (2006) not only assessed the cognitive performance of moderate cannabis 
users (i.e., median lifetime use of 1300 joints and median last year use of 350 joints) in 
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the area of attention, but also measured alterations of brain activity with functional 
Magnetic Resonance Imaging (fMRI) after one week of abstinence. Findings of the 
study were similar to Pope and colleagues’ results showing no significant differences in 
task performance compared to controls and, in addition to this, no significant 
differences in associated brain activity. Grant and colleagues (2012) examined the 
cognitive performances between cannabis users (with a 3.1 ± 2.2 times per week mean 
frequency of use within the past 12 months; n= 16) and controls (n=214). However, the 
authors did not impose a specific abstinence period as they wished to evaluate cognition 
under normal circumstances in day-to-day life. Findings from their study also indicated 
that there were no significant differences between groups in performance on sustained 
attention (as measured by the Rapid Visual Information Processing task from the 
Cambridge Neuropsychological Test Automated Battery (CANTAB; Sahakian & Owen, 
1992).  Conversely, Solowij and colleagues (1991) found that long-term cannabis users 
(with a mean of 11.2 years of use, mean level of use of 4.77 days a week, and a mean 
consumption of 766 mg per week) demonstrated significantly poorer performance than 
controls on a selective attention task as well as a reduced ability to filter out irrelevant 
information, following a minimum 12-hour period of abstinence. In a later study, it was 
found that heavy cannabis users (i.e., those that used more than or equal to 3 days per 
week) had slower reaction times during cognitive tasks compared to not only controls, 
but to light cannabis users (i.e., those that used less than or equal to 2 days per week) 
following a minimum of 24 hours abstinence (Solowij, Michie, & Fox, 1995). Findings 
from the study also indicated that the ability for cannabis users to filter out irrelevant 
information was progressively impaired as a function of duration of use. In addition, 
both long-term (with a mean of 23.9 years of regular use) and short-term cannabis (with 
a mean of 10.2 years of regular use) users were found to make more errors on a speed of 
CANNABIS USE, SCHIZOPHRENIA & EXECUTIVE FUNCTION  14 
 
comprehension task following a minimum 12-hour period of abstinence in comparison 
to controls (Solowij et al., 2002). Slower processing rates were also demonstrated in 
long-term cannabis users compared to short-term cannabis users (Solowij et al., 2002). 
Verdejo-García et al. (2013) examined whether genetic polymorphisms moderated the 
effects of cannabis use on executive function. The study included 86 cannabis users 
(with daily use of cannabis of >7 joints per week and for a minimum duration of 3 
years) and 58 non-drug using controls. Both groups were genotyped and matched for 
genetic makeup, sex, age, education and Intelligence Quotient (IQ). The authors found 
no significant differences between users and controls in sustained attention performance 
(as measured by the Rapid Visual Information Processing test; CANTAB) following a 
72-hour abstinence period. Further findings from the study suggested that certain 
genotypes of the COMT and SLC6A4 genes moderated the impact of cannabis use on 
executive functions. More specifically, results showed that cannabis users carrying the 
COMT val/val genotype exhibited lower accuracy of sustained attention than non-users 
of the same genotype.  Research into the long-term effects of cannabis use on 
attentional abilities has also produced mixed findings. It was found that heavy cannabis 
users (with a mean consumption of 93.9 joints per week, a mean level of use of 7 days a 
week, and a mean of 5.3 years duration of use) who were abstinent for a period of 
approximately 28 days were found to demonstrate deficits in reaction time (Bolla et al., 
2002). In addition, results from Solowij’s (1995) study found significant deficits in the 
ability to process irrelevant information in ex-cannabis users who were abstinent from a 
minimum of 6 weeks to an average of 2 years. However, in a study examining 
monozygotic twins, no impairments in attention or concentration were reported in 
cannabis-using twins who were abstinent for a minimum period of 1 year, in 
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comparison to non-using co-twins (Lyons, Bar, Panizzon, Toomey, Eisen, Xian, & 
Tsuang, 2004).   
Working memory. Findings from Scholes & Martin-Iverson’s (2010) study 
showed that cannabis users (n=36; with a median total duration of cannabis use of 10 
years and a median of 2 usage times per day) showed no significant differences from 
controls (n=35) on Letter-Number Sequencing (LNS; Wechsler Memory Scales – Third 
Edition (WMS-III); Wechsler, 1997), Spatial Span (WMS-III; Wechsler, 1997), and 
overall working memory (i.e., the summed score of LNS and Spatial Span). Cannabis 
users were instructed to not alter their pattern of cannabis use on the day of testing and 
therefore a set abstinence period was not imposed. This was considered by the authors 
to reduce the likelihood of abstinence syndrome. Of the cannabis users, 21 were 
daily/nearly daily users; 12 were weekly users; one was a monthly user and two used 
cannabis less than monthly. Sixteen of these users reported using other drugs in the last 
month. A similar pattern of results were also found regarding spatial working memory 
performance (measured by the Spatial Working Memory task from the CANTAB) in 
Grant and colleagues’ (2012) study. However, results also showed that cannabis users 
demonstrated significant impairments on the One Touch Stockings of Cambridge Task 
(from the CANTAB) relative to controls. While the test developers indicate that 
working memory is assessed by this task, spatial planning abilities are also tapped into 
by this measure. In addition, Gruber et al. (2012) found no significant differences 
between controls and marijuana users on tasks of visuospatial construction and working 
memory (measured by the Rey-Osterrieth Complex Figure test: for test description, see 
Lezak et al., 2004), as well as attention and working memory (measured by Digit Span). 
No significant differences in working memory (measured by Digit Span) were found 
between cannabis users (categorised as heavy and light) and a control group following a 
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minimum period of 19 hours abstinence (Pope & Yurgelun-Todd, 1996). Additional 
studies have replicated similar findings when assessing working memory with 
auditory/verbal tasks including computation span, omitted numbers, and a spatial task 
(e.g., a modified Sternberg item recognition task) (Fisk & Montgomery, 2008; Jager et 
al., 2006; Solowij et al., 2002). In a fMRI study, it was found that cannabis users 
demonstrated greater and more distributed brain activation during the performance of a 
spatial working memory task (measured by a perception task and a short-delay response 
task) in comparison to control subjects following 6-36 hours after last cannabis use 
(Kanayama, Rogowska, Pope, Gruber, & Yurgelun-Todd, 2004). Thames and 
colleagues (2014) examined neurocognitive performances across recent users (n=68; 
those who reported use in the last 4 weeks), past users (n=41; those who used more than 
28 days prior to testing) and non-users (n=49). Results indicated that recent users 
performed more poorly than past users and non-users in attention/working memory (a 
composite score of performance on the Trail Making Test – Part A, Reitan, 1958; 
Stroop Test [colour and word conditions], Golden, 1978; and the Letter-Number 
Sequencing test from the Wechsler Adult Intelligence Scale – Fourth Edition (WAIS-
IV); Wechsler, 2008). However, it is noted that the criteria of what constituted a user 
regarding frequency, amount and duration of use was not reported by the authors.  
Inhibition and impulsivity. Results from Pope and Yurgelun-Todd’s (1996) 
study indicated that heavy cannabis users (with a median use of 29 days in the past 30 
days) demonstrated significantly greater perseverations on a card sorting measure (i.e., 
Wisconsin Card Sorting Task (WCST); Heaton, 1981), in comparison to light users 
(with a median use of 2 days in the past 30 days) following a minimum period of 19 
hours of abstinence. Solowij and colleagues (2002) found that performance differences 
between task trials on the Stroop test suggested that cannabis users had greater 
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vulnerability to task complexity and increased demands following a minimum of 12 
hours abstinence relative to controls. In addition, there was also an inverse relationship 
between the number of task items completed and duration of cannabis use. In the same 
study, there were no significant differences between groups on WCST performance. 
Gruber et al. (2012) examined the relationship between age of onset of marijuana use 
and executive function performance in 34 chronic, heavy marijuana smokers (with a 
mean frequency of 19.24 ±19.58 smokes per week; mean amount of 10.86 ± 14.95 
grams per week; and mean duration of 7.24 ± 7.30 years) and 28 non-using controls 
following a minimum 12-hour abstinence period. From the results of the study, 
significantly poorer performances were found on the WCST, as well as in both the 
Word Reading and Interference condition of the Stroop test. Findings also suggested 
that early onset marijuana users were significantly more impaired than late onset users 
on both measures. However, Battisti et al. (2010) conducted a neurophysiological 
measure study using event-related potentials (ERP’s) to examine discrete cognitive 
events. Event-related brain potentials to neutral, congruent, and incongruent trials were 
compared between 21 cannabis users (with a mean of 16.4 years of nearly daily use) and 
19 non-using controls following at least a 12 hour abstinence period. Results of the 
study indicated that chronic cannabis use produced changes in accuracy and brain 
activity associated with performance on the Stroop task during the unintoxicated state. It 
was shown that users displayed increased errors on colour-incongruent trials (e.g., 
“RED” printed in blue ink) suggesting more susceptibility to the colour-naming 
interference effect. However, no significant differences were found between users and 
controls on colour-congruent (“RED” printed in red ink) or neutral trials (e.g., “*****” 
printed in green ink). Further, earlier age of cannabis use onset was found to 
significantly predict accuracy on incongruent trials. Results imply that users may have 
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difficulty suppressing more automatic responses. Attentional inhibition dysfunction 
(assessed by a visuospatial negative priming task) was demonstrated in current cannabis 
users in comparison to past cannabis users and controls following a minimum 48-hour 
abstinence period in a study conducted by Skosnik, Spatz-Glenn, and Park (2001). The 
authors proposed that as current cannabis users had significantly faster reactions times 
when performing a simple detection task, the demonstrated deficit was not the result of 
visual inattention, but instead reflective of increased disinhibition. Poorer performances 
demonstrated by cannabis users have also been reported in other studies using the 
WCST (Bolla et al., 2002; Pope, Yurgelun, & Todd, 1996; Pope et al., 2001, 2002; 
2003). Conversely, findings from Lyons and colleagues’ (2004) study did not indicate 
reduced performance on the WCST by users. Other studies have also reported no effects 
on inhibition or impulsivity to be associated with cannabis use (Gruber & Yurgelun-
Todd, 2005; Hermann, Sartorius, Welzel, Walter, Skopp, Ende, & Mann, 2007; 
Whitlow, Liguori, Brooke Livengood, Hart, Mussat-Whitlow, Lamborn et al., 2004). 
Additionally, when inhibition was measured using the Stroop test, no significant 
differences were reported between cannabis users and controls (Lyons et al., 2004; Pope 
& Yurgelun-Todd, 1996; Pope et al., 2001, 2002, 2003). It is possible that differences in 
results could possibly be due to the WCST and Stroop test measuring different 
underlying executive function subdomains. While both have been used as measure of 
inhibition and impulsivity, the WCST is also thought to be a measure of cognitive 
flexibility and abstraction ability (Milner, 1963), whereas the Stroop test also measures 
sustained attention with or without interference (MaCleod, 1991). In Verdejo-García et 
al.’s (2013) study no differences were found between users and controls in 
monitoring/shifting (as measured by the CANTAB Intradimensional/Extradimensional 
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set-shifting task). However, it was found that users carrying the COMT val allele 
committed more monitoring/shifting errors than users carrying the met/met genotype. 
Verbal fluency. While verbal fluency tasks do not traditionally fall into the 
category of being solely a frontal lobe executive function task due to also tapping into 
functions of the temporal lobe (Raskin & Rearick, 1996), verbal fluency tasks are 
thought to load heavily on executive function (Rabbitt, 1997). It is also considered a 
well established measure of executive functioning and has been commonly used to 
assess the integrity of the pre-frontal region (Kolb & Whishaw, 1985; Parkin & Java, 
1999; Warkentin & Passant, 1997). In addition, due to the tendency of verbal fluency 
measures heavily relying on processes involving strategic searching, such tests are 
deemed to be some of the most sensitive and best validated measures of dysfunction in 
the frontal lobe (Benton, 1968; Bryan & Luszcz, 2000; Lezak, 1995; Parker & 
Crawford, 1992; Stuss & Benson, 1986). Following a minimum 12-hour abstinence 
period, Gruber et al. (2012) found no significant differences between marijuana users 
and controls in verbal fluency performance (as measured by the Controlled Oral Word 
Association Test (COWAT; Benton, Hamsher, & Sivan, 1983). In Pope and Yurgelun-
Todd’s (1996) study, no significant differences were found between light and heavy 
cannabis users on verbal fluency following a minimum 19-hour abstinence period. 
However, a significant interaction was found between Verbal Intelligence Quotient 
(VIQ) and cannabis-use status indicating that out of those subjects with the lowest 
VIQ’s, the heavy users demonstrated reduced verbal fluency in comparison to light 
users. In addition, those subjects with average to high VIQ scores demonstrated no 
verbal fluency deficits. Findings from Fisk and Montgomery’s (2008) study showed no 
significant differences in verbal fluency (both letter and semantic) between cannabis 
users and controls following a minimum of 24 hours abstinence. Both recent (i.e., had 
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used in the last 7 days) and abstinent cannabis users (i.e., had not used in the last 7 days) 
were found to demonstrate deficits in verbal fluency (phonemic verbal fluency) 
following a minimum 24-hour abstinence period compared to controls (McHale & Hunt, 
2008). Pope and colleagues (2003) reported a significant difference between groups in 
verbal fluency (COWAT - FAS) following a minimum of 28 days abstinence. In this 
study, the cannabis users were grouped according to age of onset (early and late). 
Cannabis users with early age of onset (i.e., those who commenced use before 17 years 
of age) were found to demonstrate significant verbal fluency deficits compared to the 
control group. However, the researchers’ earlier studies (2001, 2002) found no 
significant differences on this domain. Results from the more recent study suggest that 
age of onset may be an influencing factor (Pope et al., 2003). 
Decision-making. In a study conducted by Whitlow and colleagues (2004) long-
term, heavy cannabis users (i.e., those that were daily users for at least 25 out of 30 days 
and for at least 5 years duration) were found to demonstrate impaired performance on 
the Iowa Gambling Task (IGT; Bechara, Damasio, Damasio, & Anderson, 1994), in 
comparison to controls (i.e., those who had a minimal use of 1-50 lifetime uses and did 
not use in the last year). Subjects in the user group were required to abstain for a 
minimum of 12 hours prior to testing. Findings from the study suggest that long-term, 
heavy cannabis users made decisions which led to larger immediate gains, but more 
losses overall in comparison to individuals with minimum cannabis use in their history. 
The authors concluded that long-term, heavy cannabis users may have a reduced ability 
to effectively weigh up costs and rewards and that this deficit may contribute to the 
continuation of their drug-use. However, it is also acknowledged by the researchers that 
such deficits may be the consequence of cannabis use, or may alternatively reflect the 
presence of pre-existing differences regarding genetics or behaviour. Additional 
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findings from Grant et al.’s (2012) study also indicated significant impairments in 
decision-making performance (as measured by the Cambridge Gamble Task from the 
CANTAB) in cannabis users. Bolla et al. (2005) examined brain activity using Positron 
Emission Tomography (PET) during the administration of the IGT. Not only did the 
authors find similar results where decision-making deficits were demonstrated in 
cannabis users (i.e., those who currently smoked at least 4 days a week, for at least 2 
years duration) following a 25-day abstinent period, but cannabis users also showed 
different patterns of brain activation than non-users. More specifically, cannabis users 
showed less activation in the right dorsolateral prefrontal cortex (DLPFC) and right 
lateral orbitofrontal cortex (OFC), in addition to greater brain activation in the left 
cerebellum. One study, examined the relationship between cocaine and cannabis users 
(i.e., those that used at least 4 times a week, for at least 2 years duration) and IGT 
learning (Verdejo-García, Benbrook, Funderburk, David, Cadet, & Bolla, 2007). Results 
suggested that while both cocaine and cannabis users demonstrated worse performance 
on the total IGT net score than controls, the pattern of learning indicated that the 
cannabis-using group showed less learning than the cocaine-using group. Dose-related 
measures of cannabis use (i.e., joints per week), were also found to predict IGT 
performance where the heavier the use, the lower the performance demonstrated. 
Contrastingly, Quednow and colleagues (2007) did not find IGT decision-making 
deficits in chronic cannabis users who had been abstinent for a mean of 7 days. The 
chronic cannabis users in this study (with a mean consumption of 3.89 times a week and 
6.55 years duration of use) did report using other drugs of abuse in their history, but 
were included in the study as long as they were deemed to not have substantially used 
amphetamine derivatives like MDMA or have substantial previous use of cocaine. In 
Verdejo-García et al.’s (2013) study, a significant difference was found between groups 
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on the IGT (block 3), which is considered to index the learning phase of the task. In 
addition, users carrying the 5-HTTLPR s/s genotype had worse decision-making skills 
than s/s non-users.  
The abovementioned studies indicate that the cognitive impairments associated 
with cannabis use are demonstrated across a range of important executive function 
processes. However, differences in findings across studies could be attributed to 
variability in sample characteristics, abstinence periods and differences in frequency, 
severity/quantity, or duration of use/cumulative amount. In addition, results indicating 
no significant differences suggest that while some of the measures mentioned above 
may be sensitive enough to tap into the neurocognitive domain of interest, they may not 
support the specificity of the measures to solely detect deficits in that specific domain. 
In other words, such measures may not serve as specific markers for deficits in the 
associated domain in question. In addition, differences in the actual tests used to assess 
specific domains may have impacted the consistency of the findings. It would also not 
be surprising that multiple brain regions and connections would be involved in a 
neurocognitive process as complex as executive function and thus, isolating the domain 
by a single psychometric task presents another concern. While the findings suggest that 
some executive function impairments related to cannabis use have been found to 
improve following the discontinuation of cannabis use (Pope et al., 2001, 2002, 2003), 
deficits have been also shown to persist following cannabis use cessation (Bolla et al., 
2005). It is also proposed that the specific factors of age of cannabis use onset, duration 
and amount of cannabis use may play a part in the manifestation of differing executive 
functioning impairments (Grant et al., 2003; Pope et al., 2003; Solowij, 1995; Solowij et 
al., 2002). Considering the differences in findings across studies, it is thought that the 
more precise and adequate assessment of executive function abilities, as well as of such 
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cannabis use parameters, is crucial in order to ensure that the measures used are 
sensitive enough to detect impairment if it indeed exists.   
Cognitive impairments associated with schizophrenia. In 1896, the first 
clinical account of schizophrenia was made by Kraepelin and was termed ‘dementia 
praecox’ (Kraepelin, 1919, 1971, cited in Sharma & Antonova, 2003). Cognitive 
impairment was emphasized to be a core part of the illness and that such impairments 
comprised of deficits in attention, problem-solving, motivation, learning and memory 
(Sharma & Antonova, 2003). In 1911, Bleuler used the term ‘schizophrenia’ and also 
conceived cognitive impairment as being a fundamental aspect of the illness (Bleuler, 
1911, 1950, cited in Sharma & Antonova, 2003). Through extensive research over the 
years, it is now universally recognised that cognitive impairment is a central and 
enduring feature of the illness and that such deficits have greater predictive ability of 
functional outcome than clinical symptoms (Green, 1996). More contemporary 
understandings of the illness indicate that cognitive impairments are more specifically 
demonstrated in the domains of sustained attention, language skills, executive functions, 
verbal learning and memory (Bilder, Lipschutz-Broch, Reiter, Geisler, Mayerhoff, & 
Lieberman, 1992; Riley, McGovern, Mockler, Doku, O’Ceallaigh, Fannon, & Sharma, 
2000).  
The cognitive impairment associated with schizophrenia is not thought to be the 
result of symptomatology, nor the effects of antipsychotic medication (Green, 2006). 
Research has suggested that the cognitive impairments associated with schizophrenia 
are present prior to the onset of clinical symptomatology and show relative stability 
across the course of the illness (Finkelstein, Cannon, Gur, Gur, & Moberg, 1997; Gold, 
2004). Cognitive dysfunction in schizophrenia has also been found to be related to, but 
distinct from, negative symptoms (Harvey, Lombardi, Leibman, White, Parrella, 
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Powchik, & Davidson, 1996; Hughes, Kumari, Soni, Das, Binneman, Drozd, & Sharma, 
2003). Impairments have also been observed to already be present in first-episode 
patients with schizophrenia (Hutton, Puri, Duncan, Robbins, Barnes, & Joyce, 1998). In 
addition, cognitive deficits have not only been found in patients with schizophrenia 
prior to illness onset, but there is evidence of similar deficits in their first degree 
relatives (Cornblatt, Obuchowski, Schnur, & O’Brien, 1998). The cognitive 
impairments found in first-episode patients with schizophrenia are also considered to be 
important predictors of long-term outcome (Green, Kern, & Heaton, 2004). 
A wide range of cognitive impairments have been associated with the illness of 
schizophrenia. While deficits in global performance have been described (Braff, Heaton, 
Kuck, Cullum, Moranville, Grant, & Zisook, 1991), as well as broad deficits spanning 
across a number of cognitive domains (Heinrichs & Zakzanis, 1998), other findings 
have shown selective cognitive deficits which are deemed over-and-above general 
cognitive impairment (Saykin et al., 1991, 1994). Meta-analytic, epidemiological and 
twin-study findings suggest that the most severe impairments are consistently observed 
in the domains of episodic memory and executive function (Reichenberg & Harvey, 
2007).  Therefore, considering the postulated relationship between executive function 
and substance abuse maintenance, this neurocognitive domain in particular will once 
again be focussed on in the following section.   
Many pathophysiological accounts of schizophrenia suggest that the illness 
results from neural network dysfunction where the PFC is considered an intrinsic part of 
these networks (Reichenberg & Harvey, 2007). The most prevalent findings from brain-
imaging studies are impairments in frontal lobe functions and ‘hypofrontality’ 
associated with the illness of schizophrenia (Davidson & Heinrichs, 2003). It is also 
found that medication variables are not significant contributors to these 
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pathophysiological differences (Davidson & Heinrichs, 2003). It has been reported that 
the similar pattern of deficits demonstrated between individuals with schizophrenia and 
frontal lesion patients not only suggest frontostriatal circuitry disturbance, but that there 
are even greater impairments in executive functioning among schizophrenia patients 
than those individuals with frontal lobe lesions (Pantelis et al., 1997).  
It has been argued that executive function deficits are a commonality across the 
cognitive deficits seen in the illness of schizophrenia (Shallice et al., 1999). The study 
of executive functions in schizophrenia is of great importance considering deficits in 
this domain have been associated with psychosis proneness (Franke, Maier, Hain, & 
Klinger, 1992). Schizophrenia patients also demonstrate profound impairments in 
executive function at the beginning of their illness and that such deficits are thought to 
mainly involve planning and strategy use, but not attentional set-shifting (Hutton et al., 
1998). Such impairments are found to progress over the course of the illness. Findings 
have also suggested that schizophrenia patients demonstrate a distinctive pattern of 
decision-making impairment on specific cognitive tasks with which performance is also 
dependent on executive function (Shurman, Horan, & Neuchterlein, 2005). Once again, 
such evidence is suggestive of specific frontal lobe function abnormalities, supporting 
the notion that the cognitive impairments associated with the illness are related to 
frontostriatal dysfunction (Robbins, 1990).  
Results from Katz et al.’s (2007) study suggested that while schizophrenia 
patients demonstrated executive deficits, those patients in the more chronic stages of the 
illness demonstrated worse executive function performance in comparison to those in a 
more acute phase. Such deficits have been shown to be associated with treatment-
refractory symptoms, such as negative symptoms (Kerns & Berenbaum, 2002; 
Voruganti, Heslegrave, & Awad, 1997), as well as with poor functional outcome 
CANNABIS USE, SCHIZOPHRENIA & EXECUTIVE FUNCTION  26 
 
(Greenwood et al., 2005; McClure et al., 2007). Impairments in this particular cognitive 
domain have also been suggested to be associated with performance in daily 
independent living skills, occupational and community functioning (Green, 1996; 
Sharma & Antonova, 2003).   
Impaired performances have been specifically demonstrated on ‘traditional’ 
executive functions measures such as the Wisconsin Card Sorting Test (WCST), tests of 
verbal fluency, and the Trail Making Test (TMT) (Chen, Chen, Chan, Lam, & Lieh-
Mak, 2000; Chen, Lam, Chen, Nguyen, & Chan, 1996; Franke, Maier, Hardt, Frieboes, 
Lichterman, & Hain, 1993; Goldberg, Torrey, Berman, & Weinberger, 1994; Hutton et 
al., 1998; Zalla, Joyce, Szöke, Schürhoff, Pillon, Komano et al., 2004). However, the 
extent of impairment on such measures has been found to vary among individuals with 
schizophrenia depending on illness presentation. For example, findings have suggested 
that there is a poor correlation between positive symptoms and reduced performance on 
executive function measures (Morris, Rushe, Woodruffe, & Murray, 1995). Some 
authors report that negative symptoms have been found to be significantly correlated 
with the severity of executive dysfunction (Voruganti et al., 1997). However, in a study 
by Rodriguez-Jimenez and colleagues (2008), it was found that while those 
schizophrenia patients who performed poorly on the WCST also exhibited more 
negative symptoms, there was no association found between WCST performance and 
negative symptoms in dually-diagnosed schizophrenia patients with substance use 
disorders. No significant association between neuroleptic medication and executive 
functioning impairment in schizophrenia has also been found (Verdoux, Magnin, & 
Bourgeois, 1995). Therefore, it is possible that there may be certain subgroups among 
the schizophrenia population that may comprise of individuals with differing illness 
pathology and possibly different executive abilities. Due to the high prevalence of 
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substance use, more specifically cannabis use, in schizophrenia, investigation into the 
neurocognitive abilities of such a subgroup is of particular interest.      
The importance of executive function to individuals with schizophrenia. The 
illness of schizophrenia has significant economic implications and it is considered as the 
most costly of the psychiatric disorders (Capri, 1994; Knapp, 1997; Torrey, 2002). 
Functional impairment in particular has been identified as one the primary factors 
contributing to the illness’ high cost (Kenny & Meltzer, 1991). In an extensive review 
of the measurement of outcome in schizophrenia, Green (1996) defined functional 
outcome as ‘the result of competence in a large number of constituent social and 
instrumental role tasks’ (p. 323). Research findings have shown that cognitive 
impairments account for significant variance in functional status measures (Green, 
1996). Both cross-sectionally (Green, 1996) and longitudinally (Green, Kern, & Heaton, 
2004), the cognitive impairments found in schizophrenia have been shown to be 
associated with impairments in everyday functioning. Past research has found that 
cognition is a stronger predictor of functional outcome than symptomatology (Harvey, 
Howanitz, Parrella, White, Davidson, Mohs, & Davis, 1998; Harvey, Napolitano, Mao, 
& Gharabawi, 2003; Kurtz, Moberg, Ragland, Gur, & Gur, 2005; Perlick, Rosenheck, 
Kaczynski, Bingham, & Collins, 2008; Velligan, Mahurin, Diamond, Hazleton, Eckert, 
& Miller, 1997). Therefore, in order for rehabilitation efforts to be more precise and 
thus ultimately have a higher success rate, identifying the specific cognitive domains 
found to be particularly associated with successful independent living is crucial. 
Current treatments targeting functional impairments typically involve 
behavioural techniques aimed at social, occupational, self-care and independent living 
skills training (Sharma & Antonova, 2003). However, despite the levels of residential 
independence demonstrated in schizophrenia outpatients (i.e., those that reside in the 
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community), widespread functional impairments are still evidenced (Auslander, 
Lindamer, Delapena, Harless, Polichar, Patterson et al., 2001). It has been postulated 
that one of the main reasons for the lack of improvement in the functional outcome of 
patients with schizophrenia is the lack of success in sufficiently treating those features 
of schizophrenia which are considered strong predictors of functional outcome, such as 
negative symptoms and cognitive impairment (Harvey, Green, Keefe, & Velligan, 
2004). Therefore, there appears to possibly be a mediating factor in influencing the 
effectiveness of such approaches and it is cognitive impairment that is considered to be 
this link (Green, 1996; Green et al., 2000).   
Specific cognitive domains have been found to be closely related to functional 
outcome (Green & Neuchterlein 1999; Green et al., 2000). It has been found that the 
utilisation of complex and higher-order cognitive abilities (i.e., executive functions) 
which include flexibility with set-shifting, reasoning, decision-making, planning and 
working memory are related to successful treatment outcomes (Gordon, Kennedy, & 
McPeake, 1988; O’Leary, Donovan, Chaney, & Walker, 1979; Weinstein & Shaffer, 
1993). Among the range of cognitive deficits which have been most commonly found in 
individuals with schizophrenia, it is acknowledged that executive functions play a 
crucial role when considering outcome (Simon et al., 2003). Through extensive reviews 
in the area of cognition in schizophrenia, performance on measures assessing executive 
functioning was consistently found to be associated with poor community outcomes in 
particular (i.e., independent living) (Green, 1999; Green et al., 2000). In addition, 
Penadés and colleagues (2003) examined the effects of cognitive rehabilitation 
strategies (i.e., the cognitive differentiation and social perception cognitive modules 
from the Integrated Psychological Therapy program, implemented in 24 group sessions 
over a 12-week period), on cognition and functional outcome in patients with 
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schizophrenia. The authors found that changes in encoding and executive function were 
specifically associated with changes in functional outcome. 
Several research studies have suggested that tests measuring executive functions 
are the best predictors of performance in activities of daily living, particularly when 
considering patients with schizophrenia (Dickenson & Coursey, 2002; Ihara, Berrios, & 
McKenna, 2003; Semkovska, Stip, Godbout, Pacquet, & Bedard, 2002). Results from a 
study conducted by McClure and colleagues (2007) indicated that two domains of 
functional capacity (i.e., social and living skills) had different neuropsychological 
correlates in schizophrenia. More specifically, it was found that both working and 
episodic memory, as well as verbal fluency abilities, were related to social competence. 
It was also found that processing speed, episodic memory and executive function were 
associated with everyday living skills. Katz et al.’s (2007) findings suggested that 
performance on executive function measures were more strongly related to performance 
in complex areas of daily living (which included social communication, IADLs, and 
occupational skills), in comparison to performance on a basic cognitive skill measure. It 
is also considered that executive function measures in general have better predictive 
ability regarding lack of insight in comparison to premorbid intellectual ability, IQ, 
memory, or language measures (Burgess, Alderman, Evans, Emslie, & Wilson, 1998). 
It has been well established that cognitive impairment is a core feature of 
schizophrenia. In addition, executive dysfunction is not only particularly implicated in 
the illness of schizophrenia, but is also identified as an important predictor of functional 
outcome status. This neurocognitive domain has been considered as an area of 
importance especially when evaluating the independent living capacity of patients in the 
community. Therefore, if this particular domain is considered as a potential target for 
treatment, then the comprehensive assessment of this neurocognitive system has 
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significant clinical importance. Without obtaining knowledge with regard to which 
specific deficits are linked to ‘real-world’ functioning, efforts towards cognitive 
rehabilitation will continue to remain not only less clearly focused, but ultimately less 
successful in their utility. In the current study, executive functions are targeted due to 
their close connections to community functioning, as well as their association with 
negative symptoms which are also linked to functional outcome. Considering the 
relationship between executive function and illness presentation, as well as outcome, 
this particular neurocognitive domain has specific relevance in the examination of 
cognitive functioning in schizophrenia.  
Cognitive impairments associated with cannabis use and schizophrenia. 
Since previous research findings have suggested an association between cannabis use in 
schizophrenia and worsened illness prognosis, in addition to the reported adverse effects 
of cannabis use alone on cognitive function without the presence of psychotic illness, it 
would be reasonable to suggest that poorer cognitive function would be expected in 
schizophrenia patients with cannabis use. However, relatively few studies have 
specifically examined the relationship between cannabis use and cognitive functioning 
in the schizophrenia spectrum disorders, with mixed results being reported. The current 
literature review will further outline these studies. Once again, only neurocognitive 
effects associated with chronic or long-term use cannabis use will be focussed on in the 
following review. 
Some studies have reported poorer performance amongst schizophrenia patients 
with cannabis use. Mata and colleagues (2008) examined the relationship between pre-
illness cannabis abuse and cognitive performance in 61 cannabis-abusing and 71 non-
abusing patients experiencing their first episode of schizophrenia-spectrum psychosis. 
The patients were grouped according to their cannabis abuse prior to illness onset and 
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cannabis abuse status was based on the criteria of at least weekly use during the 
previous year. In their study, a cognitive battery was administered which included tasks 
thought to utilise the DLPFC, such as a measure of working memory (assessed by Digit 
Span - backwards condition), a measure of verbal fluency (measured by phonemic 
fluency task – FAS), and a set-shifting task (measured by the TMT), as well as an OFC 
related task designed to measure decision-making capacity (e.g., IGT). Findings from 
their research showed no significant differences between patients who had abused 
cannabis before their psychosis onset and patients who had not abused cannabis before 
their psychosis onset on any of the DLPFC related tasks. However, results also showed 
that those patients who had abused cannabis before their psychosis onset demonstrated 
poorer total performance and lower improvement in performance on the IGT. The 
authors suggested a possible explanation for the findings is that decision-making 
differences between cannabis abusers and non-abusers may reflect a pre-existing 
condition that led abusers to make costly decisions in the gambling task. 
In a recent study conducted by Sánchez-Torres and colleagues (2013), the 
relationship between lifetime cannabis use (over 10 years of follow-up) and current 
cognitive performance was examined in a sample of 42 patients with schizophrenia, 35 
of their unaffected siblings, and 42 healthy control subjects. Drug abuse was assessed in 
patients and siblings longitudinally using the Composite International Diagnostic 
Interview (World Health Organisation, 1993). The controls were only assessed at 
follow-up and reported current consumption. A lifetime estimate of consumption was 
determined for all participants (using information from subject reports, family and 
charts) and subjects were given a rating from 0 (no consumption) to 5 (every-day 
consumption). In the patient group, longitudinal cannabis consumption was found to 
have a negative relationship with performance in a social cognition task (assessed by the 
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Managing Emotions section of the Mayer-Salovey-Caruso Emotional Intelligence Test 
(MSCEIT; Mayer, Salovey, Caruso, 2009). The investigators did not find a significant 
relationship between cannabis use in the patient group for the three time points and the 
composite scores for processing speed, attention, declarative memory, working memory 
and executive function. In the unaffected sibling group, a significant negative 
correlation between cannabis use at baseline 10 years prior to assessment, current use 
and the declarative memory composite score (assessed by the Spanish version of the 
California Verbal Learning Test, the Test de Aprendizaje Verbal Espan ˜a-Complutense 
(TAVEC; Benedet & Alejandre, 1998) and the Brief Visual Memory Test-Revised 
(BVMT-R; Benedict, 1997)) was found. However, while cannabis use was not found to 
predict cognitive performance in the healthy control group, a negative association 
between lifetime cannabis and tobacco use together and processing speed and social 
cognition performance was found. Results indicated that longitudinal cannabis use was 
associated with poorer social cognition in patients and that current cannabis use was 
associated with poorer performance in working memory, particularly when low 
premorbid IQ and earlier age of illness onset was accounted for in the explanatory 
model.  
Other research findings have suggested no differences in cognitive performance 
between cannabis-using and non-cannabis using patients with schizophrenia. Sevy and 
colleagues (2007) compared the performance of 14 schizophrenia patients with 
concurrent cannabis use disorders and 13 patients without concurrent substance use 
disorders on a number of measures of cognition as well as on a decision-making task 
(i.e., IGT), with that of 20 healthy normal subjects. Results of the study showed that 
both schizophrenia groups demonstrated more cognitive impairments and worse 
performance on the IGT, compared to healthy controls. However, no significant 
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differences on most of the cognitive tests (including the IGT) were found between 
schizophrenia patients with cannabis use disorders and schizophrenia patients without. 
While it is noted that the study conducted by Sevy and colleagues (2007) included 
subjects who also used substances other than cannabis, due to the inclusion of the IGT 
measure in their assessment of cognition (and its particular relevance to the 
neurocognitive construct of interest), the results of the study were deemed worthy of 
review.   
Scholes and Martin-Iverson (2010) investigated the cognitive performances of 
22 cannabis-using schizophrenia patients, 49 non-using schizophrenia patients, 36 
otherwise healthy cannabis-using controls and 35 non-using healthy controls. 
Performances on tasks measuring attentional control (Stroop test), auditory working 
memory (LNS), spatial working memory (Spatial Span) and card-sorting/set-shifting 
and peserveration (WCST), were assessed. Results from the study showed that while 
both schizophrenia groups demonstrated significantly poorer performance across all 
tasks relative to controls, no significant differences in cognitive performance between 
cannabis-abusing schizophrenia and non-using schizophrenia patients were found. In 
other words, cannabis use in schizophrenia was not associated with further 
neurocognitive decrements. Scholes and Martin-Iverson’s findings also suggested that 
cannabis use in healthy individuals was not associated with deficits in the measures 
administered that resemble those deficits associated with schizophrenia. However, one 
exception to this finding was noted and this was increased perseveration demonstrated 
on the WCST. From these results, the authors concluded that cannabis use has subtle 
effects on the cognitive performance of both healthy individuals and patients with 
schizophrenia across a range of tasks. 
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 Surprisingly and contrary to expectations, there has also been a number of 
studies showing superior cognitive performance amongst schizophrenia patients with 
cannabis use. Stirling and colleagues (2003, 2005) administered a neuropsychological 
battery to 69 patients at a 10-12 year follow-up. The patients in this study were recruited 
out of 112 individuals in 1987 who had experienced their first episode of psychosis 
within 2 years prior to this time. Those who had a history of cannabis use (categorised 
as ‘no use’ and ‘some use’) at the time of the onset of their illness were noted. Thirty-
seven patients were assessed with a neurocognitive battery at onset, 24 were re-assessed 
at follow-up and an additional 25 from the parent sample were also assessed at follow-
up. Findings from the study showed that patients with cannabis use demonstrated better 
performance on a verbal fluency task (COWAT – FAS), as well as on other 
neurocognitive measures such as design memory (Memory for Design; Graham & 
Kendall, 1960), visuospatial organisation (object assembly, block design, picture 
completion, picture arrangement), and recognition memory (face recognition) at follow-
up. More specifically, after controlling for the effects of age of cannabis use onset 
significantly better performance on measures of memory, verbal fluency, sequencing, 
visuospatial organisation and recognition memory was found to be associated with a 
history of cannabis use. In addition to these findings, the 26 patients who reported a 
level of continued cannabis use at follow-up demonstrated significantly better 
performance in several of these domains in comparison to those who had not sustained 
their cannabis use at this time. It was suggested by the authors that while impairment in 
executive function may be present in first episode patients, they do not appear to 
deteriorate over 10-12 years. As both the patients with cannabis use and non-using 
patients were not able to be distinguished based on their performance on any of the 
premorbid adjustment measures or in relation to social/behavioural functions (as 
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assessed by the Premorbid Adjustment Scale (PAS); Cannon-Spoor, Potkin, & Wyatt, 
1982), the authors concluded that their findings were not indicative of the presence of 
differences between groups related to premorbid social functioning. Results suggested 
that the cannabis-using group may represent a subgroup with a subtly different profile, 
characterised by relatively preserved neurocognition and fewer negative symptoms. 
While better performances demonstrated by schizophrenia patients with 
cannabis use could be considered counterintuitive, other studies have also reported a 
similar pattern of results. Jockers-Scherübl and colleagues (2007) compared the 
cognitive functioning of 39 schizophrenia patients (19 cannabis abusers and 20 non-
abusers) with 39 healthy control subjects (18 cannabis abusers and 21 non-abusers) 
following a minimum abstinence period of 28 days. The researchers excluded those 
patients with any drug abuse or dependence history other than that involving cannabis. 
The cannabis-abusing group in the study included only those individuals whom had 
consumed an average of at least 0.5g of cannabis per day for a minimum of 2 years prior 
to illness onset. Main effects of diagnostic group (i.e., schizophrenia vs. controls) 
indicated cannabis-using patients with schizophrenia demonstrated worse performance 
in most neurocognitive tests in comparison to cannabis-using controls. However, when 
only the main effect of age of cannabis use onset was considered, irrespective of 
diagnostic group, there was no significant difference found. A significant interaction 
between diagnostic group and age of onset was found for performance on a processing 
speed and working memory task (measured by the Digit Symbol Substitution Test 
(DSST): Wechsler, 1981) and performance on another measure of working memory 
(assessed by ‘other errors’ on the WCST). More specifically, control subjects with 
cannabis abuse who had commenced regular use at 16 years or younger demonstrated 
worse cognitive performance than those individuals whose age of cannabis use onset 
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was 17 years or older. Contrastingly, schizophrenia patients with cannabis abuse who 
commenced their abuse at the age of 16 years or younger performed better on the DSST, 
but demonstrated worse performance relative to controls when their cannabis abuse had 
started at 17 years or older. No significant difference in performance between control 
subjects and schizophrenia patients with early onset of regular cannabis abuse were also 
observed on this test. A similar pattern of results was observed on ‘other errors’ of the 
WCST. These results suggested that regular cannabis abuse commencing before the age 
of 17 (and prior to illness onset) was associated with better neurocognitive performance 
in patients with schizophrenia. However in the control group, early age of onset of 
regular cannabis abuse was found to be associated with worse performance. It was noted 
that once the authors made corrections to the alpha level in order to account for multiple 
statistical tests, the difference in performance remained significant for ‘other errors’ on 
the WCST (when age of onset was applied), but only approached significance for 
performance on the DSST. The authors considered that a possible explanation for the 
findings showing better performance by patients with cannabis abuse on such measures 
who commenced their cannabis use prior to the age of 17 (and also illness onset) may be 
potentially due to the latter measure not only assessing processing speed abilities. It is 
thought that the DSST in particular may also tap into a number of neurocognitive 
abilities including attention, sustained attention, psychomotor speed, working memory 
and other executive functions (Lezak et al., 2004). Therefore, it was considered by the 
authors that such a measure may be possibly more sensitive in detecting subtle 
differences that exist between groups. It is postulated that when there are slight deficits 
on a collection of neurocognitive abilities, the need to simultaneously integrate these 
abilities may consequently lead to overall impairments in performance becoming more 
evident. Therefore, the authors proposed that a possible explanation for the findings of 
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better performance on this test may suggest that those patients with cannabis abuse with 
an age of cannabis abuse onset prior to illness onset could possibly possess a better 
capacity to integrate several cognitive functions despite demonstrating poor 
performance in individual tests.  
Coulston, Perdices and Tennant (2007) examined the relationship between 
neuropsychological performance and three different indices of cannabis use in 60 males 
with schizophrenia/schizoaffective disorder and 17 male healthy control subjects. Forty-
four schizophrenia patients met the Diagnostic and Statistical Manual of Mental 
Disorders - Fourth Edition (DSM-IV; American Psychiatric Association, 2004) criteria 
for lifetime cannabis abuse/dependence. The indices used by the researchers included 
lifetime abuse/dependence (assessed according to the DSM-IV criteria of substance 
abuse/dependence), frequency of use, and recency of use. In line with the pattern of 
results of previous studies, findings indicated that cannabis use was associated with 
enhanced neurocognitive functioning in schizophrenia. More specifically, results 
showed that a larger proportion of those schizophrenia patients with lifetime cannabis 
abuse/dependence demonstrated performance classified in the normal range on one of 
the executive function measures administered (i.e., the TMT), in comparison to those 
without lifetime abuse/dependence. However, the actual component of the measure 
which was found to be significantly associated with better performance was that aspect 
of the test which assessed psychomotor speed. In this study, cognitive performance was 
classified as ‘impaired’, ‘normal’, and ‘above average’ based on scores derived from the 
control group. Subjects were deemed to demonstrate cognitive ‘impairment’ if 
performance fell 1.5 – 2.0 standard deviations or more below the mean of the control 
group (Spreen & Strauss, 1998; Ruff & Allen, 1996, both cited in Coulston et al., 2007). 
In addition, above average performance was determined if scores were 0.5 standard 
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deviations or more above the mean of the control group. Intriguingly, high frequency 
cannabis use was found to be associated with better performance on Principal 
Component Analysis derived cognitive components of speed of information processing, 
divided attention, visual conceptual switching, and planning efficiency. However in 
contrast, a larger proportion of subjects categorised as medium frequency cannabis users 
fell in the ‘impaired’ range on the cognitive components of planning efficiency and 
complex information processing. It was noted that while premorbid IQ was not found to 
be significantly different between frequency groups, the medium frequency group had a 
mean premorbid IQ at almost half a standard deviation lower than the high and low 
frequency cannabis user groups. The cannabis use indices measuring recency (i.e., 
cannabis abuse/dependence in the past week; cannabis use at a non-dependent level in 
the past month, but prior to the past week; cannabis use at a non-dependent level prior 
to the past month), were also found to be associated with better performance on the 
cognitive components reflective of speed of information processing, complex 
information processing, psychomotor speed, inhibition accuracy, planning efficiency, 
planning and organisation, and complex perceptual organisation. Worse performance on 
a non-executive cognitive component of immediate memory was however, associated 
with the recency category of non-dependent cannabis use in the past week. In addition, 
cannabis use at a non-dependent level in the past week was associated with worse 
performance on the cognitive components of planning and organisation and complex 
information processing. As the cognitive components which were found to be associated 
with better performance, as well as with the cannabis use parameters of frequency and 
recency of use, were attention/processing speed and executive function domains, the 
authors postulated that cannabis use may possibly stimulate prefrontal 
neurotransmission. 
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Further evidencing the surprising observation of better neurocognitive 
performance, Schnell and colleagues (2009) investigated the residual impact of cannabis 
use and specific parameters of cannabis consumption on cognition in a sample of 
schizophrenia patients with a lifetime diagnosis of comorbid cannabis use disorder. The 
indices of cannabis use assessed included age of onset of use, the duration of regular 
use, time since last dose, average frequency of use (joints per month), and maximum 
frequency of use (joints per month). A cognitive test battery was administered to 34 
schizophrenia patients and 35 currently abstinent schizophrenia patients with cannabis 
use disorder. The minimum period of abstinence from cannabis was 3 weeks. The 
schizophrenia patients with cannabis use disorder had poorer academic achievement and 
lower vocabulary scores. However, after potential confounds were accounted for 
schizophrenia patients with cannabis use disorder were found to demonstrate better 
performance in tests of verbal memory (measured by the Auditory Verbal Learning and 
Memory Test; Heubrock, 1992), working memory (LNS; Gold, Carpenter, Randolph, 
Goldberg, & Weinberger, 1997), and visuomotor speed and executive function (DSST; 
Tewes, 1991; TMT, Part B; Reitan 1958; Reitan & Wolfson, 1993), in comparison to 
schizophrenia patients without comorbid cannabis use disorder. Results of the study 
were in support of previous findings (Coulston et al., 2007; Jockers-Scherübl et al., 
2007; Stirling et al., 2005). More frequent cannabis use was also associated with better 
performance in tasks of attention (Continuous Performance Test (CPT); Cornblatt, 
Risch, Faris, Friedman, & Erlenmeyer-Kimling, 1988) and working memory (LNS). In 
addition, DeRosse and colleagues (2010) compared lifetime measures of psychotic 
symptoms, as well as cognitive performance in 280 schizophrenia patients without a 
history of cannabis use disorder and 175  schizophrenia patients with a history of 
cannabis use (51 patients with comorbid cannabis abuse; 124 patients with cannabis 
CANNABIS USE, SCHIZOPHRENIA & EXECUTIVE FUNCTION  40 
 
dependence). Similar results were found where schizophrenia patients with a history of 
cannabis use disorder demonstrated significantly better performances on measures of 
processing speed (TMT, Part A & B), verbal fluency (animal naming) and verbal 
learning and memory (California Verbal Learning Test). This group also had better 
Global Assessment of Functioning (GAF) scores than schizophrenia patients without a 
history of cannabis use disorder.     
Rodríguez-Sánchez et al (2010) conducted a study amongst 107 first-episode 
patients with schizophrenia (47 cannabis users and 57 non-users) and 37 healthy 
controls. Patients were considered to be cannabis users if there had been at least weekly 
use during the year prior to program entry. The aim was to compare subjects on clinical 
features, cognitive performance and premorbid adjustment, both cross-sectionally and 
longitudinally. Results showed that cannabis users demonstrated better performance in 
attention (as measured by the CPT) and executive function (as measured by the TMT-B) 
at baseline and following 1 year of treatment. In addition, cannabis users were found to 
have better social premorbid adjustment, particularly during childhood and adolescence. 
They were also found to have earlier age of illness onset. Findings also indicated that 
the amount of cannabis consumed and duration of use was not associated with cognitive 
performance. While it was noted by the investigators that some patients regularly used 
other drugs of abuse in addition to their cannabis use, it was found that results relating 
to executive function performance remained significant after the omission of these 
subjects from analyses. The authors argued that the findings of the higher presence of 
positive symptoms at baseline, better premorbid adjustment and higher performance on 
frontal related cognitive functions suggest that cannabis users may represent a specific 
subgroup of patients with better overall premorbid abilities. 
CANNABIS USE, SCHIZOPHRENIA & EXECUTIVE FUNCTION  41 
 
Leeson and colleagues (2011) aimed to explore the role of age of onset and 
cognition on outcomes in cannabis users with first-episode schizophrenia. In addition, 
the investigators aimed to evaluate the effect of cannabis use parameters such as dose 
and cessation. Ninety-nine patients were divided into 65 lifetime cannabis users (as 
defined by those who reported having used the drug at all during their lifetime) and 34 
never-users. The cannabis-using group were further parsed into a high frequency group 
(i.e., those who reported either daily or almost daily use; n = 30) and a low frequency 
group (i.e., those who reported use of either twice a week or less; n = 35). Results of the 
study showed that cannabis users had better premorbid IQ and social function at 
psychosis onset. Cannabis users also demonstrated better performance in verbal learning 
(assessed by the Rey Auditory Verbal Learning Task), working memory span (Spatial 
Span) and planning (assessed by a task analogous to the Tower of London), but not on a 
working memory manipulation task (self-ordered search task from the CANTAB), in 
comparison to non-users. However, when premorbid IQ was entered into analyses as a 
covariate, these between group differences were no longer significant except for 
planning. It was found that premorbid IQ did not explain the between group difference 
in social functioning. Low frequency users were found to have significantly higher 
current IQ than high frequency users and cannabis users had an earlier age of illness 
onset than non-users. There was also a strong relationship found between age at first 
cannabis use and age of onset of both prodromal and psychotic symptoms. The authors 
concluded from their overall findings that cannabis use may trigger the onset of 
psychosis in individuals who otherwise have good prognostic features (i.e., higher 
intellectual and social functioning prior to psychosis onset). It was also considered that 
the cannabis-using patients in the study had higher ‘cognitive reserve’ not only as 
evidence by better premorbid abilities, but by also better social function demonstrated 
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over the first 15 months of illness. It was considered that the earlier age of illness onset 
in cannabis users may therefore be due to the toxic action of cannabis instead of it 
reflecting of a form of illness that is more severe in nature.  
Yücel and colleagues (2010) conducted a meta-analysis of the research in the 
area examining the cognitive functioning of patients with established schizophrenia with 
and without comorbid cannabis use. Findings suggested that patients with history of 
cannabis use were found to have superior cognitive functioning. These particular results 
were predominantly influenced by those studies which included schizophrenia patients 
who had a lifetime history of cannabis use (defined elsewhere e.g., Schnell et al., 2009 
as those that were assessed to have a lifetime diagnosis of comorbid CUD according to 
DSM-IV-TR), rather than current or recent use factors. In a second study conducted by 
the authors, the cognitive performance of 59 first-episode patients with psychosis with a 
cannabis use history was examined in comparison to 26 patients with first-episode 
psychosis patients without a history of cannabis use and 43 healthy non-using control 
patients. Findings showed that first-episode patients with a cannabis use history 
demonstrated better performance in the neurocognitive domains of visual memory (as 
measured by Visual Reproduction (Part I) from the Wechsler Memory Scale - Revised 
(WMS-R); Wechsler, 1987), working memory (as measured by ‘SWM-errors’ on 
Spatial Working Memory from the CANTAB), and planning and reasoning (as 
measured by the Tower of London; Shallice, 1982). In addition to these results, it was 
also found that earlier onset of cannabis use was associated with less cognitive 
impairment in comparison to a later age of cannabis use onset which is in support of 
previous findings (Jockers-Scherübl et al., 2007).    
Rabin and colleagues (2011) also conducted their own meta-analysis, but instead 
only included studies that examined the direct effects of cannabis on cognition in 
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schizophrenia, with no other substance use included. Similar findings were reported, 
denoting overall superior cognitive performance in schizophrenia patients associated 
with lifetime cannabis use in comparison to non-using patients. However, the authors 
noted that the magnitude of the effect sizes found were considered to be in the small to 
medium range (mean d = .06 - .48) which were also similar to the effect sizes reported 
in Yücel and colleagues’ (2010) meta-analysis. As it is considered that effect sizes of 
0.50 or greater are deemed to be clinically significant (Lezak et al., 2004), it is possible 
that results of the meta-analysis may be reflective of variability in methodological 
design instead of between-group differences. Therefore, effect sizes of these magnitudes 
may serve to question the clinical significance of the found relationship between 
cannabis use and neurocognition in schizophrenia amongst these studies. In a recent 
study by the same authors (2013), the cognitive performance in schizophrenia as a 
function of cannabis use indices was examined. The study included 18 schizophrenia 
outpatients with current cannabis dependence and 29 patients with no current cannabis 
dependence. The latter group was then parsed into subgroups which included 21 
patients with lifetime cannabis dependence and 8 patients with no lifetime dependence. 
Results indicated no significant differences in cognitive performance between patients 
with current cannabis dependence and no current cannabis dependence. However, 
never-dependent patients were found to demonstrate poorer reaction time on a measure 
of sustained attention, concentration, psychomotor speed, response inhibition and 
impulsivity (Continuous Performance Test II (CPT-II); Conners, 2000), than current and 
former dependent patients. These results remained significant after controlling for age. 
In current dependent patients, negative correlations were found between years of 
cannabis exposure and performance on the CPT-II, a measure used to assess working 
memory (Digit Span; Wechsler, 1997), another measure of executive function (WCST), 
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a measure of verbal memory (California Verbal Learning Test—Second Edition; Delis, 
Kramer, Kaplan, & Ober, 2000), and long delayed cued recall. It is important to note 
that the reported associations with years of cannabis use exposure were found on the 
Digit Span forwards condition only. There was no association between performance on 
tests of impulsivity and risky decision making (assessed by the Kirby Delayed 
Discounting Task; Kirby, Petry, & Bickel, 1999 and the IGT - Computerized version; 
Bechara et al., 1994) and cumulative cannabis use. Results of the study suggest that the 
cessation of cannabis use was not associated with worse or better performance. Also, 
while poorer reaction times were demonstrated by never-dependent patients, reduced 
performance on a range of cognitive tasks was found to be associated with cumulative 
use in current dependent patients suggesting that years of cannabis use exposure may be 
a more important contributing factor than cannabis use status.  
The increasing picture of better cognitive performance associated with cannabis 
use in schizophrenia patients is not only counterintuitive, but rather unexpected 
considering the impact of cannabis use on cognition in otherwise healthy users. One 
possible explanation for these findings is that better cognitive functioning may serve to 
be a risk factor in patients with schizophrenia for the development of cannabis use 
disorders. In other words, this cohort of individuals may have higher social competence 
(i.e., as demonstrated by the ability to seek, obtain and maintain drug use) and therefore 
be reflective of more intact cognitive functions (DeRosse et al., 2010; Jockers-Scherübl 
et al. 2007; Leeson et al., 2011; Rodríguez-Sánchez et al., 2010). Arndt and colleagues 
(1992) found better premorbid adjustment in those individuals with schizophrenia who 
abused alcohol or cannabis. A two-stage model was proposed by the authors to attempt 
to explain substance abuse in these individuals. The authors postulated that those with 
better premorbid adjustment were more sociable in nature and thus would possibly be 
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exposed to more opportunities for substance use experimentation. Other authors have 
also suggested better premorbid abilities in substance-using schizophrenia patients, 
where such cohorts have been considered to reflect a relatively distinct group who differ 
from non-using patients in terms of premorbid social adjustment which is thought to be 
required in order to initiate and maintain drug-seeking behaviour (Wobrock, Sittinger, 
Behrendt, D’Amelio, Falkai, & Caspari, 2007). Similarly, in a study conducted by 
Kumra and colleagues (2005) which examined performances on measures of intellectual 
functioning in adolescent inpatients with schizophrenia and schizoaffective disorder, 
findings suggested that a better Full Scale Intelligence Quotient (FSIQ) and Verbal 
Intelligence Quotient (VIQ) was associated with a history of cannabis 
abuse/dependence. However, this perspective is contrary to previous findings which 
failed to identify significant differences in premorbid adjustment and social/behavioural 
functioning between groups (Coulston et al., 2007; Stirling et al., 2005). It is also noted 
that the sample in Kumra et al.’s (2005) study were adolescents.  
Limitations to Previous Research  
The results of the abovementioned sudies cannot be adequately evaluated 
without reviewing the limitations in methodology across each study. In some studies, it 
was more difficult to establish the direct impact of cannabis on cognition because 
additional substances had also been used by patients and these had not been controlled 
for in analyses (Sevy et al., 2007; Yücel et al., 2010). Yücel and colleagues (2010) 
included studies in their meta-analysis as long as cannabis was the most preferred 
substance of the sample. Therefore, some cannabis-using groups also included patients 
who did not only use cannabis. However, it is noted that in studies which included other 
substance use one would assume that this would only serve to increase the likelihood of 
detecting poorer performance in the drug-using patient group, but surprisingly most 
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found better performances. It is considered that the inclusion of other substances may 
potentially make it more difficult to establish the precise contributing factors to this 
level of performance (i.e., whether superior performances are associated with cannabis 
use related brain functioning per se, or are just simply associated with the 
neurocorrelates of substance use in schizophrenia in general). It is acknowledged that 
this issue is considered to be practically unavoidable, or at least in part a contributing 
factor, making the recruitment of larger, more specific patient sample groups more 
difficult to achieve. Some studies also only examined the effects of cannabis use prior to 
the first psychotic episode and failed to investigate the effects of continuing cannabis 
use after illness onset (Jockers-Scherübl et al., 2007; Mata et al., 2008). 
Such inconsistent findings in the existing literature may also be explained by the 
level of variability in population characteristics between the studies. One source of this 
variability in sampling includes the types of patients used. Reported better performances 
amongst cannabis-using patients have involved a relatively young sample (Coulston et 
al., 2007). It was considered that the effects of cumulative substance use may not be 
fully developed in the tested sample and therefore, the effects associated with longer 
lifetime cannabis use could not be established. Another possibility is that the deficits 
found may be a reflection of age-related cognitive decline, as there is increasing 
evidence in the literature suggesting age-related deficits in executive functioning (Fisk 
& Sharp, 2004; Fisk & Warr, 1996; Fristoe, Salthouse, & Woodard, 1997; Salthouse & 
Babcock, 1991; Van der Linden, Beerten, & Pesenti, 1998). In other words, the 
neurocognitive performances observed in these previous studies may not be directly 
related to the effects of cannabis use, but instead a function of age differences. In Rabin 
and colleagues’ (2013) study, never-dependent patients were found to be significantly 
older than current-dependent and former-dependent patients. In addition, never-
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dependent patients were found to have a significantly older age of diagnosis than 
former-dependent patients. Similar differences in age of diagnosis between never-
dependent and current-dependent patients approached significance.  
Further, the way in which cannabis users were classified or identified also varied 
between studies. For example, some studies have utilised a binary system grouping 
participants as being either users or non-users (Mata et al., 2008; Scholes & Martin-
Iverson, 2010; Sevy et al., 2007; Stirling et al., 2005) and cannabis use parameters such 
as severity/quantity, frequency, and duration were not accounted for in the researchers’ 
classification of what characterised a user. In most of these studies, either no significant 
differences were reported or worse cognitive performance was associated with cannabis. 
However, Stirling and colleagues (2005) reported better performance. Contrastingly, 
those studies which classified participants as having a cannabis use disorder diagnosis 
or being defined by a minimum amount or duration of use showed only better cognitive 
performance associated with cannabis (Coulston et al., 2007; DeRosse et al., 2010; 
Jockers-Scherübl et al., 2007; Leeson et al., 2011; Rabin et al., 2013; Rodríguez-
Sánchez et al., 2010; Schnell et al., 2009). In addition, two studies reported a 
relationship between higher frequency of cannabis use and superior cognitive 
functioning (Coulston et al., 2007; Schnell et al., 2009). Therefore, considering the 
differences in findings it seems that assessing the different parameters of cannabis use is 
of particular importance when examining the effect of cannabis on cognition in 
schizophrenia.  
Studies also differed in the range of tests used to assess cognitive functioning or 
the types of measures used to tap into specific cognitive functions. Further, it is 
acknowledged that the selection of measures used in previous studies appears to be 
relatively atheoretically driven and instead based upon face validity (i.e., they appear to 
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assess these functions) in measuring their proposed cognitive constructs. In addition, the 
cognitive assessment conducted in some studies were restricted to only a few cognitive 
domains (DeRosse et al., 2010; Schnell et al., 2009; Scholes & Martin-Iverson, 2009). 
The means in which these domains were assessed were also limited by the diminutive 
number of measures used to do so. Performance on the measures utilised in previous 
research may not precisely enough reflect the range of deficits implicated in 
schizophrenia, as well as in cannabis users, particularly when considering the multi-
faceted neurocognitive processes involved in the executive function system. Therefore, 
it is possible that these studies could fall short of being able to adequately assess the full 
range of abilities or components that are theoretically conceptualised to be involved in 
the executive functioning system. Considering the relationship between executive 
function and functional outcome in schizophrenia, consequently it may be more difficult 
to fully evaluate the clinical relevance of previous findings regarding overall cognitive 
performances. A methodological problem commonly involved in neuropsychological 
research, involves the issue of how the multi-faceted and complex construct that is 
termed ‘executive function’ has been mainly assessed by relatively few psychometric 
measures (e.g., the WCST, the Stroop test, verbal fluency or TMT). This potential 
inadequacy in assessment approach has been considered an important issue (Green, 
1996; Green et al., 2000; Thoma, Wiebel, & Daum, 2007). Therefore, previous 
neuropsychological evidence may not be reflective of the true nature of, or sufficiently 
narrow down, the various subcomponents which could be specific to the executive 
deficits deemed to be crucial to the illness of schizophrenia. It is possible that the 
inconsistencies in previous findings may be related to the methodological difficulties 
that are involved in precisely defining and measuring the construct of executive 
function, as well as assessing the range of sub-processes which fall under the executive 
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function domain. Neurocognitive test batteries should aim to target and delineate the 
construct(s) of interest (e.g., executive function) more precisely. In addition, a lack of 
examination of whether performance on such measures is related to day-to-day 
functioning abilities (i.e., functional outcome) questions the ecological validity of the 
employed measures used in previous studies (i.e., are they are adequately reflective, and 
predictive, of the abilities required to function in the ‘real-world’?). It is possible that 
outside of the testing context, there are more complex demands and distractions that an 
individual may encounter in more naturalistic settings. Therefore, any absence of 
deficits demonstrated in a psychometric assessment situation may not necessarily reflect 
intact neurocognitive function. It is possible that utilising more ecologically valid 
measures could potentially allow for the detection of more subtle deficits by creating 
conditions that could serve to place greater ‘real-world’ demands on an individual.   
The inconsistency in past findings suggests that the evaluation of neurocognitive 
function in schizophrenia patients with cannabis use requires further examination. 
Considering the results in previous studies indicating superior cognitive performances in 
cannabis-using schizophrenia patients, in comparison to patients without a cannabis-use 
history, it is possible that the use of a matched-pairs control group with cannabis use 
could potentially help to further tease apart or further explain these observations. An 
otherwise healthy control group with a similar cannabis use history could possibly allow 
for more information in addition to the previous findings, by assisting to determine 
whether cannabis acts correspondingly in otherwise healthy users in comparison to 
patient users, or whether there is something truly unique to the schizophrenia patient 
with cannabis use population. Considering the prevalence rates of cannabis use in this 
particular clinical population, cannabis use in schizophrenia is an often unavoidable 
confounding variable that needs to be carefully accounted for. Indices of cannabis use 
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are also often highly variable across individuals and consequently cannabis use per se 
can be difficult to define. Therefore, in order to address this issue it is imperative that a 
detailed assessment of the different parameters of cannabis use is conducted (e.g., 
severity/quantity, frequency, duration, time since last use). The use of a control group 
with a similar cannabis use history would also help to control for any confounding 
influence contributed to by such variations in crucial cannabis-use indices which have 
been considered to have an impact on cognitive performance. In addition, as executive 
impairments have been found to be associated with age-related cognitive decline, age is 
also deemed an important variable to control for. 
The previously mentioned methodological issues also provide scope for the 
further development of neuropsychological battery measures in not only being able to 
more effectively examine complex cognitive constructs such as executive function, but 
in addition sufficiently validate individual neurocognitive sub-components against 
various aspects of functional outcome. In order to critically examine the validity of 
various tests of executive function, further exploration into the concept of executive 
function and its specific components, will be discussed in the following section.  
Part B 
The Assessment of Executive Function 
Over the years, establishing a precise definition, as well as developing the 
effective measurement, of executive function has had its challenges. This can be 
explained in part by there being much debate about the validity of specific measures in 
being able to capture the full range of abilities which fall under this domain (i.e., being 
able to successfully ‘fractionate’ the executive system). While various studies have 
aimed to assess executive functioning in patients with schizophrenia, many of these 
studies have appeared to examine only a unitary concept of the construct using a limited 
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number of assessment measures (for review, see Green, 1996; Green et al., 2000). 
Therefore, many studies have failed to directly address the fractionation of the executive 
function system in schizophrenia and hence, it is possible that performance on selected 
measures may not adequately reflect the range of processes that fall within the construct 
that is termed ‘executive function’. It is thought that the more successful fractionation of 
the executive functions is largely dependent on the ability to develop specific theoretical 
models of this neurocognitive system (Baddeley, 1998; Burgess et al., 1998; Shallice & 
Burgess, 1991). While there is a long history of various models conceptualising the 
construct of executive function in the neurocognitive literature, for the purposes of this 
study one specific model (chosen on the basis of its comprehensive features), will be 
discussed in detail.  
Models of executive function. Developing a good understanding of the specific 
mechanisms and components of executive functioning has unfolded over various 
approaches. The conceptualisations, definitions and models of executive functioning 
subscribe to various research findings arising from neuroanatomical, neurophysiological 
and neural circuitry evidence from animal brain-behavioural relationship observations 
(for overview, see Goldman-Rakic, 1987), the examination of the relationship between 
cognitive and behavioural deficits and frontal lobe damage (e.g., Fuster, 1989; 
Goldman-Rakic, 1996; Luria, 1973; Royall, Lauterbach, Cummings, Reeve, Rummans, 
Kaufer et al., 2002), as well as theoretical model fit from statistical approaches such as 
confirmatory factor analysis methods  (e.g., Daigneault, Braun, & Whitaker, 1992).  
More recently, there has been various theoretical and psychometric approaches 
that have been developed in an attempt to determine whether executive functioning 
should be conceptualised as a unitary system or whether is it is more adequately 
described by a model involving multi-processes (Baddeley, 1998; Miyeake, Friedman, 
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Emerson, Witzky, & Howerter, 2000; Parkin, 1998; Stuss & Alexander, 2000). 
Increasingly it has become more apparent that executive functioning cannot be 
considered as a unitary construct as various executive function components have been 
able to be individualised and while found to be related, are shown to be independent to 
each other (Chevignard et al., 2008; Duncan, Johnson, Swales, & Freer, 1997; Miyake 
et al., 2000; Robbins, James, Owen, Sahakian, Lawrence, McInnes, & Rabbit, 1998). 
Models of executive function which have emerged over the years view the overall 
system as comprising of individual and distinct subcomponents (Andres, 2003; 
Baddeley, Della Sala, Robbins, & Baddeley, 1996; Goethals, Audenaert, Van de Wiele, 
& Dierckx, 2004) which are then conceptualised as being structured either in a 
hierarchical manner (e.g., Fuster, 1989; West, 1996) or as a distinction between 
'hot/cold’ processes (e.g., Damasio, 1995).  
West’s model of executive function. West’s (1996) model of executive function 
builds upon a previous hierarchical model originally proposed by Fuster (1989), which 
incorporates the conceptualisation of superordinate and subordinate functions. 
According to Fuster’s model, it is postulated that executive functioning involves an 
overarching or ‘superordinate’ function called the ‘temporal organisation of behaviour’ 
which is considered to be responsible for the initiation and maintenance of behaviours 
that have a common goal. This function is conceptualised to be subserved by three 
subordinate functions. These include provisional memory which involves the 
recollection of previous experience; prospective memory which is thought to be 
responsible for the storage and cueing of information that is required to perform a future 
goal; and interference control which serves to suppress interferance or conflicts 
irrelevant to the task at hand. This model emphasizes the concept of ‘temporal gestalt’, 
meaning that such functions support the organisation of behaviour over time in 
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sequence, connecting past actions and future events or goals in conjunction with the 
integration of information that is task-relevant and the disregard of task-irrelevant 
information (Fuster, 1989). It is acknowledged that Fuster’s model affords, at least in 
part, a way of theoretically explaining the executive function system as a hierarchy of 
cognitive processes. However, considering that many previous studies investigating 
executive function have also examined the cognitive process of inhibition, Fuster’s 
model appears to be somewhat lacking. Therefore, additional models of executive 
function will also be discussed in order to incorporate other executive function domains 
which appear to not be accounted for in this model alone.    
In addition to Fuster’s (1989) conceptualised executive processes, West included 
a fourth subordinate function to his own model which is termed the inhibition of 
prepotent responses. West also used the term ‘retrospective memory’ instead of 
provisional memory. According to West, retrospective memory involves the retrieval 
and maintenance of information that is task-relevant from its storage in memory. This 
function has also been conceptualised to be similar to the construct of working memory 
(Baddeley, Della Sala, Papagno, & Spinnler, 1997). In West’s model, prospective 
memory is thought to aid in the preparation of an individual for an upcoming action or 
behavioural response. Interference control serves to manage the intrusion of task-
irrelevant information incoming from external sources. Such task-irrelevant information 
can be incorporated into retrospective memory and, therefore, subsequently interfere 
with correct task execution if it is not adequately controlled. Finally, the inhibition of 
prepotent responses is thought to inhibit more dominant, habitual behavioural responses 
particularly when such responses are not considered to be optimal or appropriate for the 
present task. It is acknowledged that West’s (1996) model encompasses a much broader 
range of cognitive functions than other models of ‘executive functions’. However, as 
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previously mentioned Lezak et al. (2004) describes the structure of the frontal lobe as 
being associated with not only higher-order cognitive functions, but also the facilitation 
of memory functions and retrieval strategies. In addition, Fuster (2000) considers that it 
would be erroneous to localise various executive functions to the prefrontal cortex alone 
and that only part of the networks involved in memory abilities can be localised to this 
region. Both retrospective memory and prospective memory abilities are described to 
complement each other at the service of frontal executive function playing the critical 
role in the mediation of contingencies of action across time. 
There have been a number of different measures designed and utilized to capture 
the different components highlighted in this model. The following section discusses an 
approach in the measurement of each of these domains guided by West’s (1996) 
theoretical model of executive function, as well as a comprehensive investigation in 
evaluating the validity of the theoretical constructs involved.  
Num (2006) evaluated the construct validity of a hierarchical model of the 
executive functions proposed by West (1996). In the study, participants were 
administered a battery of neurocognitive tests individually selected based on the 
theoretical concepts of the individual processes outlined in West’s model. The study 
utilised the Zoo Map task from the Behavioural Assessment of the Dysexecutive 
Syndrome test battery (BADS; Wilson, Alderman, Burgess, Emslie, & Evans, 1996), a 
modified version of the Self-Ordered Pointing Task (Bryan & Luszcz, 2001), and the 
Modified Six Elements task also from the BADS, in order to assess the construct of the 
temporal organisation of behaviour. Retrospective memory was assessed using memory 
for items from the Zoo Map task, recall of items from the Self-Ordered Pointing Task, 
and a measure of working memory called the Reading Span test (Daneman & Carpenter, 
1980). Prospective memory was assessed using both event-based and time-based tasks 
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which have been used in previous research aimed to measure this particular cognitive 
construct (Einstein, McDaniel, Richardson, Guynn, & Cunfer, 1995; Park, Hertzog, 
Kidder, Morrell, & Mayhorn, 1997; Smith & Bayen, 2005). Interference control was 
assessed using the Symbol Search subtest of the Wechsler Adult Intelligence Scale – 
Third Edition (WAIS-III; Wechsler, 1997), and the Letter Cancellation test (Diller, Ben-
Yishay, Gerstman, Goodkin, Gordon, & Weinberg, 1974). The inhibition of prepotent 
responses was measured using the Stroop test (Dodrill, 1978), a modified version of the 
Rule Shift card test from the BADS, and the Trail Making Test from the Delis-Kaplan 
Executive Function System test battery (D-KEFS; Delis, Kaplan, & Kramer, 2001). 
Results of the study demonstrated that measures of the temporal organisation of 
behaviour, retrospective memory, prospective memory, interference control and the 
inhibition of prepotent responses significantly correlated within each of the constructs 
tested. However, it was also found that only retrospective memory performance 
predicted temporal organisation of behaviour performance after controlling for the 
effects of fluid intelligence. Through factor analysis these measures were compared in 
order to determine whether the pattern of results served to support West’s hierarchical 
model of executive function. Overall, results of the study suggested that ‘executive 
functions’ operate as a group of individual, though related, functions. It was also found 
that performance on these functions were found to be independent of performance on a 
measure of fluid intelligence, suggesting that such functions were distinct from general 
intellectual ability. Findings of the study were in support of West’s (1996) theoretical 
hierarchical model of executive function. These findings are particularly relevant to the 
current study as previous reseach investigating the executive functioning of 
schizophrenia patients with cannabis use appear to fall short of examining the range of 
abilities that have been considered to be reflective of the executive function construct as 
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a whole. It should be noted that this particular testing protocol has also yet to be utilised 
among clinical samples.   
Damasio’s somatic marker hypothesis. Taking a different perspective, 
Damasio’s ‘somatic marker hypothesis’ model (Damasio, 1995; Damasio, Everitt, & 
Bishop, 1996; Damasio, Grabowski, Frank, Galaburda, & Damasio, 1994) 
conceptualises the role of frontal lobe functions in emotion and interpersonal behaviour, 
specifically in relation to reasoning and decision-making. It was considered by Damasio 
that emotion is mediated by the prefrontal regions, via the complex links found between 
the cortical (which involve the ventromedial cortex) and subcortical (which involve the 
mediodorsal nucleus of the thalamus, the amygdala, and the hypothalamus) linkages. 
This model considers and emphasizes the ‘hot’ or emotional-related component of 
executive function and its associated relationship with ‘cold’ or more mechanistic 
cognitive components of executive function with regard to decision-making processes 
and the development and/or maintenance of social relationships. Damasio (1995) 
developed the model to help explain impairments such as dramatic personality change, 
emotional and interpersonal problems which are commonly seen after VPFC damage in 
patients. It is thought that individuals with damage to the VPFC experience difficulties 
in behaviour regulation due a reduced ability to utlise emotion-related somatic signals 
which are used to ‘mark’ inappropriate behaviours. Therefore, considering the 
conceptualised relationship between the prefrontal cortex and executive function, 
Damasio’s model provides further insight into the construct of executive function and 
its potential subcomponents.  
The Iowa Gambling Task (IGT) was developed by Damasio and his colleagues 
in order to test the somatic marker hypothesis (Bechara et al., 1994; Bechara, Damasio, 
Tranel, & Damasio, 1997; Bechara, Tranel, & Damasio, 2000; Bechara, Tranel, 
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Damasio, & Damasio, 1996). Studies have shown the IGT to demonstrate sound 
sensitivity in individuals with VPFC lesions. Previous research has also utilised the IGT 
in the examination of cognitive function related to the frontal regions in cannabis users, 
schizophrenia patients, as well as schizophrenia patients who also abuse cannabis (Mata 
et al., 2008; Sevy et al., 2007; Shurman et al., 2005; Whitlow et al., 2004). However, 
studies have reported that performance on ‘traditional’ measures of executive function, 
such as the WCST, is poorly correlated with performance on the IGT (Ritter, Meador-
Woodruff, & Dalack, 2004; Wilder, Weinberger, & Goldberg, 1998). These findings 
therefore suggest that the IGT is more sensitive in tapping into other components of 
executive function which have yet to be adequately measured by more traditional tests 
of executive function, and fails to be addressed through West’s (1996) model alone.    
The Validity of Tests of Executive Function 
One of the difficulties in the neuropsychological examination of executive 
functioning (and its potential in determining corresponding rehabilitation regimes) lies 
in the ability of traditional psychometric tests in providing a true and accurate 
assessment of the executive functions per se (i.e., whether such tests are really 
measuring what they claim to measure), as well as whether performance on such 
measures relates to performance in the real world. In other words, the question is 
whether commonly used psychometric measures of executive function are ‘ecologically 
valid’. Although meta-analytic results have shown that performance on neurocognitive 
tests have the ability to predict everyday functioning on a relatively global scale, more 
often than not, the typical standardised neuropsychological tests used to conduct such 
assessments are selected on the basis of their ability to detect pathology (Green et al., 
2000). Therefore, it is plausible that such measures may not truly capture the essence of 
the demands and routines involved in everyday life. Wilson and colleagues (1997) 
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emphasised that some clinical patients who exhibit deficits in day-to-day functioning 
can also demonstrate normal performance on executive functioning tests. Accordingly, 
it seems reasonable that the evaluation of the ecological validity of executive 
functioning tests as an empirical research target has specific clinical relevance to the 
schizophrenia population. 
Many common neuropsychological test approaches involve presenting the 
subject with a single explicit task at any one time, relatively short task trials, prompts or 
instructions by the examiner regarding when to initiate behaviour, and some type of  
indication of the intended/expected successful outcome (Shallice & Burgess, 1991). 
However, through the process of administering a set of standard instructions and scoring 
systems in such approaches, it is reasonable to consider that these approaches may not 
adequately correspond to the naturalistic demands involved in everyday life. The use of 
quantitative approaches in research is mainly thought to capture an individual’s 
performance at either the pathological or impairment level, but fails to tap into more 
clinical concerns such as functional everyday life deficits (Whyte, Polanski, Cavallucci, 
Fleming, Lhulier, & Coslet, 1996). It is considered that much of the discrepancy 
between cognitive performances demonstrated in formal testing and real-world 
situations could possibly be explained by the notion that such testing contexts provide a 
structured and often well-controlled environmental setting for the examinee (Chaytor & 
Schmitter-Edgecombe, 2003; Lezak et al., 2004; Manchester, Priestley, & Jackson, 
2004, Shallice & Burgess, 1991; Whyte et al., 1996). Due to these characteristics, many 
traditional tests of executive function are said to lack ecological validity (Acker, 1990; 
Cripe, 1996), and consequently may fail to sufficiently assess the complex interplay of 
behaviours that are involved in ‘real-world’ living.  
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A general limitation involved in standardised test procedures is that such 
experimental contexts strongly prompt the participant toward exhibiting certain 
behaviours. It is therefore plausible that situations that require behaviours such initiative 
or volition may not be able to adequately be assessed and represented by such measures. 
This notion is particularly relevant to the assessment of executive functioning, which 
can be conceptualised as reflecting not solely what an individual does, but how they do 
it as well as whether or not the individual exhibits the behaviour in the first place (Lezak 
et al., 2004). It is thought that measures sensitive to executive dysfunction should 
involve those contexts which are ill-structured and capture strategic planning, and 
retrospective memory and prospective memory abilities, particularly when considering 
the relationship between performance on such measures and performance in daily living 
(Burgess, Veitch, de Lacy Costello, & Shallice, 2000; Fortin, Godbout, & Braun, 2003; 
Godbout, Grenier, Braun, & Gagnon, 2005; Goel et al., 1997). Due to the structured and 
standardised nature of many traditional executive function tests, it is argued that such 
measures may not be adequate in their sensitivity to detect true executive deficits, such 
as the ability to deal with multi-task demands that are required for day-to-day 
functioning (Burgess, 2000; Shallice & Burgess, 1991). 
‘Traditional’ tests of executive function. Typical measures which have been 
deemed to assess executive abilities are usually those which have been found to be 
related and sensitive to dysfunction of the frontal lobe. Examples of such measures 
include the WCST (Milner, 1963). Deficits have also been shown on other widely used 
measures of executive functioning such as the TMT (Reitan, 1958), verbal fluency 
(Allen, Liddle & Frith, 1993; Benton, 1968), and the Stroop test (MacLeod, 1991; 
Stroop, 1935). However, it is considered that the construct validity of many traditional 
tests of executive function, such as the WCST, verbal fluency, the Tower of Hanoi, and 
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the TMT, is not well established despite their extensive use in neuropsychological 
assessment (Kafer & Hunter, 1997; Phillips, 1997; Rabbit, 1997). In the schizophrenia 
literature, the WCST is the single most commonly applied measure in the investigation 
of executive functioning (Reicheberg & Harvey, 2007). However, despite its 
widespread use not all schizophrenia patients have been found to demonstrate deficits in 
WCST performance (Braff et al., 1991; Goldstein, 1990; Goldstein, Beers & 
Shemansky, 1996). Reports of normal performances in schizophrenia patients on the 
WCST further suggests that the construct of executive function is not only complex, but 
comprises a range of different components. Therefore, the ability of psychometric 
measures to fractionate the executive functions seems crucial in order to be more 
sensitive to individual variation in executive functioning performance. Considering the 
importance of executive functions in schizophrenia, previous research has failed to 
employ a range of neurocognitive measures aimed at tapping into the various 
subcomponents theorized to be involved in the construct of executive function. It also 
appears that the construction of many commonly used measures of executive function 
has been fundamentally atheoretical in nature. The selection of such tests which are 
hypothesised to assess this neurocognitive domain more often than not, rely on their 
apparent face validity which is largely subjectively based (Salthouse, Atkinson, & 
Berish, 2003). New research in this area should endeavour to take into account this issue 
as an important methodological consideration when assessing a neurocognitive domain 
that is as complex and multi-faceted as executive function.    
However, there are some more theoretically-driven psychometric measures that 
exist which have been specifically developed in order to attempt to tap into the 
processes conceptualised be involved in executive function and validated to assess their 
reliability in the detection of executive dysfunction. Such tests include the Tower of 
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London test (Shallice, 1982), the Cognitive Estimates Test (Shallice & Evans, 1978), 
and the Self-Ordered Pointing Task (Petrides & Milner, 1982; Bryan & Luszcz, 2001). 
However, establishing the construct validity of such tests has not been without 
difficulty. For example, Kafer and Hunter (1997) utilised a structural equation 
modelling approach in order to evaluate the relationship among four tests 
conceptualised to measure planning/problem-solving abilities (i.e., the Tower of London 
test, the Six Element Test, the Twenty Questions Test, and the Rey Complex Figure 
Test) and the latent construct of planning/problem-solving. Findings indicated that an 
adequate statistical model was not able to be estimated in their analyses. Such results 
therefore served to question the construct of planning/problem-solving, as well as 
problems were specifically identified with the psychometric structure of the Tower of 
London test. O’Carroll, Egan and MacKenzie (1994) conducted a study in order to 
provide normative data for the Cognitive Estimates Test from a representative sample of 
the general population. A Principal Component Analysis resulted in a five-factor 
solution, suggesting that the test does not measure a single factor. In addition, while the 
test demonstrated adequate inter-rater reliability, it was also found to have poor internal 
reliability. From the results obtained, the investigators concluded that the Cognitive 
Estimates Test is psychometrically unsatisfactory. Issues in establishing the validity of 
measures has also been the case where various classic tests of executive function (e.g., 
WCST, COWAT/phonemic verbal fluency, and the Stroop test), have shown sensitivity 
to frontal lobe lesions, but fail to demonstrate specificity to frontal lobe pathology alone 
(Alvarez & Emory, 2006).   
Despite the importance of the various theoretical models of executive function, it 
was not until approximately the last two decades that specific constructs were 
incorporated into the development of clinical and experimental assessments of executive 
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functions. For example, the Behavioural Assessment of the Dysexecutive Syndrome 
(BADS) is an executive function test battery that is specifically designed to assess the 
everyday deficits in executive functioning among clinical groups (Wilson, Alderman, 
Burgess, Emslie, & Evans, 1996) and was developed as a modification of the Six 
Elements Test and Multiple Errands Test (Shallice & Burgess, 1991). It consists of six 
subtests aimed at measuring different facets of executive functioning such initiation and 
task implementation, as well as planning and cognitive flexibility. However, this test 
battery as a whole has been limited in its use when assessing schizophrenia patients 
(Evans, Chua, McKenna, & Wilson, 1997; Katz et al., 2007; Krabbendam, de Vugt, 
Derix, & Jolles, 1999). Findings from Katz and colleagues’ (2007) study confirmed the 
ecological validity of the BADS test battery in its sensitivity and predictive validity in 
determining ‘real-world’ functioning in individuals with schizophrenia. 
Another major difficulty related to the assessment of the executive functions lies 
in the ability for performance on one particular test of executive function in not only 
having predictive value in performance on another test of executive function, but also in 
coping and performance in the functional domains of ‘real world’ contexts (Burgess, 
1997; Burgess et al., 1998). Due to this issue, reduced performance on executive 
function tests may be due to many different reasons and could be independent of actual 
executive dysfunction. It is also possible that individuals may demonstrate adequate 
performance on such measures and still experience significant difficulties in their ability 
to navigate the complex demands of day-to-day life activities (Shallice & Burgess, 
1991). Therefore, incorporating more ‘real-world’ characteristics into specific 
assessment measures has been considered imperative when attempting to make progress 
in this area (Schwartz, Reed, Montgomery, Palmer, & Mayer, 1991; Shallice & Burgess, 
1991). Particular assessment methods have been developed to attempt to achieve this 
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such as in the Modified Six Elements test from the BADS test battery (MSE; Evans et 
al., 1997; Wilson, Alderman, Burgess, Emslie, & Evans, 1996). The MSE aims to assess 
planning abilities by allowing subjects to complete several tasks and navigate their work 
according to their own self-driven plan, as well as a set of prescribed rules. This test has 
been shown to demonstrate superior ecological validity, as well as sensitivity, in 
comparison to other subtests in schizophrenia patients (Evans et al., 1997). There 
appears to be many factors to take into account when considering the more precise and 
effective measurement of specific cognitive domains, particularly in the case of those 
conceptualised to be multi-faceted and fractionable in nature, such as executive 
function. 
Assessing Functional Outcome 
A number of methods have also been employed to assess functional outcome 
status. In order to achieve a more ecological approximation in the measurement of 
executive functions, several approaches have been taken such as the use of 
questionnaires (Bennett, Ong, & Ponsford, 2005; Broadbent, Cooper, Fitzgerald, & 
Parkes, 1982; Burgess, Alderman, Wilson, Evans, & Emslie, 1996), or through 
laboratory tasks approximating real-life situations, such as those tasks used in the 
BADS (Evans et al., 1997; Katz et al., 2007; Krabbendam et al., 1999; Wilson et al., 
1996; 1998). Other means involve observing and assessing the behaviours demonstrated 
by patients in daily activity simulations (Knight, Titov, & Crawford, 2006; Zalla, 
Plassiart, Pillon, Grafman, & Sirigu, 2001; Zhang, Abreu, Seale, Masel, Christiansen, & 
Ottenbacher, 2003). In a study by Rempfer, Hamera, Brown and Cromwell (2003), the 
relationship between performance on various cognitive tests and performance on a 
functional outcome measure, namely the Test of Grocery Shopping Skills (TGSS), was 
examined. The TGSS evaluates the performance of shopping skills within the natural 
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context of a grocery store, with the measure yielding three outcome scores (1) accuracy; 
(2) redundancy (a measure of shopping efficiency); and (3) time. Associations were 
found between shopping accuracy and measures from the first two trials of the Stroop 
test, namely word reading and colour naming. There were also correlations between 
accuracy and verbal recall on the Rey Auditory Verbal Learning Test (Rey, 1964) and 
perseverative errors on the WCST. In addition, ‘redundancy’ while shopping was found 
to be significantly related with poorer performance on three measures of executive 
functioning (WCST total correct and perseverative errors, verbal fluency/FAS, and 
performance on the colour-naming and colour-word trials of the Stroop test). Total time 
on the Letter Cancellation test was also correlated with redundancy. Verbal memory 
was shown to be associated with both shopping accuracy and redundancy. However, 
while this investigative approach provides a good demonstration of the ecological 
validity of certain standardised psychometric tasks, the results of this study were limited 
specifically to the particular skill of independent living that was simulated (e.g., grocery 
shopping). Therefore, addressing real-world functioning in a more precise manner by 
making distinctions amongst the various aspects of social and community living 
activities are warranted. 
Keefe and colleagues (2006) examined the relationship between cognitive 
performance in schizophrenia with functional capacity and functional outcome. In their 
study, functional capacity was assessed using the UCSD Performance-based Skills 
Assessment (UPSA; Patterson, Goldman, McKibbin, Hughs, & Jeste, 2001) and ‘real-
world’ functional outcome was measured using the Independent Living Skills Inventory 
(ILSI; Menditto, Wallace, Liberman, Wal, Jones, & Stuve, 1999). The UPSA requires 
patients to perform a number of tasks reflective of a range of skills considered important 
for functioning in the community. Patients are then rated on their performance on these 
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tasks. The ILSI is a functional assessment tool which also aims to measure an 
individual’s competence in a broad range of skills considered pertinent for successful 
autonomous community living. Ratings are made on the basis of an interview with the 
patient or the reports/observations of care givers. Findings from the study indicated that 
cognitive performance (as assessed by the Brief Assessment of Cognition in 
Schizophrenia (BACS); Keefe, Goldberg, Harvey, Gold, Poe, & Coughenour, 2004), 
was found to be significantly correlated with both functional capacity and real-world 
functional outcome. Results also suggested that measures of cognition and functional 
capacity significantly predicted variance in real-world functional outcome. However, 
only the measures of cognition independently accounted for significant variance in real-
world functional outcome, when compared to the contribution of performance-based 
functional skills. The authors concluded that the latter measure appeared to fail to 
uniquely contribute to real-world outcomes above and beyond that which was accounted 
for by the cognitive performance measures. Results of the study are suggestive that 
performance-based skills assessment may not necessarily have better predictive capacity 
when considering ‘real-world’ functional outcome in schizophrenia in comparison to the 
cognitive measures used.        
While there are a range of methods in assessing functional outcome, it is 
acknowledged that such an assessment can be difficult to achieve through observation 
of real-world performance on activities in a research setting. In addition, the observation 
of performance on specific daily activities is not only time consuming, but is limited to 
the assessment of only the activity or task in question. While skill demonstrations and 
task simulations have their important merits, the number and wide range of daily skills 
thought to be required in successful community functioning would render such an 
approach difficult when attempting to make a thorough assessment. Thus, a critical 
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advantage of the questionnaire method (e.g., the ILSI) is that it permits a more 
comprehensive assessment of functional outcome across a variety of independent living 
skill domains while at the same time allowing for a more resource efficient approach as 
opposed to task simulation methods.  
The Current Study 
It has been widely established that cognitive impairment is a fundamental 
characteristic of the illness of schizophrenia. In addition, the cognitive domain of 
executive function is not only considered to be particularly implicated, but is also shown 
to be significantly related to functional outcome. As cannabis is a commonly used 
substance of abuse in schizophrenia, but in addition has also been found to contribute to 
detrimental effects on the illness’ presentation, the examination of the relationship 
between cannabis use, schizophrenia and neurocognitive performance has clinical 
significance. There is already substantial evidence comparing schizophrenia patients 
with non-schizophrenia controls, demonstrating deficits across different executive tasks. 
Similarly, there is also extensive research demonstrating executive function impairment 
associated with cannabis use. However, there have been some mixed and surprising 
findings in relation to the associations between schizophrenia, cannabis use and 
neurocognition. Contrary to expectation (which has been largely based on the premise 
of well established cognitive deficits associated with the illness of schizophrenia, as 
well as cannabis use alone, thus leading to a hypothesis of additive effects), some of the 
findings that have emerged over the years have suggested that cannabis use in 
schizophrenia is associated with better neurocognitive performances. Factors related to 
variability in sample characteristics, neurocognitive assessment protocols, research 
design, and failure to adequately control for potential confounds have been considered 
as possible contributors to the inconsistent results. 
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Many previous studies have employed measures of executive function which are 
adopted from frontal lobe neuropsychological paradigms based on lesion studies. On the 
whole, it appears that the majority of schizophrenia research regarding cognition has 
failed to adopt comprehensive enough theoretical approaches and assessment 
methodologies in order to adequately tap into the range of executive abilities, and 
therefore fall short of achieving the successful fractionation of the executive function 
system. The current study employed the use several theory-driven selected tests of 
executive function guided by West’s (1996) hierarchical model of executive function. 
The current study proposes to apply a theoretical model of executive function, in 
particular West’s model, to examine the executive functioning of schizophrenia patients 
with a cannabis use history. A verbal fluency and an emotion-based decision-making 
measure were also included in the present study. Verbal fluency (particulary letter 
verbal fluency) has been shown to be sensitive to frontal dysfunction (for review, see 
Parker & Crawford, 1992) and deficits on this measure is found to be consistently 
observed in patients with schizophrenia (Chen et al., 2000, Crawford, Obonsawin, 
Bremner, 1993, Gruzelier, Seymour, Wilson, Jolley, & Hirsch, 1988). In addition, 
emotions are known to play a key role in decision-making processes (Bechara et al., 
1997). These additional components do not appear to be accounted for in West's model. 
Therefore, this assessment approach will permit us to examine executive functioning 
with a range of measures sampling both the conceptualised mechanistic and emotion-
related components of executive function.  
Considering the inconsistency in the literature regarding the assessment of 
executive function, it is important to evaluate and further develop the theoretical 
conceptualisation of this neurocognitive domain that will in turn lead to the better 
refinement, clarification and successful measurement of the construct. As it has been 
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shown in previous research that there are executive functioning deficits in individuals 
with schizophrenia, as well as in individuals who use cannabis, it is important to 
ascertain whether cannabis use in schizophrenia is associated with poorer executive 
functioning and hence greater impairment and poorer adjustment in everyday life. While 
previous studies have examined the relationship between executive function and various 
aspects of functional outcome in schizophrenia, there appears to be a paucity of a 
comprehensive examination of the the link between performance on tests of executive 
function and functional outcome measures amongst the schizophrenia with cannabis use 
population.  
In the first part of the present study, the aim was to identify the relative 
differences in executive functioning associated with cannabis use in schizophrenia 
compared to those which are associated with cannabis use alone. Exploring the pattern 
of executive functioning in schizophrenia patients with cannabis use and non-
schizophrenia controls with a similar cannabis use history will help to tease out such 
differences. Since performance on executive function tests is rarely evaluated for its 
'real-world' significance, in the second part of the study another aim was to examine the 
relationship between performance on the tests selected in the current research and 
ratings on a measure of ‘real-world’ functional outcome. This will enable not only the 
comprehensive evaluation of executive functioning in schizophrenia patients with a 
cannabis-use history, but also allow for the examination of whether performance on a 
range of tests of executive function serve as effective predictors of performance in 
specific ‘real-world’ functional outcome domains. This in turn, will permit an 
evaluation of whether such executive function measures are 'ecologically valid' (i.e., 
reflective of 'real world' abilities and adjustment). The assessment of this clinical 
population with ecologically valid measures may therefore help to better inform and 
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guide future treatment planning. This may be achieved by being able to more precisely 
identify the various executive functioning components thought to more closely relate to 
the specific functional skills that are required for successful independent living. From 
the results of the study, it is hoped that through the neurocognitive sub-typing of 
individuals with schizophrenia who use cannabis, specific cognitive rehabilitation 
and/or behavioural strategies can be better directed and consequently help to assist in 
the prediction of those who are more likely to successfully respond to such intervention. 
Hypotheses. The aims of the current study will thus be achieved by dividing the 
study into two parts. Part A of the study specifically aimed to examine the relative 
differences in executive functioning associated with cannabis use in schizophrenia 
patients, in comparison to individuals with no psychiatric or mental illness diagnoses 
with a similar pattern of cannabis use. It was predicted that schizophrenia patients with 
cannabis use will demonstrate poorer performance in constructs of executive 
functioning, compared to healthy controls with a similar cannabis use history. Further, 
performances falling greater than 1.0 standard deviation below normative mean criteria 
will be described in schizophrenia patients with cannabis use, compared to controls. In 
addition, it was hypothesised that the discontinuation or abstinence from cannabis use 
will be associated with the recovery of executive function (i.e., ‘non-current users’ will 
demonstrate significantly better performance on executive function measures than 
‘current’ users). It was also predicted that former users who have ceased their cannabis 
use for a longer period of time will have significantly better executive function 
performance, in comparison to those individuals who have ceased cannabis use for a 
shorter period of time.  
 Part B of the study aimed to further our understanding of the functional 
outcome correlates associated with the executive functioning of schizophrenia patients 
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with cannabis use, relative to matched-control subjects with a similar cannabis use 
history. The investigation into the relationship between the executive function 
components belonging to West’s (1996) model and functional outcome is exploratory in 
nature. However, due to reports of a significant association between executive function 
and functional outcome in the literature, it is predicted that executive function scores 
will have a significant relationship with functional outcome ratings. More specifically, it 
was hypothesised that executive function scores will have significant predictive ability 
in relation to functional outcome ratings. 
 
Method 
Participants 
Participants included in the current study were aged between 18 and 55 years. 
Schizophrenia patients were recruited as outpatients from public mental health services 
in South Australia. Clinical participants were eligible for the study if they had a current 
diagnosis of schizophrenia according to the DSM-IV (American Psychiatric 
Association, 2004), which was verified by the patient’s clinical file information upon 
their consent. Control subjects were eligible for the study if they did not have any 
current psychotic, anxiety, or mood disorder diagnoses. While this was based on the 
self-report of the healthy control group, subjects were also screened for elevated and 
clinically significant levels of depression, anxiety and stress symptoms (see below for 
further detail regarding the determination of the presence of group differences in 
depression, anxiety and stress symptoms). An overall sample of 76 was recruited for the 
study. However, data from 4 participants in the schizophrenia group were excluded 
from the study due to these individuals not having a reported cannabis use history. Due 
to the total sample size of this subgroup being too low, the maintenance of these cases 
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in the final data set was considered insufficient for meaningful between-subject 
statistical analyses to be conducted. Data from an additional participant from the 
schizophrenia patient group who did however have a reported history of cannabis use, 
was also excluded due to the participant not being able to complete the full 
neurocognitive battery. It was observed by the researcher that the participant 
demonstrated significant difficulty in being able to understand the instructions of the 
psychometric measures and was therefore assessed to be ineligible for the continuation 
of testing. Data from two schizophrenia patients with cannabis use were also excluded 
from the study, due to these participants not being able to be adequately matched to a 
corresponding control subject on the matched variables. In addition, data from 13 
otherwise healthy control subjects with cannabis use were also excluded from the study, 
due to these participants not being able to be adequately matched to a corresponding 
schizophrenia patient on the matched variables. The final sample included 28 
individuals with schizophrenia (both former and current users) who had a regular 
cannabis use history and 28 matched-controls (both former and current users) with a 
similar cannabis use history. The process of recruiting matched controls involved 
finding a suitable matched pair for an already recruited patient subject. Premorbid IQ 
was matched with a suitable pair within +/- .05 standard deviation (SD) of the 
schizophrenia patient’s score. The age, years of education, severity/quantity, duration, 
and time since cessation variables were matched with a suitable pair in the control 
groups within +/- 1.0 SD of the schizophrenia patient’s score. The frequency variable 
was matched with a suitable pair according to frequency group category (i.e., light users 
≤ 2 times per week; heavy users ≥ 3 times per week). Gender was equally matched 
between groups. While the +/- 1.0 SD matching criteria was acknowledged to be much 
less conservative than a +/- 0.5 SD matching criteria, it was considering necessary due 
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to the large variability found in such variables and consequently attempting to match 
within +/- 0.5 SD would have made the process increasingly more difficult considering 
the timeframes and resources available. However, independent sample t-tests indicated 
that no significant differences were found between groups on the cannabis use 
parameters (all p’s > .05), suggesting that the two groups were well matched on all of 
these indicators of cannabis use. Participants were considered to be regular cannabis 
users if they used cannabis for more than 2 years duration, with a frequency of use of 
one or more days per week. Further, 34 participants (17 schizophrenia patients and 17 
matched-controls) who reported regular cannabis use in their history, were currently 
abstinent at the time of testing. In addition, 22 participants (11 schizophrenia patients 
and 11 matched-controls) who reported to be regular users of cannabis were current 
users at the time of testing. All participants were required to provide written informed 
consent, as well as have the physical capacity to participate in cognitive assessment.  
Participants with ages falling outside the range of 18 to 55 years, who had any 
other mental illness diagnoses (other than schizophrenia for the patient group only), a 
medical history of head or brain injury, a history of neurological disorder, or an 
intellectual or developmental disability, were excluded from the study. Subjects who 
regularly used other drugs of dependence or had a history of alcohol abuse/dependence 
were also excluded from the study. This criteria was assessed in a structured interview 
(see Appendix A) via self-report. Participants were required to abstain from cannabis 
use for at least 24 hours prior to testing (if still a current user), as well as abstain from 
the consumption of caffeine and nicotine use within 1 hour of testing. Adherence to the 
24-hour and 1-hour abstinence period was assessed using self-report. Participants were 
also required to be proficient in understanding and speaking the English language. All 
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participants were given a $25 Coles-Myer voucher as a token of appreciation for their 
participation in the study. 
The sociodemographic characteristics of the two groups are detailed in Table 1. 
Independent sample t-tests indicated that no significant differences were found between 
groups on the sociodemographic variables (all p’s > .05), suggesting that the groups 
were well matched on all of these characteristics. No significant difference was found 
between groups in nicotine use (p > .05). The groups also did not significantly differ on 
self-reported depression, anxiety or stress symptoms (as measured by the Depression 
Anxiety Stress Scales (DASS); S. H. Lovibond & P. H. Lovibond, 1995) (all p’s >.05). 
It was noted that the between group differences in reported anxiety symptoms 
approached significance (p = .052). However, the mean ratings for the schizophrenia 
group fell in the moderate range for depressive and anxious symptomatology and in the 
mild range for stress symptomatology. Mean ratings for the matched-controls group fell 
in the mild range for depressive, anxious and stress symptomatology. A chi-square test 
for goodness of fit examining symptom categories (as assessed by the the Structured 
Clinical Interview for the Positive and Negative Syndrome Scale (SCI-PANSS); Kay, 
Fiszbein & Opler, 1987) indicated that there was no significant difference in the 
proportion of schizophrenia patients with cannabis use, falling in either the positive 
symptom subtype or negative symptom subtype category, χ2(1, N = 27) = .333, p= .564, 
w = .111. All but one schizophrenia patient were taking antipsychotic medications. Four 
patients were taking typical antipsychotics, 16 were taking atypical antipsychotics, 7 
were on combined therapy (i.e., taking both typical and atypical antipsychotic 
medications), and 1 patient was currently not taking any medication. 
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Table 1. Sociodemographic characteristics of the sample 
 Total 
(N=56) 
Schizophrenia Patients  
(n=28) 
Matched Controls 
(n=28) 
 Mean (SD) Mean (SD) Range Mean (SD) Range 
Age 34.50 (7.20) 34.57 (7.71) 23-51 34.43 (6.78) 25-49 
Male:Female 38:18 19:9  19:9  
Years of 
Education 
11.83 (1.77) 11.77 (2.05) 8.0-16.0 11.89 (1.47) 9.0-14.0 
Estimated 
Premorbid IQ 
99.09 (6.17) 98.75 (7.02) 82-108 99.43 (5.31) 88-107 
Nicotine Use 11.21 (10.76) 13.50 (13.16) 0-40 8.93 (7.19) 0-25 
Frequency 
(days per week) 
5.43 (2.08) 5.61 (2.15) 1.0-7.0 5.25 (2.03) 1.0-7.0 
Severity 
(grams) 
1.42 (1.03) 1.44 (1.21) .25-5.0 1.39 (.82) .25-4.0 
Duration 
(years) 
13.14 (8.85) 13.57 (10.04) 2.0-38.0 12.71 (7.64) 3.0-33.0 
Time Since 
Cessation 
(years) 
3.63 (5.40) 3.71 (5.74) .00-28.0 3.55 (5.14) .00-25.0 
DASS      
   Depression 13.18 (11.23) 16.00 (13.84)  0-42 10.36 (6.99) 0-20 
   Anxiety 9.98 (7.80) 12.00 (9.36) 1-30 7.96 (5.27) 0-14 
   Stress 12.88 (8.57) 14.21 (10.02) 0-34 11.54 (6.74) 0-24 
PANSS      
   Positive  18.25 (6.97) 7-36   
   Negative     18.79 (5.71) 10-33   
   General  39.18 (12.07) 16-69   
   Composite  -.54 (4.84) -9-12   
 
 Recruitment 
Advertisements (see Appendix B: (i) and (ii)) were distributed to the Royal 
Adelaide Hospital, the Queen Elizabeth Hospital, Lyell McEwin Hospital Service, 
Flinders Medical Centre, various local public mental health service locations (Port 
Adelaide Mental Health Service, Beaufort Clinic, Southern Mental Health Service, 
Adaire Clinic), a community-based mental health organisation (The Mental Illness 
Fellowship of South Australia), mental health community centres and supported 
residential facilities, requesting for patient volunteers willing to participate in the 
current research study. The contact details of the researcher were provided for any 
prospective patient participants to contact in order to express their interest. The 
advertisement also informed potential participants that a form could alternatively be 
completed and posted at the reception desk (found in each location) in order for the 
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participant to leave their contact details should they wish to be contacted by the 
researcher instead. An information sheet about the study (see Appendix C) was then 
provided through reception, upon request. In addition, the researcher attended the local 
clinics on a arranged basis in order to be available to talk to individuals who were 
interested in participating in the study.  
Advertisements (see Appendix D) were also posted in various locations in the 
local community (e.g., shopping/public community centre notice boards) requesting for 
otherwise healthy control volunteers willing to participate in the research study. 
Potential control subjects were initially screened using a telephone interview gathering 
demographic details and information pertaining to patterns of cannabis use. Once 
individuals were deemed eligible for inclusion in the study, an appointment time was 
scheduled to attend a testing location in order to be assessed and an information sheet 
(see Appendix E) was then sent out to the participant via post.  
The current study employed a matched-control design to ensure that any 
individual differences occurring between groups (outside of the variables of interest), 
were controlled for. Due to the variation in indices of cannabis use (i.e., frequency, 
severity/quantity, duration and time since last use), the interpretation of results based on 
comparisons between groups is made more difficult. Therefore, the current study aimed 
to take these indices into account when matching control subjects. Control subjects were 
matched with schizophrenia subjects based on age, gender, years of education, 
estimated premorbid IQ, frequency of cannabis use, severity of cannabis use, duration 
of cannabis use and time since cannabis use cessation. 
Measures 
Demographics. The demographic information gathered included age, gender, 
years of education, medical history (e.g., head/brain injury, neurological conditions, 
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stroke, cardiac problems etc.), medication, frequency, severity/quantity, duration of 
cannabis use, time since cessation (if relevant), as well as other types of drugs used and 
their patterns of use. Average days of use per week, average grams consumed per using-
day (where 1 joint was estimated to be .5 grams (Zeisser et al., 2011); and 1 cone was 
estimated to be .25 grams), years of use, and years since last use were determined as 
measures of frequency, severity/quantity, duration and time since cessation, 
respectively. This was assessed through the structured interview conducted prior to 
neurocognitive testing. This information was also gathered to assess the exclusion 
criteria.  
Clinical symptoms. To assess the positive and negative symptom profile of the 
schizophrenia group, the Structured Clinical Interview for the Positive and Negative 
Syndrome Scale (SCI-PANSS) was administered. The SCI-PANSS was used to 
evaluate the presence and severity of positive, negative and general symptoms of 
schizophrenia. Thirty items were rated on a 7-point scale from 1 = absent to 7 = extreme 
and total scores were then calculated for the positive, negative and general symptom 
areas. High internal reliability (r = .73 - .83) (Kay et al., 1987; Kay, Opler, & 
Lindenmayer, 1988) is reported across each scale of the instrument.    
To assess whether there were any significant differences between groups in 
affective state the Depression Anxiety Stress Scales (DASS; S. H. Lovibond & P. F. 
Lovibond, 1995) was administered. The DASS is divided into 3 scales (constituting 14-
items each) which correspond to the syndromes of depression, anxiety and stress. Each 
syndrome has been found to be correlated, but distinct from each other (P. F. Lovibond 
& S. H. Lovibond, 1995; S. H. Lovibond & P. F. Lovibond, 1995). Subjects were asked 
to indicate the presence of symptoms occurring over the past week only, with responses 
to the items based on a 4-point severity/frequency scale, ranging from ‘did not apply to 
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me at all’ (0) to ‘applied to me very much, or most of the time’ (3). The DASS has been 
reported to have internal reliability coefficients of r  = .87 - .95. 
Neuropsychometric battery. Standardised measures of estimated premorbid 
intelligence and executive function were chosen from the Behavioural Assessment of 
the Dysexecutive Syndrome (BADS; Wilson et al., 1996), the Delis-Kaplan Executive 
Function System (D-KEFS; Delis, Kaplan, & Kramer, 2001), the Wechsler Adult 
Intelligence Scale – Third Edition (WAIS-III; Wechsler, 1997), and also included tests 
modified or developed by previous researchers (e.g., Num, 2006). Considering a 
number of tests used in the current study originate from well validated test batteries, the 
validity of the batteries themselves will be discussed first. Individual test information 
will then be further discussed in the sections following.  
The main purpose of the BADS battery was to predict the presence and severity 
of everyday executive problems amongst brain injured groups. The technical manual 
reports correlations (using Pearson’s method), between the BADS profile score, each of 
the six individual subtests, age, the National Adult Reading Test - Second Edition 
(NART-II; Nelson & Willison, 1991), and WAIS FSIQ, with others’ and self-ratings on 
the Dysexecutive Questionnaire (DEX) for a brain injured patient group. The degree of 
insight, which is measured by the discrepancy between others’ and self-ratings is also 
reported. Significant moderate negative correlations between each of the six individual 
subtests and others’ ratings of executive problems were found. The negative correlations 
indicate that satisfactory performance on any subtest in the BADS is indicative of low 
ratings by significant others who know the patient well regarding the presence or 
severity of executive problems, demonstrating the construct and predictive validity of 
the BADS tests in detecting every day executive problems. Katz and colleagues (2007) 
examined the construct validity and sensitivity of the BADS in differentiating between 
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different types of schizophrenia patients. The predictive validity of the BADS with 
regard to functional outcomes within the outpatient group was also examined. 
Performances were compared between adult schizophrenic inpatients who were in an 
acute episode of the illness, adult schizophrenic outpatients who were in the more 
chronic stages of the illness, and healthy control subjects. Results of the study showed 
not only significant differences between schizophrenia patients and control subjects, but 
also between both of the schizophrenic patient groups such that patients in the 
outpatient (chronic) group demonstrated greater executive function deficits. It was also 
found that within the outpatient group that performance on the BADS significantly 
predicted Independent Activities of Daily Living (IADLs) and communication outcome 
areas. These results were demonstrated to be beyond that which was accounted for by a 
measure of basic cognitive skills. Not only do the results of the study show the BADS to 
be a valid measure in the assessment of executive function of individuals with 
schizophrenia by distinguishing between patients and healthy subjects, but in addition 
distinguishing between patients with differing illness phases.    
The technical manual for the D-KEFS (Delis et al., 2001) reports evidence for 
the validity of the D-KEFS measures. The range of tests included in the current study 
(see below for further discussion of specific tests used) are those which were either 
developed by the test authors or modified versions of well-established, standardised 
executive function measures. The modified D-KEFS instruments (i.e., versions of the 
Stroop test, Trail Making Test, verbal and design fluency tests, Tower Task, the 
Twenty-Questions test, and proverb interpretation) have demonstrated validity 
evidenced across a number of neuropsychological studies spanning over 50 years. 
Reviews of these studies are reported in Lezak (1995, cited in Delis et al., 2001, p. 47) 
and Spreen and Strauss (1998, cited in Delis et al., 2001, p. 47). Validity studies have 
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also indicated that various D-KEFS measures have reasonable sensitivity in the 
assessment of executive functioning of different clinical populations which include 
patients with focal frontal-lobe lesions (Baldo, Shimamura, Delis, Kramer, & Kaplan, 
2001; Delis, Squire, Bihrle, & Massman, 1992; Dimitrov, Phipps, Zahn, & Grafman, 
1999), as well as schizophrenia (Beatty, Jocic, Monson, & Katzung, 1994; Savla, 
Twamley, Thompson, Delis, Jeste, & Palmer, 2011). The current study only selected 
those tests from the D-KEFS that were modifications of pre-existing, long-standing 
clinical tests with proven validity.  
The WAIS-III is a popular and widely used scale of intellectual ability. In a 
study conducted by Dickinson, Iannone and Gold (2002), exploratory and confirmatory 
analyses revealed that a four-factor model of WAIS-III performance (which was similar 
to that reported by the developers of the scale), adequately fit data from a sample of 
schizophrenia patients. In fact, the factor structure suggested by the developers (i.e., 
with correlated factors for verbal comprehension, perceptual organisation, working 
memory, and processing speed) fit the clinical sample just as well as it did for the 
comparison sample of non-clinical subjects. These results suggest the construct validity 
of the scale and its subtests in the assessment of individuals with schizophrenia.    
The test selections in the current study were guided by West’s (1996) model of 
executive functioning and were also similar measures to those used in Num’s (2006) 
study. A total of 12 tests were administered, including a measure of estimated 
premorbid intelligence and 11 measures of executive functioning. All of the tests were 
in paper-and-pencil format, with some verbal responses recorded on a tape recorder, and 
time recorded using a stopwatch. All scores from the standardised tests used were 
converted to standard scores based on norms which were reported in each test manual.  
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Premorbid intelligence. The National Adult Reading Test - Second Edition, 
(NART-II; Nelson & Willison, 1991), was administered to assess estimated premorbid 
intelligence and to determine if any differences in premorbid general cognitive ability 
existed between groups. The NART-II consists of a list of 50 irregularly spelt words in 
the English language. In this test, the reader is required to ‘know’ the word, rather than 
rely on phonology in order to be able to read it correctly (e.g., ‘topiary’). Scores 
represent the number of correct responses, with higher scores representing higher 
estimated premorbid intelligence. The NART  test manual reports a test-retest reliability 
of r = .98.  
Crawford and colleagues (1992) aimed to determine whether the National Adult 
Reading Test would provide a valid estimate of premorbid intelligence in a sample of 
schizophrenia patients. The overall sample comprised of a group of patients who resided 
in long-stay wards and a group of patients residing in the community. Schizophrenia 
subjects were individually matched with healthy control subjects on the variables of 
age, sex, and education. Findings from the study indicated that a significant discrepancy 
was found between the two IQ measures administered, where current WAIS IQ scores 
were significantly lower than NART-derived estimated premorbid IQ scores. Such 
results indicated a decline in cognitive functioning was present in the sample. These 
results are indicative of the NART measure providing a valid measure of estimated 
premorbid IQ in a schizophrenia sample. O’Carrol et al. (1992) also found NART 
scores estimated significantly higher IQ scores than a current measure of IQ (i.e., the 
Wechsler Adult Intelligence Scale - Revised (WAIS-R); Wechsler, 1981) in a 
schizophrenia patient sample. Results of the study were consistent with Crawford et 
al.’s (1992) findings.  
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Executive Function  
The temporal organisation of behaviour. Two measures of the temporal 
organisation of behaviour were used: the Zoo Map task from the BADS (Wilson et al., 
1996), and the Modified Six Elements test also from the BADS. In the Zoo Map task, 
participants were required to plan and execute a trip on a map of a zoo visiting various 
locations which were specified prior to commencing the test. They were also required to 
follow rules involving using designated paths with which some can be travelled along 
multiple times and others only once. Other rules in the task required the participant to 
begin the trip at the entrance and finish at the picnic area. Two trials of the task were 
administered. The first trial is of high demand (i.e., participants are required to negotiate 
the trip independently) and the second trial is of low demand (i.e., participants are given 
directions as to the route required). Scores on this measure reflected overall planning 
time (i.e., the time that has elapsed between the participant finishing reading the 
instructions and when they began the trial), the total time to complete the trial itself, the 
number of places correctly visited and number of rules correctly adhered to. A profile 
score was then calculated reflecting the extent to which participants followed the correct 
path sequence minus error deductions, with a low profile score reflecting poor planning 
and temporal organisation of behaviour. The BADS manual reports the Zoo Map test to 
have inter-rater reliabilities of r = .88 – 1.0 and a test-retest reliability correlation of r = 
.39. 
The Modified Six Elements test comprised of six sub-tasks which require the 
solving of two sets of arithmetic problems, the identification of pictures in two sets of 
picture booklets, and two verbal tasks involving dictation (e.g., one task describing the 
best holiday the participant has ever experienced and the second task describing any 
memorable event in their life). Participants were required to attempt each task within an 
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allocated 10-minute period and attempt to spend equal amounts of time on each task. 
However, participants were not allowed to attempt two tasks from the same superset 
consecutively (e.g., not attempting two arithmetic tasks in a row). If the participant 
failed to attempt every task within the allocated 10 minutes, if they spent more than 271 
seconds on a single task, or if the participant attempted two tasks from the same 
superset consecutively, then errors were incurred. A profile score was calculated based 
on the number of tasks completed minus error deductions. A high profile score on this 
measure reflected higher planning and temporal organisation of behaviour ability. For 
this test, inter-rater reliabilities of r = .90 – .97 and a test-retest reliability of r = .33 is 
reported. 
Retrospective memory. Retrospective memory was assessed using two  
measures: memory for items from the Zoo Map task from the BADS (which assessed 
task-specific retrospective memory), and the Digit Span subtest from the WAIS-III. 
Measures of task-specific retrospective memory were derived from Num’s (2006) study. 
For memory for items from the Zoo Map task, participants were required to remember 
the places they were asked to visit in the original Zoo Map task. Scores ranged from 0 to 
7, with higher scores representing higher retrospective memory performance. 
In the Digit Span subtest of the WAIS-III, participants were read a series of 
numbers and were required to repeat them back to the examiner in sequence. The length 
of the series of numbers was increased until the participant was no longer able to repeat 
them back to the examiner in correct sequence across two trials. Two forms of digit-
spans were presented, one in which the participant was required to repeat the series of 
numbers forwards and the other in which the participant was required to repeat the 
series of numbers in reverse order to how they were verbally presented. Each length of 
number series has two trials, with participants obtaining 1 point if they passed only one 
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trial and 2 points if they passed both trials. The maximum score on digits forwards is 16 
points and maximum score on digits backwards is 14 points. The sum of digits forwards 
and backwards gave a total Digit Span score. Higher scores on this measure represented 
higher retrospective memory performance. The Digit Span subtest has a test-retest 
reliability correlation of r = .90. 
Prospective memory. For the current study, an event-based prospective  
memory task was used. This measure was also derived from Num’s (2006) study. In the 
event-based prospective memory task, participants were informed at the beginning of 
neurocognitive testing to place a paperclip into a plastic cup at the completion of every 
second task administered throughout the testing session. Paperclips and the plastic cup 
were positioned in front of the participant on the table used for test administration. 
Scores ranged from 0 to 6, with higher scores reflecting higher performance on 
prospective memory.  
Interference control. Interference control was assessed using two measures:  
the Symbol Search subtest from the WAIS-III, and the Trail Making Test from the D-
KEFS. In the Symbol Search test, participants were required to indicate whether either 
of two symbols which were printed on the left of the page, were present in a row of a 
five symbols printed on the right of the page. They were given a time limit of 120 
seconds to complete as many rows (trials) as possible. Scores represented the number of 
trials completed correctly minus the number of incorrect trials, with higher scores 
indicating an increased ability to control for interference. The Symbol Search test has a 
test-retest reliability correlation of r = .77. 
Trial 4 of the Trail Making Test from the D-KEFS was also used to assess 
interference control. In this trial of the Trail Making Test, the participant was presented 
with an array of 16 circles with consecutive numbers in them and 16 circles with 
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consecutive letters in them. Participants were required to join the numbers and letters 
with a continuous line, by alternating between them (e.g., 1-A-2-B-3-C and so forth) in 
the quickest time possible, without sacrificing accuracy. Scores represented the number 
of errors and the time taken to complete the task. If the participant took longer than 240 
seconds then they were required to stop completion of the task. Higher scores reflected 
a lower ability to control interference. A Trial 4 Contrast score was also calculated to 
provide a measure of the time taken to complete Trial 4 divided by the time taken to 
complete both Trial 2 and Trial 3 (which provide an index of visuo-motor speed). Trial 
2 of the TMT involved joining an array of circles with consecutive numbers in them 
with a continuous line, in sequence and in the quickest time possible. Trial 3 of the 
TMT involved joining an array of circles with consecutive letters in them with a 
continuous line, in sequence and in the quickest time possible. Both Trial 2 and Trial 3 
were administered prior to the participant commencing Trial 4 as part of an overall 
TMT subtest administration procedure. The D-KEFS manual reports a test-retest 
reliability correlation of r = .36 for this trial. 
Inhibition of prepotent responses. The inhibition of prepotent responses was 
assessed using two measures: the Color-Word Interference subtest (D-KEFS) and a 
modified version of the Rule Shift card test from the BADS. Trial 3 of the Color-Word 
Interference subtest was used in the current study, which is a variant of the Stroop test. 
In this trial, participants were presented with a page of names of colours which were 
printed in incongruent coloured ink. The participant is asked to name the colour of the 
ink that each word is printed in, as quickly as possible but not naming the actual word 
printed. The time taken to complete the trial, as well as the number of errors, was 
recorded. A higher score reflected a lower ability to inhibit a prepotent response. In 
addition, a Color-Word Trial 3 Contrast score was calculated to provide a measure of 
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the time taken to complete Trial 3 divided by the time taken to complete Trial 1 (which 
is an index of processing speed). Trial 1 of the Color-Word subtest required the 
participant to name colours (presented as colour patches on the page) in the quickest 
time possible. Trial 1 was administered prior to the participant commencing Trial 3 as 
part of the overall Color-Word Interference subtest administration procedure. Test-retest 
reliabilities are reported to be in the moderate to high range (r = .60 - .90). 
A modified version of the Rule Shift card test from the BADS was derived from 
Num’s (2006) study. In this task, participants were provided with a booklet of 20 
playing cards which were presented in random order throughout the booklet. In the first 
trial, the participant was required to say ‘yes’ if the colour of the card suit was red and 
‘no’ if the colour of the card suit was black, until the participant went through all of the 
cards in the booklet. Using the same 20-card booklet, on the second trial participants 
were required to say ‘yes’ if the colour of the card suit was black and ‘no’ if the colour 
of the card suit was red. In the third trial (which was a modified addition to the original 
test), participants were required to once again go through the booklet and say ‘yes’ if the 
card colour was the same colour as the previous card and ‘no’ if the card colour was 
different to the colour of the card previously presented. In the fourth trial (also a 
modified addition to the original test), participants were required to say ‘no’ if the card 
colour was the same colour to the previous card and ‘yes’ if the card colour was 
different to the colour of the card previously presented. The participant was required to 
go through each trial as quickly as they could, without sacrificing accuracy. The overall 
time taken to complete each trial, as well as the number of errors, was recorded. Profile 
scores were calculated for performance on trial 2 and trial 4 of the test by the summing 
the number of errors incurred minus an error deduction if the completion time on either 
of these two trials was over 67 seconds. A Rule Shift Trial 2 and 4 combined score was 
CANNABIS USE, SCHIZOPHRENIA & EXECUTIVE FUNCTION  86 
 
calculated to represent the average score across both trials. A lower profile score 
reflected a lower ability to inhibit a response. A test-retest reliability coefficient of r = 
.76 is reported for the original version of this test. 
Verbal fluency. The Letter Fluency subtest of the D-KEFS was used to assess 
verbal fluency. Participants were asked to generate as many words as they could, 
beginning with a specified letter (e.g., F, A, S), within a timeframe of 60 seconds for 
each letter. Participants were asked to exclude proper nouns, numbers, and multiple 
forms of the same word. The total score was the number of correct responses summed 
across the three letters. Sound internal consistency is reported for this subtest ranging 
from .60 to .90, as well as adequate test-retest reliability (r = .60 - .90).  
Emotion-based decision-making. The Iowa Gambling Task (IGT; Bechara et al., 
1994) was used to measure emotion-related decision-making. A computerized version 
of the IGT was administered where participants were required to choose between decks 
of cards which yielded high immediate gains but large future loss, and decks which 
yielded lower immediate gains but a smaller future loss. The goal of the task was to 
optimise profit on a loan of play money. Participants were presented with four decks of 
cards (1, 2, 3 & 4), and were given a $2000 loan of play money. Participants were 
informed that the game requires a series of card selections, one card at a time, from any 
of the four decks, until they were told to stop (which was after 100 trials). Decks 1 and 2 
were ‘disadvantageous’ because they resulted in larger overall loss, whereas decks 3 
and 4 were ‘advantageous’ because they resulted in larger overall gain. A total score 
was calculated by subtracting the total number of cards selected from the two 
disadvantageous decks from the total number of cards selected from the two 
advantageous decks. Lower total scores reflected poorer decision-making abilities. 
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The ability of the IGT to detect decision-making impairments has been demonstrated 
across a variety of clinical samples which have included populations with VPFC lesions 
(Bechara et al., 1994; Bechara et al., 1997; Bechara et al., 2001; Ernst, Grant, London, 
Contoreggi, Kimes, & Spurgeon, 2003). These findings are suggestive of the construct 
validity of this test. More specifically to the current study, individuals with 
schizophrenia have been found to demonstrate a distinct pattern of impaired decision-
making (as assessed by the Iowa Gambling Task), that is somewhat different to that 
found in patients with OFC lesions, as well as healthy participants (Ritter et al., 2004; 
Shurman et al., 2005). Published reliability information on the computerised version of 
the test is not available and internal consistency on this measure is difficult to calculate 
due to the IGT not consisting of test items that usually make up conventional 
neuropsychological tests (Dunn, Dalgleish, & Lawrence, 2006). There are also 
difficulties examining the reliability of the measure as the ability to assess the temporal 
stability of the test could be potentially impacted by practice effects on retesting 
(Beulow & Shur, 2009).  
Functional outcome. The Independent Living Skills Inventory (ILSI; Menditto 
et. al., 1999), was used to measure functional outcome. This inventory measures the 
extent to which individuals are able to perform competently on a broad range of skills 
which have been found to be important for successful community living. The inventory 
was completed on the basis of obtaining ratings from the patient’s key worker or 
community support worker. The original version of the ILSI included 89 items divided 
into 11 subscales. Items assessed a range of skills including personal management, 
hygiene and grooming, clothing, basic skills, interpersonal skills, home maintenance, 
money management, cooking, resource utilisation, general occupation skills and 
medication management. Each item was rated in relation to the extent in which the 
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individual was considered to be able to perform particular skills in conjunction to the 
extent in which assistance or support is required. Ratings ranged from ‘No Competence’ 
(0) to ‘Independent Competence’ (3). A total ILSI score was calculated as the average 
score across all of the ILSI subscales. The present study used the current version of the 
inventory which contained 55 items. The shorter version was based on the psychometric 
properties of items from the original scale, as well as on the feedback from raters about 
their usefulness. The internal consistency among the items of the orginal version of this 
scale is 0.82 (Cronbach’s coefficient alpha). This measure has been used in previous 
research investigating the relationship between cognitive impairments in individuals 
with schizophrenia and 'real-world' functional outcome (Keefe et al., 2006). As the 
matched-control participants were not clinical patients, the measure was completed as a 
self-report questionnaire by these subjects.     
Procedure 
After patient participant recruitment, an information sheet about the study was 
provided and a mutually convenient time for testing was scheduled. Testing took place 
at various local public mental health service suburban clinics. At the beginning of each 
testing session, participants were informed that participation was voluntary and they had 
the right to withdraw at any given time. Informed consent was then obtained (see 
Appendix F). The structured interview gathering demographic information was 
conducted after informed consent was obtained and this took approximately 10 minutes 
to complete. The DASS and the SCI-PANSS were administered afterwards, taking 
approximately 30 minutes to complete. Neurocognitive testing followed taking 
approximately 60 to 90 minutes to complete. Tests were administered in a standardised 
order so as to minimize measurement error due to test order interaction. A break was 
also provided to participants depending on the level of participant motivation and 
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fatigue demonstrated/reported. All testing was completed by the researcher who is a 
registered psychologist and has professional training in the administration and scoring 
of neuropsychometric assessments, as well as additional professional training in the 
administration and scoring of the SCI-PANSS. The Independent Living Skills Inventory 
was given to the rater which was nominated by the patient participant as being able to 
give the most accurate evaluation of their independent living skills. This questionnaire 
was then returned to the researcher via post by a self-addressed stamped envelope which 
was either provided to the participant at the time of testing or posted directly to the 
nominated rater.  
The matched-control subjects underwent a similar procedure. Testing took place 
at one of the available testing locations selected by the participant. Informed consent 
was obtained prior to the testing session (see Appendix G) and overall testing time for 
this group of participants was approximately 60 to 90 minutes. The SCI-PANSS was 
not administered to this group. For matched-control subjects, the Independent Living 
Skills Inventory was self-completed in their own time and then sent back to the 
researcher via post.   
Debriefing information (see Appendix H) was given at the conclusion of testing 
detailing the use of the obtained data from the research. 
 
Results 
Data Screening  
Prior to testing hypotheses, data was entered into a statistical analysis program, 
SPSS Version 22.0 (2013), and checked for missing values, outliers and departures from 
normality. There were no missing values in the final data set. Outliers were detected on 
two variables, Color-Word Trial 3 and the Iowa Gambling Task. The distributions of 
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these variables were Winsorised whereby the ranks of extreme scores (i.e., values 
falling outside of 3.29 standard deviations from the mean) were maintained by assigning 
them a value of the closest score that was not greater than 3.29 standard deviations from 
the mean (for discussion, see Erceg-Hurn & Mirosevich, 2008; Field, 2009). Two scores 
on the Color-Word Trial 3 variable and one score on the Iowa Gambling Task variable 
were dealt with using this protocol in order to maintain the integrity of the data and 
protect against any departures from normality. Following winsorisation of these 
variables, normality was achieved. Further data screening demonstrated that there were 
no departures from normality on any of the other variables. 
Part A 
Group Differences in Executive Function   
As the first aim of the current study was to determine if schizophrenia patients with 
cannabis use demonstrate poorer performance in constructs of executive functioning 
compared to a matched-control group with a similar cannabis use history, the focus of 
the initial statistical analyses was to compare the executive function performance of 
these two groups. For further exploration, the proportion of schizophrenia patients with 
cannabis use which demonstrated executive function performance falling in the 
‘impaired’ range (compared to normative criteria), was described. Prior to analyses, 
standardised scores (z) were calculated using normative means and standard deviations.  
However, as Zoo Map recall, Rule Shift Trial 4, the Rule Shift Trial 2 and 4 combined 
score, and the event-based prospective memory task did not have normative mean 
criteria available, scores relating to these measures were left in their original form. In 
order to examine the executive function performances of schizophrenia patients with 
cannabis use, relative to matched-controls with a similar cannabis use history, a series 
of Analysis of Covariance (ANCOVA) analyses were conducted to determine the effect 
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of Group on executive function performance when accounting for the effects of 
premorbid IQ. Examination of Shapiro-Wilk statistics and histograms for each group 
indicated that the ANCOVA assumption of normality was supported. Scatterplots 
indicated that the relationship between the covariate (premorbid IQ) and the dependent 
variables (performance on the individual executive function measures) was linear. 
Finally the assumptions of homogeneity of regression slopes and homogeneity of 
variances were supported by the absence of a significant interaction between the 
independent variable and the covariate. The ANCOVA results will be categorised 
according to the executive function components defined by West’s (1996) hierarchical 
model of executive function specifically: (i) the Temporal Organisation of Behaviour, 
(ii) Retrospective Memory, (iii) Interference Control, (iv) the Inhibition of Prepotent 
Responses and (v) Prospective Memory. Performance in the additional executive 
function domains included in the current study that were not outlined in West’s model, 
specifically verbal fluency and emotion-based decision making, will also be discussed. 
Table 2 displays the results of the covariate analyses of executive function performance 
for the schizophrenia group with cannabis use and matched-control group with a similar 
cannabis use history, with premorbid IQ as a covariate. Premorbid IQ was found to have 
an impact on Modified Six Elements, Digit Span and Letter Fluency task performance. 
However, the main effects of Group remained significant for Digit Span after 
accounting for the effects of premorbid IQ. An examination of the adjusted means 
indicated that schizophrenia patients with cannabis use demonstrated significantly lower 
scores on the Temporal Organisation of Behaviour (except for on the Modified Six 
Elements measure), Retrospective Memory, Interference Control (except for the Trail 
Making Test Trial 4 Contrast score), and the Inhibition of Prepotent Responses (except 
for the Color-Word Trial 3 Contrast score), relative to controls. Adjusted means  
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Table 2. Results of ANCOVAs of executive function performance for Group with covariate of premorbid 
IQ 
Executive Function 
Performance 
 
Adjusted Mean 
 
 
Effects 
Group Premorbid IQ 
 SCH /C 
n=28 
MC 
n=28 
F p ηp
2
 F p ηp
2
 
TOB         
Zoo Map .055 .936 11.46 .001** .178 .095 .759 .002 
Modified Six Elements -.008 .315 3.03 .088 .054 10.97 .002** .172 
         
RM         
Zoo Map Recall 4.79 6.39 21.42 <.001** .288 .008 .930 .000 
Digit Span -.511 .392 26.93 <.001** .337 7.47 .009** .123 
         
IC         
Symbol Search -.662 .377 20.05 <.001** .275 .456 .502 .009 
TMT Trial 4 -.729 .420 34.05 <.001** .391 2.48 .121 .045 
TMT Trial 4 Contrast .043 -.019 .081 .777 .002 1.32 .255 .024 
         
IPR         
Rule Shift Trial 2 -.260 .518 7.60 .008**† .125 .206 .652 .004 
Rule Shift Trial 4 2.01 3.31 25.32 <.001** .323 3.32 .074 .059 
RS Trial 2 and 4 5.37 7.27 27.84 <.001** .344 2.50 .120 .045 
Color-Word Trial 3 -.817 .531 26.23 <.001** .331 .985 .325 .018 
Color-Word Trial 3 
Contrast  
.484 .778 1.85 .179 .034 .555 .460 .010 
         
PM         
Event-based task 3.05 3.52 1.52 .224 .028 1.94 .170 .035 
         
Verbal Fluency         
Letter Fluency -.552 -.210 2.28 .137 .041 9.84 .003** .157 
         
Emotion-based 
decision making 
        
Iowa Gambling Task 15.23 13.57 .062 .804 .001 .319 .574 .006 
df = 2 
SCH/C schizophrenia patients with cannabis use, MC matched-controls with a similar cannabis-use 
history, TOB Temporal Organisation of Behaviour, RM Retrospective Memory, IC Interference Control, 
IPP Inhibition of Prepotent Responses, RS Rule Shift, PM Prospective Memory, TMT Trail Making Test 
Note.*p< .05, **p< .01, †non sig. following post hoc analyses 
 
comparisons also revealed no significant differences between schizophrenia patients 
with cannabis use and matched-control subjects with a similar cannabis use history on 
the event-based prospective memory, verbal fluency and emotion-based decision 
making tasks. Post hoc analyses using a Holm-Bonferroni correction method revealed 
that no significant differences were detected between groups on Rule Shift Trial 2 
performance while controlling for family-wise Type I error rate at level α = .05. 
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Level of executive function impairment between groups. To gain further 
insight into the extent and level of executive function impairment in the sample groups, 
a number of calculations using normative data and impairment criteria or impairment 
cut-off scores were conducted prior to analysis. The z-scores calculated prior to 
analyses were used for this examination. Used as a guide in Coulston et al.’s (2007) 
study, ‘impairment’ status was defined if neurocognitive performance fell 1.5 – 2.0 
SD’s or more below the mean of the control group. Lezak et al. (2004) also suggests 
that a neurocognitive test performance change of 1.0, 1.5 and 2.0 SD’s may be used for 
determining impairment. Lezak considers that while a test performance reflective of a 
1.0 SD change may not be sufficient enough to indicate a difference of statistical 
significance, some examiners may still classify this performance as ‘probably impaired’. 
However, as approximately 15% of individuals who are considered ‘intact’ are expected 
to obtain scores greater than 1.0 SD below normative means and therefore, potentially 
resulting in too many false positives, a change in performance of 2.0 SD’s is considered 
to be a clear indication of impairment (Lezak, 2004). Therefore, the current study aimed 
to examine performances between groups across the different impairment criteria of 1.0, 
1.5 and 2.0 SD’s below the normative mean in order to better our understanding of the 
nature of any impairment that may be shown. Table 3 displays the chi-square results for 
proportional differences in each group that demonstrated neurocognitive performance 
across the different impairment ranges (i.e., greater than 1.0, 1.5 and 2.0 standard 
deviations below normative mean criteria) for each of the six executive function 
measures where significant differences were demonstrated in the previous analyses. It 
should be noted that as Zoo Map recall, Rule Shift Trial 4, the Rule Shift Trial 2 and 4 
combined score, and the event-based prospective memory task, did not have normative 
mean criteria available they were therefore not included in the table. The Iowa  
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Table 3. The proportion (n) of each sample group and effect size of proportional differences in executive function performance across each of the impairment level categories  
Executive 
Function 
Performance 
Mean 
(SD) 
Proportion of sample > 
-1.0 SD’s below 
normative mean 
n 
 
Proportion of sample 
between  
-1.0 to -1.49 SD’s below 
normative mean 
n 
 
Proportion of sample 
between  
-1.5 to -1.99 SD’s below 
normative mean 
n 
 
Proportion of sample < 
-2.0 SD’s below 
normative mean 
n 
 
Effect Size of difference 
between frequencies 
within each group 
w 
 SCH/C 
(n= 28) 
MC 
(n= 28) 
SCH/C 
(n= 28) 
MC 
(n= 28) 
SCH/C 
(n= 28) 
MC 
(n= 28) 
SCH/C 
(n= 28) 
MC 
(n= 28) 
SCH/C 
(n= 28) 
MC 
(n= 28) 
SCH/C 
(n= 28) 
MC 
(n= 28) 
TOB             
Zoo Map .05 (1.14) .94 (.74) 23 27 2 1 0 0 3 0 1.04** .929** 
             
RM             
Digit Span -.52 (.64) .40 (.73) 19 27 7 1 1 0 1 0 1.05** .929** 
             
IC             
Symbol 
Search 
-.67 (-.87) .38 (.85) 16 26 8 2 3 0 1 0 .827** .857** 
TMT Trial 4 -.74 (.91) .43 (.53) 14 27 8 1 3 0 3 0 .647** .929** 
             
IPP             
Rule Shift 
Trial 2 
-.26 (.56) .52 (.24) 21 28 0 0 0 0 7 0 .500**  
CW Trial 3 -.81 (1.29) .52 (.52) 16 28 6 0 0 0 6 0 .505**  
             
Note.**p< .01 
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Gambling Task will then be discussed due to impairment criteria for this measure 
involving a cut-off score instead of normative means and standard deviations. 
Symbol Search and Trail Making Test Trial 4 had the highest proportion of 
participants that performed at greater than 1.0 below the normative mean. A chi-square 
test for goodness of fit (with α = .01) was used to assess whether certain levels of 
performance (according to the impairment level criteria of 1.0, 1.5 and 2.0 SD’s below 
the normative mean) were more common than others in each sample group. The chi-
square test was statistically significant on all measures for the schizophrenia group with 
cannabis use (p < .001), indicating that some impairment criteria levels were achieved 
with significantly greater frequencies than others. Results indicate that a significantly 
larger proportion of schizophrenia patients with cannabis use demonstrated performance 
on all of the 6 measures above the impairment level criteria of greater than 1.0, 1.5 and 
2.0 standard deviations below normative mean than patients with cannabis use falling 
below these criteria. In other words, a larger proportion of schizophrenia patients with 
cannabise use demonstrated performances which were classified in the normal range on 
these executive function measures than those which were deemed to be at the probably 
impaired or clinically impaired range. These findings suggest that a statistically 
significant larger proportion of patients with schizophrenia with cannabis use did not 
perform at a level that was considered to be even ‘probably impaired’, let alone fall into 
the clinically impaired category and this was significantly different than chance (p < 
.001). Similar results were found for matched-controls (p < .001) indicating a 
significantly larger proportion of the group demonstrating performances in the normal 
range. An examination of the index of effect size Cohen’s w ranged from 0.50 to 1.05, 
which can be considered large. These results suggest that the previously reported 
significant results showing significant differences between groups is more reflective of 
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‘poorer’ performance by the schizophrenia group, but does not reflect ‘impaired’ 
performance relative to normative criteria.  
Adjusted mean comparisons also reveal that neither group performed below the 
cut-off score for impaired performance on the Iowa Gambling Task (i.e., net score <10) 
(Bechara et al., 2001). This result also suggests that neither the schizophrenia group 
with cannabis use (M = 15.23), nor the matched-controls group (M = 13.57), in the 
current study demonstrated impairment on this measure according to this criterion.  
The Effect of Cannabis-Use Status on the Recovery of Executive Function  
As another aim was to investigate whether continued/current cannabis use is 
associated with the non-recovery of executive function, the groups were partitioned into 
current cannabis users and abstinent cannabis users based on self-reported current use at 
the time of testing. In order to examine this relationship, a series of two-way 
ANCOVA’s were conducted to determine the effect of Group and cannabis-use status 
on executive function, when controlling for the effects of duration of use. Once again, 
the results will be grouped according to the executive function domains outlined in 
West’s (1996) model and the additionally included measures of executive function will 
then be reported.    
The ANCOVA assumption of normality was supported via the examination of 
Shapiro-Wilk statistics and histograms for each group and cannabis-use status 
categories. Scatterplots indicated that the relationship between the covariate (duration of 
use) and the dependent variables (executive function performance) was linear. Finally 
the assumptions of homogeneity of regression slopes and homogeneity of variances 
were supported by the independence of the covariate and both of the independent 
variables. Table 4 outlines the ANCOVA results of executive function performance for 
each group, with duration of use as a covariate. No statistically significant interactions  
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Table 4. Results of ANCOVAs of executive function performance for Group and cannabis-use status with covariate of duration of use 
Cognitive  
performance 
Adjusted Mean  
 
Effects 
Group Cannabis-Use Status Group Cannabis-Use Status Duration of Use 
 SCH/C 
n=28 
MC 
n=28 
Current 
Users 
n=22 
Non-Current 
Users 
n=34 
F p ηp
2
 F p ηp
2
 F p ηp
2
 
TOB              
Zoo Map .021 .958 .461 .518 112.23 .001** .193 .043 .836 .001 .826 .368 .016 
Modified Six Elements -.038 .339 .135 .165 3.15 .082 .058 .019 .892 .000 .108 .743 .002 
              
RM              
Zoo Map Recall 4.72 6.40 5.44 5.68 21.98 <.001** .301 .421 .519 .008 .039 .845 .001 
Digit Span -.508 .429 .053 -.133 24.33 <.001** .323 .909 .345 .018 .687 .411 .013 
              
IC              
Symbol Search -.674 .378 -.172 -.124 18.75 <.001** .269 .038 .846 .001 .028 .869 .001 
TMT Trial 4 -.747 .449 -.122 -.176 32.71 .001** .391 .065 .800 .001 .000 .989 .000 
TMT Trial 4 Contrast .024 -.024 -.055 .055 .047 .829 .001 .227 .636 .004 1.30 .260 .025 
              
IPP              
RS Trial 2 -.298 .527 .044 .184 8.09 .006** .137 .220 .641 .004 .013 .909 .000 
RS Trial 4 2.06 3.36 2.96 2.47 23.80 <.001** .318 3.18 .080 .059 1.60 .212 .030 
RS Trial 2 and 4 5.39 7.33 6.55 6.17 26.50 <.001** .342 .96 .332 .018 .92 .341 .018 
CW Trial 3 Contrast  .430 .778 .478 .730 2.65 .110 .049 1.32 .256 .025 1.56 .218 .030 
              
PM              
Event-based task 3.03 3.57 3.37 3.24 1.77 .189 .034 .100 .754 .002 .594 .445 .012 
              
Verbal Fluency              
Letter Fluency -.495 -.146 -.039 -.602 2.05 .159 .039 5.05 .029* .090 .036 .850 .001 
              
Emotion-based decision 
making 
             
Iowa Gambling Task 15.54 13.46 14.96 14.03 .091 .756 .002 .017 .896 .000 .292 .591 .006 
Note.*p< .05, **p< .01  
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between the independent variables and executive function performance were found after 
adjustment for duration of use. Duration of use was not found to have an impact on 
performance for the majority of the executive function measures. However, a significant 
interaction between the covariate of duration of use and the independent variables of 
Group and cannabis-use status on Color-Word Trial 3 was found, F(6, 49) = 3.01, p 
=.039, ηp
2
 = .156. Therefore, the assumption of the homogeneity of regression slopes 
was violated in this instance and an ANCOVA was not conducted. Inspection of the 
regression slopes revealed a poor association between duration of use and Color-Word 
Trial 3 scores across the test groups (i.e., schizophrenia patients with cannabis use and 
matched-control subjects with a similar cannabis use history). However, for the 
cannabis-use status groups, an association between duration of use and Color-Word 
Trial 3 scores was found. As a general pattern, the regression slopes indicated that in the 
current-user group, a longer duration of use was associated with higher Color-Word 
Trial 3 scores indicating better performance on this measure due to the conversion to z-
scores using normative criteria. Contrastingly, in the non-current user group, longer 
duration of use was found to be associated with lower Color-Word Trial 3 scores 
indicating poorer performance.  
A two-way ANOVA revealed a significant main effect of Group on Color-Word 
Trial 3, F(3, 52) = 26.86, p <.001, ηp
2
 = .341. Main effects of cannabis-use status, F(3, 
52) = 3.41, p = .071, ηp
2
= .062 and the interaction, F(3, 52) = .446, p = .512, ηp
2
= .008 
were not significant. Comparison of means indicated that the schizophrenia group with 
cannabis use (M = -.81) had significantly lower scores on Color-Word Trial 3, than 
matched-controls (M = .53). Although, current users (M = -.44) and non-current users 
(M = .05) showed similar performance on this measure. 
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An examination of the adjusted means for the other executive function domains 
indicated that schizophrenia patients with cannabis use had significantly lower scores on 
the Temporal Organisation of Behaviour (except on the Modified Six Elements 
measure), Retrospective Memory, Interference Control (except for the Trail Making 
Test Trial 4 Contrast score), and the Inhibition of Prepotent Responses (except for the 
Color-Word Trial 3 Contrast score), relative to controls. Adjusted means comparisons 
also revealed no significant differences between schizophrenia patients with cannabis 
use and matched-control subjects with a similar cannabis use history on the event-based 
Prospective Memory, Verbal Fluency and Emotion-based Decision-making tasks. 
Further, results showed no significant differences in performance on all of the executive 
function domains between current users and non-current users, except for in the domain 
of verbal fluency. Findings revealed that current users (M = -.04) had higher scores on 
Letter Fluency than former users (M = -.60), suggesting that continued cannabis use is 
associated with better performance on Letter Fluency. The effect size of this result is 
considered moderate. Holm-Bonferroni correction was applied to adjust for multiple 
comparisons, with all results remaining statistically significant following correction.   
The Effect of Length of Abstinence on the Recovery of Executive Function 
An additional aim of the study was to investigate if a longer period of abstinence 
is associated with the recovery of executive function. In order to examine this 
relationship, a series of two-way ANCOVA’s were conducted to determine the effect of 
Group and time since cessation (i.e., abstinence for less than 5 years and abstinence for 
equal to, or greater than, 5 years) on executive function, when controlling for duration 
of use. For this analysis, non-current users were divided into two groups using a median 
split. Following this, 16 subjects were in the less than 5 years abstinence group and 18 
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subjects were in the equal to, or greater than, 5 years abstinence group. The following 
analyses were only conducted on the sample of non-current cannabis users (n = 34).  
Examination of Shapiro-Wilk statistics and histograms for each group and time since 
cessation categories indicated the ANCOVA assumption of normality was supported. 
Scatterplots indicated that the relationship between the covariate (duration of use) and 
the dependent variables (performance on the individual executive function measures) 
was linear. Finally the assumptions of homogeneity of regression slopes and 
homogeneity of variances were supported by the absence of a significant IV-by-
covariate interaction. Table 5 outlines the ANCOVA results of executive function 
performance for Group and time since cessation categories amongst the non-current 
user sample, with duration of use as a covariate. There were no statistically significant 
interactions found between either group, or time since cessation categories, and 
executive function performance after adjustment for duration of use. Duration of use 
was not found to have an impact on performance for the majority of the executive 
function measures, except for Color-Word Trial 3. However, the main effect of group 
on Color-Word Trial 3 remained significant after accounting for the effects of duration 
of use. Comparison of adjusted means show that schizophrenia patients with cannabis 
use had significantly lower scores on Retrospective Memory, Interference Control 
(except for the Trail Making Test Trial 4 Contrast score), and the Inhibition of Prepotent 
Responses domains, relative to controls (except for Rule Shift Trial 2 and the Color-
Word Trial 3 Contrast score). Adjusted means comparisons also revealed no significant 
differences between schizophrenia patients with cannabis use and matched-control 
subjects with a similar cannabis use history on the Temporal Organisation of Behaviour 
(on the Modified Six Elements measure only), Prospective Memory, Verbal Fluency 
and Emotion-based Decision-making domains. Post hoc analyses using the Holm- 
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Table 5. Results of ANCOVAs of executive function performance for Group and time since cessation categories with covariate of duration of use 
Cognitive  
performance 
Adjusted Mean 
 
Effects 
Group Time Since Cessation Group Time Since Cessation Duration of Use 
 SCH+C 
n=28 
C CTRL 
n=28 
< 5 years 
n=16 
≥5 years 
n=18 
F p ηp
2
 F p ηp
2
 F p ηp
2
 
TOB              
Zoo Map .210 .830 .920 .110 3.17 .086 .098 4.57 .041* .136 .116 .736 .004 
Modified Six Elements .014 .311 .290 .034 1.25 .273 .041 .767 .388 .026 .619 .438 .021 
              
RM              
Zoo Map Recall 5.08 6.30 5.98 5.40 6.86 .014*† .191 1.29 .266 .043 1.10 .302 .037 
Digit Span -.664 .345 -.244 -.075 14.35 .001* .331 .337 .566 .011 2.72 .110 .086 
              
IC              
Symbol Search -.584 .373 -.126 .085 9.11 .005** .239 .014 .906 .000 2.14 .154 .069 
TMT Trial 4 -.677 .338 -.143 -.196 11.43 .002** .283 .027 .872 .001 .644 .429 .022 
TMT Trial 4 Contrast .111 .024 .056 .079 .078 .782 .003 .004 .947 .000 .266 .610 .009 
              
IPP              
RS Trial 2 -.085 .480 .308 .086 3.44 .074 .106 .441 .512 .015 .043 .837 .001 
RS Trial 4 1.76 3.17 2.24 2.70 12.95 .001** .309 1.16 .290 .039 .098 .756 .003 
RS Trial 2 and 4 5.26 7.11 6.04 6.33 14.37 .001** .331 .295 .591 .010 .124 .727 .004 
CW Trial 3 -.484 .606 .050 .067 17.16 <.001** .372 .003 .956 .000 6.55 .016* .184 
CW Trial 3 Contrast  .722 .728 .671 .779 .001 .976 .000 .185 .670 .006 2.79 .105 .088 
              
PM              
Event-based task 3.12 3.43 3.34 3.20 .377 .544 .013 .065 .801 .002 .132 .719 .005 
              
Verbal Fluency              
Letter Fluency -.821 -.367 -.427 -.762 1.72 .200 .056 .776 .386 .026 .002 .964 .000 
              
Emotion-based decision 
making 
             
Iowa Gambling Task 14.00 14.96 11.07 17.90 .009 .923 .000 .403 .531 .014 .006 .938 .000 
Note.*p< .05, **p< .01, †non sig. following post hoc analyses
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Bonferroni correction method revealed that significant differences no longer remained 
between groups on Zoo Map recall performance after adjusting the alpha level for 
multiple comparisons. Further, results showed no significant differences in performance 
on all of the executive function domains between non-current users who were abstinent 
for less than 5 years and non-current users who were abstinent for equal to, or greater 
than, 5 years, except for in the Temporal Organization of Behaviour domain (on the Zoo 
Map measure only). Findings revealed that non-current users who were abstinent for 
less than 5 years (M = .92) had higher scores on Zoo Map than non-current users who 
were abstinent for equal to, or greater than, 5 years (M = .11), suggesting that shorter 
abstinence periods (i.e., less than 5 years) was associated with better performance on 
this measure. The effect size of this result is considered moderate.  
The Validity of West’s Theoretical Model of Executive Function  
Principal Components Analysis. Principal Components Analysis (PCA) was 
conducted to determine what, if any, factor structures underlie the following executive 
function measures: Zoo Map, Zoo Map recall, Digit Span, Symbol Search, Trail Making 
Test Trial 4, Rule Shift Trial 2, Color-Word Trial 3, the event-based prospective 
memory task, Letter Fluency, and the Iowa Gambling Task. Rule Shift Trial 4 and the 
Rule Shift Trial 2 and 4 combined score were not included in the analyses as they 
involved modified versions of the original measures. The Trail Making Test Trial 4 
Contrast score and Color-Word Trial 3 Contrast score were also not included in PCA as 
the Trail Making Test Trial 4 and Color-Word Trial 3 appeared to be more successful in 
detecting differences between groups. This was considered an important concern when 
attempting to determine any underlying factors amongst the executive function 
measures administered which may serve to be more sensitive and thus, reflective of the 
fundamental construct in question. The purpose of the PCA was exploratory in nature. 
CANNABIS USE, SCHIZOPHRENIA & EXECUTIVE FUNCTION 103 
 
This type of analysis was conducted in order to determine which executive function 
measures were related to each other in a theoretically consistent way. 
 Criteria to determine the best factor model included: (a) exclusion of measures 
or items exhibiting Kaiser’s measurement of sampling adequacy (MSA), Kaiser-Meyer-
Olkin (KMO) or communality values < .5; (b) Bartlett’s test of sphericity exhibiting 
significance (p < .0001); (c) retention of factors with eigenvalues > 1 that were 
supported by scree plot analysis and clinical/theoretical plausibility of factors; (d) factor 
loadings ≥ .4 for interpretation of factors (explaining ≥ 16% of total variance); and (e) 
stability of factor solutions across analyses employing oblique and orthogonal rotations 
(Field, 2009; Tabachnick & Fidell, 2007).  
PCA was conducted utilising both orthogonal (varimax) and oblique (oblimin) 
rotations. During initial analysis, one item (the Iowa Gambling Task) failed to meet the 
minimum criterion of .5 for Kaiser’s MSA and was excluded in further analyses. 
Subsequently, PCA of the remaining 10 executive function measures yielded near-
identical factor solutions across orthogonal (varimax) and oblique (oblimin) rotations. 
However, results of the former are reported only as varimax rotation provided the best 
defined factor structure (see Table 6). A three-factor solution explaining 61.57% of the 
total variance in executive function was extracted. Of this variance, 40.26% was 
accounted for by factor 1 (‘Mental Control and Self-Regulation’; 8 variables), 11.22% 
by factor 2 (‘Voluntary Response Generation and Disinhibition’; 2 variables), and 
10.09% by factor 3 (‘Maintenance of Intention for Future Action’; 2 variables). 
The outcomes of the PCA indicate that the executive function measures which 
loaded onto factor 1 include mostly those tests which were guided by West’s (1996) 
theoretical model of executive function. However, verbal fluency (which was included 
as an additional executive function component for exploration and did not appear to be  
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Table 6. Factor loadings based on a Principal Components Analysis utilising orthogonal (varimax) 
rotation of 10 executive function measures (N=56) 
   Loading  
Theoretical 
Construct 
Item Measure Factor 1 Factor 2 Factor 3 
Temporal 
Organisation of 
Behaviour 
Zoo Map .576   
Modified Six 
Elements 
.513   
     
Retrospective 
Memory 
 
Zoo Map Recall .646   
Digit Span .692   
     
Interference 
Control 
 
Symbol Search .703   
Trail Making Test 
Trial 4 
.798   
     
Inhibition of 
Prepotent 
Responses 
 
Rule Shift Trial 2 .707 -.473  
Color-Word Trial 
3 
.637  .405 
     
Prospective 
Memory 
Event-based task   .903 
     
Verbal Fluency Letter Fluency  .847  
     
Note. Factor loadings less than the absolute value of ± .4 are omitted 
included in West’s model), appeared to load onto a separate factor relative to the 
remaining measures (i.e., factor 2). Taken together with the negative loading of Rule 
Shift Trial 2 onto factor 2, this may indicate that the underlying structure of this 
component involves response generation/fluency abilities or cognitive responses that 
require disinhibition. Moreover, the positive loadings of both Color-Word Trial 3 and 
the event-based prospective memory onto factor 3 potentially reflect an underlying 
structure involving cognitive responses that require the ability to remember an intention 
for future action. Finally, the Iowa Gambling Task (which did not meet criterion for 
PCA and was excluded in the subsequent analysis) may not have been sensitive enough 
to sufficiently tap into the executive function constructs of interest, albeit in this 
particular sample. 
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While the sample size in the current study is notably low, it has been suggested 
by Stevens (1986; 2002) that as low as 5 subjects per variable is the minimum needed in 
Principle Components Analysis based on Gorsuch’s (1983) guidelines. The current  
study’s sample size is just over 50 with the combined sample and is therefore just above 
the minimum requirements in the recommended guidelines. In addition, 
recommendations arising from a study by Guadagnoli and Velicer (1988) outline that 
‘components with four or more loadings above .60 in absolute value are reliable, 
regardless of sample size’ (cited in Stevens, 2002, p. 395). As the results indicate 6 
loadings above .60, it can be considered that at least factor 1 is a reliable component. 
Another recommendation arising from Guadagnoli and Velicer’s (1988) study is that 
‘components with only a few low loadings should not be interpreted unless sample size 
is at a least 300’ (Stevens, 2002, p. 395). It is outlined that a low loading would include 
those .40 and below. However, Stevens (2002) suggested that a factor which was 
defined by only a few loadings was not considered as much of a factor and instead, the 
factor could be considered as variable specific. Therefore, as factor 2 included loadings 
of only two variables (Rule Shift Trial 2 at -.473 and Letter Fluency at .847), and factor 
3 including loadings of only two variables (Color-Word Trial 3 at .405 and Prospective 
Memory at .903) this could indeed represent some of those cases. 
Overall, these results are in partial support of the construct validity of the 
selected executive function measures (which were those guided by West’s model). That 
is, the measures which loaded on factor 1 seemed to adequately tap into a single 
theoretical neurocognitive construct, namely executive function. However, the results 
also suggest that the while the measure of Letter Fluency may assess executive function 
abilities, it may also rely upon other cognitive abilities that are separate, or independent, 
to executive function alone. In addition, the event-based prospective memory measure 
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utilised may not have been sensitive enough to detect the true construct of prospective 
memory abilities. In alternative, the prospective memory measure used may have tapped 
into other cognitive processes that fall outside of the executive function domain.  
Part B 
The Relationship Between Executive Function and Functional Outcome 
The predictive ability of executive function measures in predicting 
functional outcome ratings. The investigation into the relationship between the 
executive function domains belonging to West’s (1996) model and functional outcome 
is exploratory in nature. However, due to reports of an association between executive 
function and functional outcome in the literature, it was hypothesized that executive 
function performance would be significantly related to functional outcome. More 
specifically, scores on executive function measures would have significant predictive 
ability in relation to functional outcome ratings (as measured by the Independent Living 
Skills Inventory (ILSI)). The purpose of the following analyses is to assist in identifying 
a measure (or measures) of executive functioning that significantly predicts a specific 
domain of functional outcome in schizophrenia patients (e.g., if measures of prospective 
memory are shown to predict a given functional outcome domain then cognitive 
remediation specific to enhancing prospective memory abilities could be utilised to 
ultimately target improvements in that functional outcome domain). From this 
perspective, the goal of the analyses (and in turn the consequent results) is to assist in 
identifying whether there is potential for improvements to specific cognitive abilities 
which may in turn affect associated functional outcomes. 
In order to identify the predictors that would be considered important to enter 
into regression analyses, Pearson correlation analyses between each of the individual 
executive function measures and each of the ILSI sub-scale ratings, as well as the Total 
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ILSI score, were first computed. Correlations were calculated for the schizophrenia 
group with cannabis use, the matched-control group with a similar cannabis use history, 
and the overall combined sample. Table 7, 8 and 9 display the correlation matrices. 
A series of multiple regression and hierarchical multiple regression analyses 
(divided into three stages) were conducted for each functional outcome sub-domain, as 
well as for overall functional outcome. Only the schizophrenia group with cannabis use 
were used the analyses (n = 28). In the first stage of regression analysis, the measure(s) 
showing significant correlations in the schizophrenia group with cannabis use were 
entered as predictors into a multiple regression analysis. For stage 2, at step 1 these 
same predictors are entered simultaneously. At step 2, only the predictor from Stage 1 
showing a significant slope was then entered. At step 3, this same predictor as well as 
those executive function measures showing significant correlations in the matched 
control group (not including those already entered), were then entered as predictors. At 
stage 3, all of the previous steps were used again. However, in step 4 only the 
predictor(s) from previous steps showing a significant slope were entered. In the final 
step, these same significant predictors in addition to those measures showing significant 
correlations in the combined sample (not including those already entered previously), 
were entered as predictors. Before interpreting the results of the regression analyses, a 
number of assumptions were tested and checks were performed. Firstly, an inspection of 
the normal probability plot of standardised residuals and the scatterplot of standardised 
residuals against standardised predicted values indicated that the assumptions of 
normality, linearity and homoscedasticity of residuals were met. In addition, 
Mahalanobis distance did not exceed the critical χ2 for degrees of freedom for any cases 
in the data, indicating that multivariate outliers were not of concern. Finally, relatively  
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Table 7. Correlations between executive function measures and ILSI sub-scales and total ILSI score for 
the schizophrenia group 
Executive Function Measures 
Independent 
Living Skills  
Zoo 
Map 
Zoo 
Map 
Recall 
Digit 
Span 
Symbol 
Search 
Trail 
Making 
Test 
Trial 4 
Rule 
Shift 
Trial 2 
Rule 
Shift 
Trial 4 
Rule Shift 
Trial 2 and 
4 
Combined 
Color-
Word 
Trial 3 
Personal 
Management  
.223 .220 -.097 .316 .038 -.067 -.209 -.063 .310 
 
Hygiene & 
Grooming  
 
.185 
 
.123 
 
.429* 
 
.335 
 
.089 
 
.146 
 
.015 
 
-.084 
 
.353 
 
Clothing  
 
-.051 
 
.108 
 
.278 
 
.118 
 
-.108 
 
-.207 
 
-.120 
 
-.215 
 
.260 
 
Basic Skills 
 
-.083 
 
-.057 
 
.216 
 
.170 
 
.043 
 
-.266 
 
.154 
 
-.276 
 
.145 
 
Interpersonal 
skills  
 
.178 
 
.257 
 
.181 
 
.457* 
 
.241 
 
-.135 
 
.138 
 
.007 
 
.361 
 
Home 
Maintenance 
 
.160 
 
.274 
 
.083 
 
.251 
 
-.038 
 
-.171 
 
-.137 
 
-.203 
 
.300 
 
Money 
Management 
 
-.087 
 
.307 
 
.194 
 
.209 
 
-.107 
 
-.202 
 
-.063 
 
-.173 
 
.162 
 
Cooking 
 
.145 
 
.331 
 
.169 
 
.456* 
 
.119 
 
-.178 
 
.138 
 
-.021 
 
.371 
 
Resource 
Utilization 
 
.097 
 
.304 
 
.113 
 
.390* 
 
.199 
 
-.009 
 
-.042 
 
-.035 
 
.288 
 
General  
 
.225 
 
.053 
 
.012 
 
.289 
 
.136 
 
-.172 
 
.105 
 
-.040 
 
.352 
Occupational  
Skills 
         
 
Medication 
Management 
 
.197 
 
.368 
 
.074 
 
.431* 
 
.252 
 
-.016 
 
.074 
 
.040 
 
.309 
 
Total 
. 
141 
 
.271 
 
.183 
 
.389* 
 
.096 
 
-.152 
 
.036 
 
-.074 
 
.328 
Note. *p<.05, **p<.01 
high tolerances indicated that multicollinearity would not interfere with the ability to 
interpret the outcome of the regression analyses. 
Personal Management (Independent Living Skills Inventory). There were no 
significant correlations found in each of the separate groups (i.e., schizophrenia group  
with cannabis use and matched-controls group with a similar cannabis use history), 
therefore stage 1 and 2 of the regression analyses were not conducted. For stage 3, 
results indicate that the overall model which included Zoo Map, Zoo Map recall, Digit 
Span, Symbol Search, Trail Making Test Trial 4, Rule Shift Trial 4, the Rule Shift Trial 
2 and 4 combined score, and Color-Word Trial 3 as predictors, did not significantly 
predict ratings in Personal Management on the Independent Living Skills Inventory in  
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Table 8. Correlations between executive function measures and ILSI sub-scales and total ILSI score for 
the matched-control group  
Executive Function Measures 
Independent 
Living Skills  
Zoo 
Map 
Zoo 
Map 
Recall 
Digit 
Span 
Symbol 
Search 
Trail 
Making 
Test 
Trial 4 
Rule 
Shift 
Trial 2 
Rule 
Shift 
Trial 4 
Rule Shift 
Trial 2 and 
4 
Combined 
Color-
Word 
Trial 3 
Personal 
Management  
-.055 -.115 .287 -.195 -.280 .173 -.027 .016 -.367 
 
Hygiene & 
Grooming  
 
.070 
 
.226 
 
.088 
 
-.211 
 
-.233 
 
.556** 
 
.157 
 
.270 
 
-.098 
 
Clothing  
 
.337 
 
.098 
 
.416* 
 
-.095 
 
.140 
 
.694** 
 
.321 
 
.448* 
 
-.260 
 
Basic Skills 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
- 
 
Interpersonal 
skills  
 
.290 
 
.199 
 
.158 
 
-.176 
 
-.287 
 
.125 
 
.011 
 
.039 
 
-.558** 
 
Home 
Maintenance 
 
.213 
 
.110 
 
.049 
 
.168 
 
.226 
 
.662** 
 
.222 
 
.353 
 
-.092 
 
Money 
Management 
 
.051 
 
-.148 
 
.387* 
 
-.224 
 
-.238 
 
.306 
 
-.130 
 
-.045 
 
-.322 
 
Cooking 
 
.284 
 
.150 
 
-.062 
 
-.307 
 
-.150 
 
.540** 
 
.188 
 
.294 
 
-.263 
 
Resource 
Utilization 
 
.314 
 
.041 
 
.419* 
 
.032 
 
.074 
 
.970** 
 
.306 
 
.499** 
 
-.128 
 
General 
Occupational 
Skills 
 
-.117 
 
-.105 
 
.199 
 
-.220 
 
-.336 
 
-.037 
 
-.184 
 
-.173 
 
-.307 
 
Medication 
Management 
 
.282 
 
-.087 
 
.245 
 
-.231 
 
-.317 
 
.243 
 
-.104 
 
-.036 
 
-.430* 
 
Total 
 
.240 
 
.032 
 
.331 
 
-.233 
 
-.218 
 
.647** 
 
.106 
 
.246 
 
-.414* 
Note. *p<.05, **p<.01  
schizophrenia patients with cannabis use, R
2
 = .247, R
2
adj = -.070, F(8, 19) = .780, p = 
.625.  
Hygiene and Grooming (Independent Living Skills Inventory). At stage 1, 
Digit Span significantly accounted for 15.3% of the variance in Hygiene and Grooming 
ratings on the Independent Living Skills Inventory in schizophrenia patients with 
cannabis use, R
2
 = .184, R
2
adj = 153,  F(1, 26) = 5.87, p = .023. By Cohen’s (1988) 
conventions, an effect of this magnitude can be considered ‘medium’ (f 2 = .23). At 
stage 2, Rule Shift Trial 2 was added as a predictor to the regression equation and 
accounted for an additional 4.2% of the variance in Hygiene and Grooming ratings. 
However, this change was not statistically significant, ∆R2 = .042, ∆F(1, 25) = 1.345, p 
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Table 9. Correlations between executive function measures and ILSI sub-scales and total ILSI score for 
the overall sample  
Executive Function Measures 
Independent 
Living Skills  
Zoo 
Map 
Zoo 
Map 
Recall 
Digit 
Span 
Symbol 
Search 
Trail 
Making 
Test 
Trial 4 
Rule 
Shift 
Trial 
2 
Rule 
Shift 
Trial 4 
Rule Shift 
Trial 2 and 
4 
Combined 
Color-
Word 
Trial 3 
Personal 
Management  
.392** .441** .358** .459** .399** .188 .345** .342** .520** 
 
Hygiene & 
Grooming  
 
.334* 
 
.350** 
 
.488** 
 
.418** 
 
.347** 
 
.071 
 
.297* 
 
.247 
 
.508** 
 
Clothing  
 
.205 
 
.342** 
 
.451** 
 
.324* 
 
.264* 
 
.034 
 
.235 
 
.184 
 
.451** 
 
Basic Skills 
 
.108 
 
.176 
 
.331* 
 
.301* 
 
.271* 
 
-.086 
 
.122 
 
.042 
 
.325* 
 
Interpersonal 
skills  
 
.393** 
 
.489** 
 
.455** 
 
.544** 
 
.519** 
 
.142 
 
.444** 
 
.388** 
 
.562** 
 
Home 
Maintenance 
 
.355** 
 
.464** 
 
.370** 
 
.439** 
 
.350** 
 
.090 
 
.260 
 
.231 
 
.514** 
 
Money 
Management 
 
.193 
 
.446** 
 
.453** 
 
.369** 
 
.271* 
 
.061 
 
.269* 
 
.222 
 
.396** 
 
Cooking. 
 
.354** 
 
.490** 
 
.380** 
 
.476** 
 
.398** 
 
.084 
 
.409** 
 
.344* 
 
.526** 
 
Resource  
Utilization 
 
.355** 
 
.497** 
 
.458** 
 
.517** 
 
.504** 
 
.250 
 
.364** 
 
.388** 
 
.519** 
 
General 
Occupational 
Skills 
 
.405** 
 
.379** 
 
.391** 
 
.471** 
 
.473** 
 
.119 
 
.425** 
 
.363** 
 
.571** 
 
Medication 
Management 
 
.385** 
 
.506** 
 
.384** 
 
.505** 
 
.490** 
 
.203 
 
.370** 
 
.367** 
 
.509** 
 
Total 
 
.369** 
 
.487** 
 . 
.467** 
 
.508** 
 
.448** 
 
.138 
 
.394** 
 
.350** 
 
.547** 
Note. *p<.05, **p<.01 
= .257. At stage 3, results indicate that the overall model which included Zoo Map, Zoo  
Map recall, Symbol Search, Trail Making Test Trial 4, Rule Shift Trial 4, and Color-
Word Trial 3 as additional predictors, accounted for an additional 15.1% of the variance 
in Hygiene and Grooming ratings. However, again this change was not statistically 
significant, ∆R2 = .151, ∆F(6, 19) = .766, p = .605. 
Clothing (Independent Living Skills Inventory). There were no significant 
correlations found in the schizophrenia group with cannabis use for Clothing ratings. 
Therefore, stage 1 of the regression analyses was not conducted. At stage 2, Digit Span, 
Rule Shift Trial 2 and the Rule Shift Trial 2 and 4 combined score were entered as 
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predictors to the regression equation. This model was not found to be statistically 
significant, R
2
 = .198, R
2
adj = .098, F(3, 24) = 1.975, p = .145. Due to the non-significant 
results in the previous stage, at stage 3 only Zoo Map recall, Symbol Search, Trail 
Making Test Trial 4, and Color-Word Trial 3 were entered as predictors in the model. 
Results indicate that the overall model did not significantly predict the variance in 
Clothing ratings, R
2
 = .125, R
2
adj = -.027, F(4, 23) = .819, p = .526. 
Basic Skills (Independent Living Skills Inventory). As there were no significant 
correlations found in each of the separate groups for Basic Skills ratings, stage 1 and 2 
of the regression analyses were not conducted. At stage 3, Digit Span, Symbol Search, 
Trail Making Test Trial 4, and Color-Word Trial 3 were entered as predictors. Results 
indicate that the overall model did not significantly predict ratings in Basic Skills, R
2
 = 
.068, R
2
adj = -.094, F(4, 23) = .418, p = .794. 
 Interpersonal skills (Independent Living Skills Inventory). At stage 1, Symbol 
Search significantly accounted for 17.9% of the variance in Interpersonal Skills ratings 
in schizophrenia patients with cannabis use, R
2
 = .209, R
2
adj = .179, F(1, 26) = 6.881, p 
= .014. The effect size is considered to be ‘medium’ (f 2 = .26) (Cohen, 1988). At stage 
2, Color-Word Trial 3 was added as a predictor to the regression equation and 
accounted for an additional 0.9% of the variance in Interpersonal Skills ratings, with 
this change being non-significant, ∆R2 = .009, ∆F(1, 25) = 2.83, p = .599. At stage 3, 
the overall model which included Zoo Map, Zoo Map recall, Digit Span, Trail Making 
Test Trial 4, Rule Shift Trial 4, and the Rule Shift Trial 2 and 4 combined score as 
additional predictors, accounted for an additional 0.7% of the variance in Interpersonal 
Skills ratings. Once again, this change was not statistically significant, ∆R2 = .074, 
∆F(6, 19) = .328, p = .914. 
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Home Maintenance (Independent Living Skills Inventory). There were no 
significant correlations found in the schizophrenia group with cannabis use, hence stage 
1 of the regression analyses was not conducted. At stage 2, Rule Shift Trial 2 was 
entered as a predictor into the regression equation. This model was not found to be 
statistically significant, R
2
 = .029, R
2
adj = -.008, F(1, 26) = .783, p = .384. Due to this 
non-significant result, at stage 3 only Zoo Map, Zoo Map recall, Digit Span, Symbol 
Search, Trail Making Test Trial 4, and Color-Word Trial 3 were entered as predictors, 
with again no significant results, R
2
 = .193, R
2
adj = -.038, F(6, 21) = .835, p = .557. 
 
Money Management (Independent Living Skills Inventory). No significant 
correlations were found in the schizophrenia group with cannabis use. Therefore, stage 
1 of the regression analyses was not conducted. At stage 2, Digit Span was entered as a 
predictor into the regression equation with the model not being statistically significant, 
R
2
 = .037, R
2
adj = .000, F(1, 26) = 1.013, p = .324. Due to this result, at stage 3 only Zoo 
Map recall, Symbol Search, Trail Making Test Trial 4, Rule Shift Trial 4, and Color-
Word Trial 3 were entered as predictors. No significant results were found, R
2
 = .211, 
R
2
adj = .032, F(5, 22) = 1.179, p = .351. 
 
Cooking (Independent Living Skills Inventory). At stage 1, Symbol Search 
significantly accounted for 17.7% of the variance in Cooking ratings in schizophrenia 
patients with cannabis use, R
2
 = .207, R
2
adj = .177, F(1, 26) = 6.807, p = .015. The effect 
size is ‘medium’ (f 2 = .26) (Cohen, 1988). At stage 2, Rule Shift Trial 2 was added as a 
predictor to the regression equation and accounted for an additional 7.3% of the 
variance in Cooking ratings with this change not being statistically significant, ∆R2 = 
.073, ∆F(1, 25) = 2.502, p = .126. For stage 3, the overall model which included Zoo 
Map, Zoo Map recall, Digit Span, Trail Making Test Trial 4, Rule Shift Trial 4, Rule 
Shift Trial 2 and 4 combined score, and Color-Word Trial 3 as additional predictors, 
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accounted for an additional 13.5% of the variance in Cooking ratings, with no further 
significant results found, ∆R2 = .135, ∆F(7, 19) = .557, p = .781.  
Resource Utilization (Independent Living Skills Inventory). At stage 1, Symbol 
Search significantly accounted for 11.9% of the variance in Resource Utilization ratings 
in schizophrenia patients with cannabis use, R
2
 = .152, R
2
adj = .119, F(1, 26) = 4.663, p 
= .040, with a ‘medium’ effect size (f 2 = .18) (Cohen, 1988). At stage 2, Digit Span, 
Rule Shift Trial 2 and the Rule Shift Trial 2 and 4 combined score were added as 
additional predictors to the model and accounted for an additional 10.9% of the variance 
in Resource Utilization ratings. However, this change was not significant, ∆R2 = .109, 
∆F(3, 23) = 1.133, p = .357. At stage 3, the overall model which included Zoo Map, 
Zoo Map recall, Trail Making Test Trial 4, Rule Shift Trial 4, and Color-Word Trial 3 
as additional predictors, accounted for an additional 13.2% of the variance in Resource 
Utilization ratings with this change being non-significant, ∆R2 = .132, ∆F(5, 21) = .775, 
p = .579.  
General Occupational Skills (Independent Living Skills Inventory). No 
significant correlations were found in each of the separate groups, therefore stage 1 and 
2 of the regression analyses were not conducted. At stage 3, Zoo Map, Zoo Map recall, 
Digit Span, Symbol Search, Trail Making Test Trial 4, Rule Shift Trial 4, the Rule Shift 
Trial 2 and 4 combined score, and Color-Word Trial 3 were entered as predictors. 
Results indicate that the overall model did not significantly predict ratings in General 
Occupational Skills in schizophrenia patients with cannabis use, R
2
 = .200, R
2
adj = -.136, 
F(8, 19) = .595, p = .771.  
Medication Management (Independent Living Skills Inventory). At stage 1, 
Symbol Search significantly accounted for 15.5% of the variance in Medication 
Management ratings in schizophrenia patients with cannabis use, R
2
 = .186, R
2
adj = .155, 
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F(1, 26) = 5.945, p = .022, with a   ‘medium’ effect size (f 2 = .23) (Cohen, 1988). At 
stage 2, Color-Word Trial 3 was added to the equation and accounted for an additional 
0.2% of the variance in Medication Management ratings with results not being 
statistically significant, ∆R2 = .002, ∆F(1, 25) = .069, p = .795. At stage 3, the overall 
model included Zoo Map, Zoo Map recall, Digit Span, Trail Making Test Trial 4, Rule 
Shift Trial 4, the Rule Shift Trial 2 and 4 combined score, and Color-Word Trial 3 as 
additional predictors and accounted for an additional 9.6% of the variance in 
Medication Management ratings. Again, no further significant results were found, ∆R2 = 
.096, ∆F(6, 20) = .448, p = .838.  
Total ILSI Score (Independent Living Skills Inventory). At stage 1, Symbol 
Search significantly accounted for 11.9% of the variance in the Total ILSI Score in 
schizophrenia patients with cannabis use, R
2
 = .151, R
2
adj = .119,  F(1, 26) = 4.630, p = 
.041.  The effect size is considered ‘medium’ (f 2 = .18) (Cohen, 1988). At stage 2, Rule 
Shift Trial 2 and Color-Word Trial 3 were included as additional predictors to the 
regression equation and accounted for an additional 6.2% of the variance in the Total 
ILSI Score with the results however, being non-significant, ∆R2 = .062, ∆F(2, 24) = 
.938, p = .405. At stage 3, the overall model included Zoo Map, Zoo Map recall, Digit 
Span, Trail Making Test Trial 4, Rule Shift Trial 4, and the Rule Shift Trial 2 and 4 
combined score as additional predictors and accounted for an additional 12.3% of the 
variance in the Total ILSI Score. However, again this change was not statistically 
significant, ∆R2 = .123, ∆F(6, 20) = .566, p = .753.  
Following post hoc Holm-Bonferroni correction, the abovementioned significant 
results were found to no longer remain. However, considering the small sample size and 
extent to the nature of the analyses performed, it is acknowledged that the current study 
was likely underpowered in order to detect more significant results. Therefore, the 
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significant results prior to correction will still be reported and further considered in the 
following chapter.  
Table 10 displays a summary of significant regression statistics for the 
individual ILSI sub-scale models and total ILSI score model. 
Moderation effects on executive function measures for functional outcome. 
The results outlined in Table 7 & Table 8 indicate that the relationships between 
executive function test performance and functional outcome differ across groups and 
hence suggestive of possible moderation effects on 8 of the functional outcome sub-
domains, namely: Hygiene & Grooming, Clothing, Interpersonal Skills, Home 
Maintenance, Money Management, Cooking, Resource Utilization, Medication 
Management, as well as on the Total ILSI Score. Therefore, additional regression 
analyses were conducted in order to further explore these potential moderation 
relationships. In this phase of regression analyses, 3 variables were entered into the 
regression equation in order to examine possible moderation effects. Firstly, a new 
variable was computed which calculated the interaction between Group (schizophrenia 
patients with cannabis use and matched-controls with a similar cannabis use history) 
and the executive function measure of interest. This variable was then entered, in 
addition to the executive function measure of interest, as well as the Group variable. 
Once again, only those executive function measures which showed a significant 
correlation with the functional outcome sub-scale ratings (from the Pearson correlation 
analyses), or the Total ILSI score, in each of the separate groups (i.e., schizophrenia 
group with cannabis use and matched-controls group with a similar cannabis use 
history) were entered into the regression analyses. Regression analyses in this phase 
were conducted using the overall combined sample (N = 56). Once again, before 
interpreting the results of the regression analyses, assumption tests and checks were  
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Table 10. Regression models for predicting ILSI ratings 
Outcome 
Variable 
Predictor 
Variable 
B Standard 
error 
Beta  
(β) 
Effect size  
(f 2) 
p-value 
Hygiene & 
Grooming 
Digit Span .150 .062 .429 .23 .023* 
       
Interpersonal 
Skills 
Symbol Search .123 .047 .457 .26 .014* 
       
Cooking Symbol Search .141 .054 .456 .26 .015* 
       
Resource 
Utilization  
Symbol Search .110 .051 .390 .18 .040* 
       
Medication 
Management 
Symbol Search .156 .064 .431 .23 .022* 
       
Total ILSI 
Score  
Symbol Search .098 .045 .389 .18 .041* 
Note. *p<.05, **p<.01 
 
performed with results indicating assumptions of normality, linearity and 
homoscedasticity of residuals were met. Further, multivariate outliers and 
multicollinearity were not found to be an issue. 
Hygiene and Grooming (Independent Living Skills Inventory). Results indicate 
that the overall model which included Digit Span significantly accounted for 34.3% of 
the variance in Hygiene and Grooming ratings on the Independent Living Skills 
Inventory in the combined sample, R
2
 = .379, R
2
adj = .343,  F(3, 52) = 10.591, p < .001. 
Digit Span (B = .297, β = 1.33, p =.004) and Group (B = 1.76, β = 1.61, p = .004) were 
found to have a significant impact on Hygiene and Grooming ratings at an individual 
level. The Group*Digit Span variable was also found to have a significant impact on the 
outcome variable (B = -.146, β = -2.07, p = .017), suggesting that a moderation effect 
between groups on Digit Span was present for Hygiene and Grooming ratings. Figure 1 
displays the moderation effect between groups on Digit Span for Hygiene and 
Grooming ratings. The difference in slopes between groups shown in Figure 1 indicate 
that Digit Span has more predictive power for the schizophrenia group, than it does for 
the matched-control group in relation to predicting Hygiene and Grooming ratings.     
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Figure 1. Moderation effect between groups on Digit Span for Hygiene and Grooming ratings 
 
The overall model which included Rule Shift Trial 2 as the executive function 
measure of interest, significantly accounted for 22.2% of the variance in Hygiene and 
Grooming ratings in the combined sample, R
2
 = .264, R
2
adj = .222,  F(3, 52) = 6.218, p = 
.001. However at an individual level, Rule Shift Trial 2 (B = -.481, β = -.748, p = .362), 
Group (B = -.967, β = -.884, p = .629), and the Group*Rule Shift Trial 2 variable (B = 
.393, β = 1.748, p = .438) were not found to have a significant impact on Hygiene and 
Grooming ratings. 
Clothing (Independent Living Skills Inventory). The overall model which 
included Digit Span significantly accounted for 28.2% of the variance in Clothing 
ratings in the combined sample, R
2
 = .321, R
2
adj = .282, F(3, 52) = 8.201, p < .001. 
However, results additionally indicate that Digit Span (B = .155, β = .781, p = .094), 
Group (B = 1.04, β = .553, p = .066), and the Group*Digit Span variable (B = -.069, β = 
-1.101, p = .217) were not found to have any individual significant impact on Clothing 
ratings. 
Results also indicate that the model which included Rule Shift Trial 2, 
significantly accounted for 26.1% of the variance in Clothing ratings in the combined 
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sample, R
2
 = .301, R
2
adj = .261, F(3, 52) = 7.467, p < .001. No further significant results 
were found at an individual level for Rule Shift Trial 2 (B = -.537, β = .455, p = .244), 
Group (B = -1.127, β = -1.153, p = .518), and the Group*Rule Shift Trial 2 variable (B = 
.427, β = 2.126, p = .333).  
The model including the Rule Shift Trial 2 and 4 combined score significantly 
accounted for 25.9% of the variance in Clothing ratings in the combined sample, R
2
 = 
.299, R
2
adj = .259,  F(3, 52) = 7.403, p < .001. At the individual level, no additional 
significant results were found for Rule Shift Trial 2 and 4 combined score (B = -.195, β 
= -.658, p = .162), Group (B = -.242, β = -.248, p = .759), and the Group*Rule Shift 
Trial 2 and 4 combined score variable (B = .121, β = 1.271, p = .280).  
Interpersonal Skills (Independent Living Skills Inventory). By including 
Symbol Search as a predictor, the model significantly accounted for 52.1% of the 
variance in Interpersonal Skills ratings in the combined sample, R
2
 = .547, R
2
adj = .521,  
F(3, 52) = 20.939, p < .001. In addition, Symbol Search (B = .252, β = 1.152, p = .002), 
Group (B = 1.913, β = 1.461, p < .001) and the Group*Symbol Search variable (B = -
.129, β = -1.617, p = .010) were found to each have a significant impact on the outcome 
variable. The significant results of the interaction term suggest a moderation effect 
between groups on Symbol Search for Interpersonal Skills ratings (see Figure 2). Figure 
2 displays the difference in the regression slopes between groups which suggest that 
Symbol Search had better predictive ability for Interpersonal Skills ratings for the 
schizophrenia group, than for matched-controls.   
The model which included Color-Word Trial 3, significantly accounted for 
47.7% of the variance in Interpersonal Skills ratings in the combined sample, R
2
 = .506, 
R
2
adj = .477,  F(3, 52) = 17.731, p < .001. Significant individual results for Color-Word 
Trial 3 (B = .165, β = .887, p = .034) and Group (B = 1.741, β = 1.330, p = .019), were  
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Figure 2. Moderation effect between groups on Symbol Search for Interpersonal Skills ratings 
also found. However, there were no further significant results for the Group*Color-
Word Trial 3 variable (B = -.099, β = -1.289, p = .127).    
Home Maintenance (Independent Living Skills Inventory). Including Rule 
Shift Trial 2 as a predictor resulted in a model which significantly accounted for 32.5% 
of the variance in Home Maintenance ratings in the combined sample, R
2
 = .362, R
2
adj = 
.325,  F(3, 52) = 9.843, p < .001. At the individual level, no further significant results  
were found for Rule Shift Trial 2 (B = -.639, β = -.693, p = .364), Group (B = -.988, β = 
-.630, p = .711), and the Group*Rule Shift Trial 2 variable (B = .501, β = -1.552, p = 
.459). 
Money Management (Independent Living Skills Inventory). Results indicate 
that the model including Digit Span, significantly accounted for 30.7% of the variance 
in Money Management ratings in the combined sample, R
2
 = .344, R
2
adj = .307, F(3, 52) 
= 9.103, p < .001. However, no significant individual results were found for Digit Span 
(B = .126, β = .435, p = .338), Group (B = 1.060, β = .744, p = .187), and the 
Group*Digit Span variable (B = -.044, β = -.476, p = .585).  
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Cooking (Independent Living Skills Inventory). The model including Symbol 
Search as a predictor, significantly accounted for 41.4% of the variance in Cooking 
ratings in the combined sample, R
2
 = .446, R
2
adj = .414, F(3, 52) = 13.972, p < .001. 
Results additionally indicated that Symbol Search (B = .308, β = 1.311, p = .001), 
Group (B = 2.198, β = 1.567, p < .001), and the Group*Symbol Search variable (B = -
.167, β = -1.948, p = .005) were found to have a statistically significant impact on the 
outcome variable at an individual level. The significant result of the interaction term 
suggests that a moderation effect between groups on Symbol Search is present for 
Cooking ratings (see Figure 3). Figure 3 highlights the differences in regression slope 
between groups showing that Symbol Search had better predictive ability for Cooking 
ratings in the schizophrenia group, than for the matched-control group.  
The model including Rule Shift Trial 2, significantly accounted for 30.4% of the 
variance in Cooking ratings in the combined sample, R
2
 = .342, R
2
adj = .304, F(3, 52) = 
9.013, p < .001. However, no further significant results were found for Rule Shift Trial 
2 (B = -.879, β = -1.066, p = .172), Group (B = -2.119, β = -1.510, p = .384), and the 
Group*Rule Shift Trial 2 variable (B = .750, β = 2.600, p = .224), at an individual level.  
Resource Utilization (Independent Living Skills Inventory). The overall model 
including Symbol Search as a predictor, significantly accounted for 46.3% of the 
variance in Resource Utilization ratings in the combined sample, R
2
 = .492, R
2
adj = .463,  
F(3, 52) = 16.818, p < .001. In addition, Symbol Search (B = .218, β = .941, p = .013) 
and Group (B = 1.738, β = 1.256, p = .002) were each found to have a statistically 
significant impact on Interpersonal Skills ratings. However, following Holm-Bonferroni 
adjustment the result related to the individual impact of Symbol Search no longer 
remained significant. The impact of the Group*Symbol Search variable on the outcome  
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Figure 3. Moderation effect between groups on Symbol Search for Cooking Ratings 
variable was found to approach significance (B = -.108, β = -1.274, p = .051), 
suggesting a trend towards a moderation effect between groups on Symbol Search for 
Resource Utilization ratings (see Figure 4). The regression line differences seen in 
Figure 4 illustrate the higher predictive ability of Symbol Search for Resource 
Utilization ratings in the schizophrenia group, than in the matched-control group. 
By including Digit Span into the regression equation, the model significantly 
accounted for 38.8% of the variance in Resource Utilization ratings in the combined 
sample, R
2
 = .422, R
2
adj = .388, F(3, 52) = 12.647, p < .001. No individual significant 
results were found for Digit Span (B = .050, β = .178, p = .675), Group (B = .836, β = 
.604, p = .253), and the Group*Digit Span variable (B = -.007, β = -.073, p = .929).  
The model including Rule Shift Trial 2, significantly accounted for 41.1% of the 
variance in Resource Utilization ratings in the combined sample, R
2
 = .443, R
2
adj = .411, 
F(3, 52) = 13.813, p < .001. However, additional results were not significant for Rule 
Shift Trial 2 (B = -1.003, β = -1.234, p = .087), Group (B = -3.065, β = -2.215, p = 
.167), and the Group*Rule Shift Trial 2 variable (B = .997, β = 3.503, p = .077), at the 
individual level.  
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Figure 4. Moderation effect between groups on Symbol Search for Resource Utilization ratings 
Including the Rule Shift Trial 2 and 4 combined score in the regression equation, 
the model significantly accounted for 38.5% of the variance in Resource Utilization 
ratings in the combined sample, R
2
 = .418, R
2
adj = .385, F(3, 52) = 12.456, p < .001. No 
additional significant results were found for the Rule Shift Trial 2 and 4 combined score 
(B = -.148, β = -.354, p = .407), Group (B = -.062, β = -.045, p = .952), and the 
Group*Rule Shift Trial 2 and 4 combined score variable (B = .134, β = .946, p = .356), 
when examining individual effects.   
Medication Management (Independent Living Skills Inventory). With Symbol 
Search included as a predictor, the overall model was found to significantly account for 
43.7% of the variance in Medication Management ratings in the combined sample, R
2
 = 
.468, R
2
adj = .437, F(3, 52) = 15.241, p < .001. Additional results found Symbol Search 
(B = .324, β = 1.175, p= .003), Group (B = 2.359, β = 1.431, p = .001), and the 
Group*Symbol Search variable (B = -.168, β = -1.670, p = .013) to each have a 
significant impact on the outcome variable. Results suggest a moderation effect between 
groups on Symbol Search for Medication Management ratings (see Figure 5). Once 
again, differences in regression slopes are displayed in Figure 5 indicating that Symbol  
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Figure 5. Moderation effect between groups on Symbol Search for Medication Management ratings 
Search has better predictive ability for Medication Management ratings in the 
schizophrenia group, than for matched-controls.    
By adding Color-Word Trial 3 into the regression equation, the model 
significantly accounted for 37.8% of the variance in Medication Management ratings in 
the combined sample, R
2
 = .412, R
2
adj = .378,  F(3, 52) = 12.127, p < .001. No further 
individual significant results were found for Color-Word Trial 3 (B = .189, β = .808, p = 
.076), and the Group*Color-Word Trial 3 variable (B = -.114, β = -1.173, p = .201). The 
individual impact of Group on the outcome variable was found to approach significance 
(B = 1.985, β = 1.204, p = .050). 
Total ILSI Score (Independent Living Skills Inventory). The overall model 
which included Symbol Search, significantly accounted for 48.6% of the variance in 
Total ILSI scores in the combined sample, R
2
 = .514, R
2
adj = .486, F(3, 52) = 18.320, p < 
.001. Examining individual effects, it was found that Symbol Search (B = .203, β = 
.995, p = .007), Group (B = 1.671, β = 1.368, p = .001), and the Group*Symbol Search 
variable (B = -.106, β = -1.416, p = .027) each had a statistically significant impact on 
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the outcome variable. The significant result of the interaction term suggests a 
moderation effect between groups on Symbol Search for the Total ILSI score (see 
Figure 6). The regression line differences shown in Figure 6 demonstrate that Symbol 
Search has better predictive power for the schizophrenia group regarding the Total ILSI 
score, than for the matched-control group. 
By including Rule Shift Trial 2 as a predictor into the regression equation, the 
model significantly accounted for 41.4% of the variance in Total ILSI scores in the 
combined sample, R
2
 = .446, R
2
adj = .414,  F(3, 52) = 13.941, p < .001. No additional 
individual significant results were found for Rule Shift Trial 2 (B = -.483, β = -.673, p = 
.345), Group (B = -.707, β = -.579, p = .715), and the Group*Rule Shift Trial 2 variable 
(B = .394, β = 1.567, p = .423). 
The model including Color-Word Trial 3, significantly accounted for 46.1% of 
the variance in Total ILSI scores in the combined sample, R
2
 = .490, R
2
adj = .461,  F(3, 
52) = 16.685, p < .001. Color- Word Trial 3 (B = .135, β = .780, p = .066), and the 
Group*Color-Word Trial 3 variable (B = -.080, β = -1.109, p = .194) were not found to 
have any individual significant impact on Total ILSI scores. However, Group was found 
to have a significant impact on the outcome variable (B = 1.497, β = 1.226, p = .033). 
Once again, it is important to note that considering the small sample size and the 
extent to the nature of the abovementioned analyses performed, it is acknowledged that 
the current study was likely underpowered in order to detect more significant results 
following post hoc Holm-Bonferroni correction. Therefore the results that no longer 
remained significant following adjustment will still be reported and considered.  
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Figure 6. Moderation effect between groups on Symbol Search for Total ILSI Score  
The overall reported regression analyses results indicate, as well as confirm, that 
Digit Span is a significant predictor of Hygiene and Grooming ratings, and Symbol 
Search significantly predicts Interpersonal Skills, Cooking, Resource Utilization, 
Medication Management ratings, as well as the Total ILSI score, for schizophrenia 
patients with cannabis use. However, results also suggest that these measures have 
greater predictive power for the schizophrenia group, than they have for the matched-
control group, in predicting ratings in the abovementioned ILSI areas, and Total ILSI 
score.  
 
General Discussion 
The current study sought to further our understanding of the neurocognitive 
profiles associated with schizophrenia patients with cannabis use and more specifically, 
their distinct profiles in relation to executive function. Previous research has explored 
this by examining group differences in neurocognitive performance between cannabis-
using schizophrenia patients and non-cannabis using schizophrenia patients. However, 
the literature evaluating these differences has produced contradictory findings. Such 
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mixed results are likely due to variations in methodology, the failure to account for 
various indicators of cannabis use (e.g., a range of cannabis use parameters such as 
frequency, severity/quantity, duration and length of abstinence), a lacking in the 
examination of clinical ‘impairment’ levels, and varying approaches in classifying 
cannabis users. The present research aimed to address these issues not by directly 
investigating the possible additive relationship between cannabis use and schizophrenia 
on neurocognitive performance, but instead by examining the differential effects of 
cannabis use on cognitive performance in individuals with schizophrenia in comparison 
to otherwise healthy subjects with a similar cannabis use history, in relation to one 
specific neurocognitive system namely, executive function.   
While the neurocognitive profiles of individuals with schizophrenia have been 
already well established in the literature, little is known about specific patterns that may 
exist in the schizophrenia patient with cannabis use population particularly in relation to 
the different aspects of executive function. The neurocognitive system of executive 
function is considered to have particular clinical relevance as executive function deficits 
have been found to be specifically associated with the illness of schizophrenia (Pantelis 
et al., 1997; Reichenberg & Harvey, 2007, Shallice et al., 1999), and have also been 
associated with functional outcome (Greenwood et al., 2005; McClure et al., 2007; 
Williams et al., 2008). 
The current study was divided into two parts. Part A of the research aimed to 
determine whether differences exist in executive function performance between 
schizophrenia patients with cannabis use and otherwise healthy controls with a similar 
cannabis use history. This was achieved by assessing the neurocognitive performance of 
both groups on several measures of executive functioning which were guided by West’s 
(1996) theoretical model of executive function. Additional executive function constructs 
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which appeared to not be described in West’s model, were also included in the study for 
exploration purposes. In line with this further exploration, the construct validity of 
West’s theoretical model of executive function in the current sample was also 
examined. The present research also permits some comment on whether cannabis use 
status and length of abstinence have an impact on differences in executive function 
performance. Part B to the study aimed to explore the relationship between executive 
function performance and functional outcome. Of particular interest was determining 
whether performance on specific executive function measures predicted performance in 
different functional outcome sub-domains, as well as overall functional outcome. 
Overall, there are four principal findings from Part A of the present study: a) 
schizophrenia patients with cannabis use demonstrated poorer performances on a range 
of executive function domains when compared to participants from the matched-control 
group with a similar cannabis use history; however, a significantly larger proportion of 
the schizophrenia group with cannabis use demonstrated performances that were not at 
an impaired level compared to those falling in the impaired range; b) an underlying 
structure was found to exist on a number of selected tests of executive function, 
providing partial support for the construct validity of West’s (1996) theoretical model of 
executive function in the current sample; c) the discontinuation of, or abstinence from, 
cannabis use was mainly not found to be associated with the recovery of executive 
functioning; d) longer abstinence periods were mainly not found to be associated with 
the recovery of executive function. 
The main findings from Part B of the study were that: a) performance on two 
executive function measures were shown to significantly predict specific functional 
outcome domains, namely Digit Span and Symbol Search, and that: b) moderation 
effects on the executive function measures were found for 8 of the individual functional 
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outcome sub-domains, as well as for overall functional outcome. Each of the main 
findings will now be discussed. 
Part A 
Group Differences in Executive Function  
With the interpretation of results being conceptually guided by West’s (1996) 
model, schizophrenia patients with cannabis use were found to have poorer performance 
in the Temporal Organisation of Behaviour (on the Zoo Map measure only), 
Retrospective Memory (on both Zoo Map recall and Digit Span measures), Interference 
Control (on both Symbol Search and Trail Making Test Trial 4 measures), and the 
Inhibition of Prepotent Responses (on both the Rule Shift Trial’s 2 and 4 and Color-
Word Trial 3 measures), when compared to matched-controls with a similar cannabis 
use history. These differences were found after accounting for the possible effects of 
estimated premorbid IQ. However, while the Modified Six Elements test was also used 
to assess the Temporal Organisation of Behaviour domain, no significant differences 
between the two groups was demonstrated on this particular measure. In addition, no 
significant differences were found between the two groups in the executive function 
domains of Prospective Memory (assessed by an event-based prospective memory task), 
Verbal Fluency (assessed by Letter Fluency), and Emotion-based Decision-making 
abilities (assessed by the Iowa Gambling Task). Overall these findings could be 
interpreted as cannabis possibly playing a different role for patients with schizophrenia, 
in comparison to healthy individuals. The pattern of results found in the current study is 
somewhat similar to the findings of Jockers-Schrübel and colleagues (2007) showing 
that overall, cannabis-using schizophrenic patients performed worse than cannabis-
using healthy controls in most of the neurocognitive tests administered in their study. 
Scholes and Martin-Iverson (2010) also found poorer performances across cognitive 
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tasks in cannabis-using patients relative to healthy cannabis-using controls. In addition 
to these findings, contrastingly Jockers-Schrübel and colleagues found that cannabis use 
was however associated with better test performance in schizophrenia patients, and 
conversely worse performance in healthy control subjects when the regular consumption 
of cannabis commenced prior to the age of 17.  
It is difficult to compare the current study’s findings when evaluating group 
differences in neurocognitive performance as we did not aim to specifically examine 
additive effects. However, despite schizophrenia patients with cannabis use 
demonstrating poorer performance on a number of executive function measures relative 
to controls, a significantly larger proportion of the schizophrenia group with cannabis 
use demonstrated performances in the normal range and were not reflective of even 
probable neurocognitive impairment. This was determined following examining their 
performances against normative mean criteria. As the current study compared the 
neurocognitive performances of individuals with schizophrenia to individuals without a 
mental illness (with cannabis use being controlled for), it would be reasonable to 
interpret the current results as potentially reflecting the effects of schizophrenia alone. 
However, as schizophrenia patients have been found to demonstrate neurocognitive 
performance on a variety of tests at 1.0 - 2.0 standard deviations below the norm of 
healthy populations (Heinrichs & Zakzanis, 1998; Wilk, Gold, Humber, Dickerkson, 
Fenton, & Buchanan, 2004), the significantly larger proportion of the schizophrenia 
group with cannabis use in the current study demonstrating performances falling in the 
normal range is contrary to such observations. Therefore, the current findings are 
unlikely to be reflective of just the simple effects of the illness of schizophrenia on 
neurocognitive performance alone. If the current findings specifically related to the 
schizophrenia group with cannabis use are considered to be a mere reflection of the 
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effects of the illness of schizophrenia alone, then one would expect performances falling 
even in the probable impairment range. However, this was not the case in the present 
study. 
Despite there being mainly poorer neurocognitive performances demonstrated 
by schizophrenia patients with cannabis use on a number of executive function domains 
in comparison to those in the matched-control group, there were no significant 
differences shown in performance in the domains of Prospective Memory, Verbal 
Fluency and Emotion-based Decision-making. These results potentially suggest that 
schizophrenia patients with cannabis use show nominal disruptions in performance in 
these particular executive function domains. In the current literature review, no research 
to date has been located where measures assessing the domain of Prospective Memory 
have been used to directly examine the neurocognitive performance of schizophrenia 
patients with cannabis use in particular. Therefore, a comparison of the results on this 
executive function domain to past findings is difficult. However, in a meta-analytic 
review of 11 studies examining prospective memory performance in schizophrenia 
patients, impairments were found on time-, event-, and activity-based prospective 
memory tasks compared to controls (Wang, Cui, Chan, Deng, Shi, Hong et al., 2009). In 
addition, performances on time-based prospective memory tasks were demonstrated to 
be more impaired than performances on event-based tasks. It was considered by the 
authors that time-based prospective memory measures may require a greater level of 
self-initiation than tests of event-based prospective memory. Therefore, while the 
present findings may suggest that schizophrenia patients with cannabis use show 
nominal disruptions in this domain, in alternative it could also indicate that the event-
based prospective memory measure used may not have sufficiently loaded onto 
prospective memory abilities. Previous research has also found no difference in 
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performance amongst cannabis-abusing patients in verbal fluency in comparison to non-
abusers (Mata et al., 2008; Schnell et al., 2009). The current results involving emotion-
based decision making abilities were somewhat inconsistent with Sevy and colleagues’ 
study (2007), where it was reported that both schizophrenia groups (i.e., both cannabis 
users and non-users) were found to be more cognitively impaired, and demonstrated 
worse performance on the Iowa Gambling Task, when compared to healthy controls. 
However, the healthy participants in this study were not matched for cannabis use and 
included six individuals who reported smoking marijuana less than 10 times in their 
lifetime, as well as individuals who did not report any cannabis use history. Therefore, it 
is possible that the measures selected in order to assess these domains may actually be 
sensitive enough measures in detecting deficits in executive function, but do not 
demonstrate specificity in identifying differences in this particular schizophrenia sub-
population. 
While the Temporal Organisation of Behaviour was also measured by the 
Modified Six Elements test in the current study, a lack of significant difference in 
performance between groups on this measure may suggest that this particular test was 
also perhaps not sensitive enough, nor did not sufficiently load onto this particular 
executive function domain, in order to detect differences in these samples. It is also 
possible that the samples recruited in the current study may have high heterogeneity, 
thus creating more variability within groups and making differences between groups 
harder to locate. However, as group differences were demonstrated on another measure 
of the Temporal Organisation of Behaviour (namely the Zoo Map task), as well as many 
other measures tapping into additional executive function domains, it is unlikely that 
this was the case. In addition, estimated premorbid IQ was found to have an impact on 
Modified Six Elements task performance and this could suggest that while this test may 
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assess an aspect of executive function, it may also rely upon other cognitive abilities 
specifically related to premorbid IQ. There has also not been any research located to 
date directly examining the performance of cannabis-using schizophrenia patients in 
particular on the Modified Six Elements test which limits the ability to compare and 
contrast the current results with previous findings.  
Level of executive function impairment between groups. The different 
performances of the two groups, requires further comment. Due to the lack of clinically 
impaired performances observed in a significant proportion of the schizophrenia group 
with cannabis use and the expected performance of 1.0 - 2.0 standard deviations below 
the norm for cannabis-naive schizophrenia patients, it appears that cannabis use in 
schizophrenia may have relatively nominal clinical effects on executive function 
performance when compared to normative criteria. A possible explanation for this result 
may be due to cannabis use in schizophrenia being potentially associated with outcomes 
of a more preserving nature. Cannabinoids have been shown to possess characteristics 
serving to protect individuals from brain insult and are associated with improvements in 
a range of illnesses which are considered neurodegenerative in nature (Sarne & 
Mechoulam, 2005). Thus, the findings of the present study may be reflective of 
differential effects of cannabis on the brain of individuals with schizophrenia, as 
opposed to a healthy brain, potentially as a consequence of neuroprotective effects. 
As the examination of impairment level was based on normative criteria, it is 
also reasonable to consider that schizophrenia patients with cannabis use may represent 
a distinct schizophrenia sub-population that has specific executive function abilities 
remaining at a non-impaired level when compared to individuals with schizophrenia 
who are cannabis naive. It has been postulated that the onset of psychosis in this 
subgroup may be aetiologically different to non-using schizophrenic patients, such that 
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cannabis use may serve as a catalyst to the onset of the illness in these individuals who 
may already possess better premorbid adjustment, social skills and hence a better 
prognosis, than their non-using counterparts (Dixon et al., 1991, Leeson et al., 2011; 
Rodríguez-Sánchez et al., 2010). It has also been suggested that this sub-group may 
have a lower vulnerability to the illness compared to those patients whose illness onset 
occur independent of the context of cannabis use (Schnell et al., 2009). Therefore, it is 
possible that such individuals already have better cognitive abilities due to not 
possessing as many neurodevelopmental risk factors, as well as having more enhanced 
prognostic characteristics (Leeson et al., 2011). Findings from Kumra and colleagues’ 
study (2005) showed that a history of cannabis use/dependence was associated with 
better FSIQ, as well as better VIQ, scores which also suggests the presence of better 
cognitive adjustment in cannabis-using schizophrenics. The lack of clinical impairment 
demonstrated by schizophrenia patients with cannabis use in the current research is 
consistent with the theme that has emerged from previous studies suggesting better 
neurocognitive performances in this group when compared to non-using schizophrenia 
patients.  
The Effect of Cannabis-Use Status on the Recovery of Executive Function  
Cannabis-use status (i.e., current users and non-current users) was mainly not 
found to have an impact on executive function performance, when controlling for the 
effects of duration of use (although there were a few notable exceptions to this, as 
discussed below). In other words, in general, cannabis use cessation or abstinence was 
not associated with the recovery of executive function. These results are also somewhat 
consistent with previous findings indicating no significant differences between patients 
with current cannabis dependence and patients without a current cannabis dependence 
diagnosis (which included both former users and those with minimal or no use) (Rabin 
CANNABIS USE, SCHIZOPHRENIA & EXECUTIVE FUNCTION 134 
 
et al., 2013). However, in the present study this was not the case for performance on 
Letter Fluency, such that current cannabis users demonstrated better performance on 
this task compared to non-current users. A possible explanation for this contrasting 
result may be related to premorbid IQ being shown to significantly influence 
performance on the Letter Fluency measure, in the earlier analyses of the current study. 
Therefore, this finding could provide possible further evidence for current cannabis 
users representing a group of individuals with better premorbid IQ, independent of 
whether or not they have the illness of schizophrenia. Further, it is plausible that 
individuals with better premorbid IQ may be more likely to continue cannabis use due 
to possessing the abilities required to continually seek avenues in order to maintain their 
drug use. In a recent study which specifically compared the relationship of cannabis use 
to premorbid IQ in a group of first episode psychosis patients, results showed that those 
patients who had ever smoked cannabis in their lifetime had higher premorbid IQ than 
those who had never used cannabis in their lifetime (Ferraro, Russo, O'Connor, Wiffen, 
Falcone, Sideli et al., 2013). However, as the current study controlled for premorbid IQ 
through the matching process, the findings may not solely be related to premorbid IQ 
(as measured by an estimated verbal premorbid IQ measure). Another possible 
explanation for these results are in line with previous suggestions that this subgroup of 
schizophrenia appears to demonstrate characteristics of having a less severe form of the 
illness in relation to neurocognitive abilities and therefore remain relatively cognitively 
preserved once psychosis develops potentially in the presence of early cannabis use. 
Findings from Barnett, Salmond, Jones, and Sahakian’s (2006) study indicated that 
superior cognitive function (i.e., cognitive reserve) may act as a protective function 
from cognitive decline. Cognitive reserve is defined as the ‘individual differences in 
how people process tasks which allow some to cope better than others with brain 
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pathology’ (Stern, 2009, p. 2016). In other words, individuals with higher cognitive 
reserve are less affected by the same extent of neurological damage caused by either the 
effects of the normal aging process, or from the effects of unhealthy aging (i.e., the 
result of illnesses which may serve to compromise cognitive function). Barnett and 
colleagues (2006) concluded from their results that this higher level of cognitive 
function may impact on neuropsychiatric disorders by either influencing the risk for 
developing the disorder, the expression of illness symptomatology, or the functional 
outcome of the individual. Therefore, the current results suggest that it may not be that 
cannabis is neuroprotective in nature, but instead findings implicate the possibility of a 
higher overall cognitive reserve in individuals who may belong to this specific 
schizophrenia subgroup. 
The Effect of Length of Abstinence on the Recovery of Executive Function 
The findings of the current study also showed that the length of abstinence was 
mainly not associated with the recovery of executive function, independent of duration 
of use. More specifically, shorter abstinence periods were not related to poorer 
performance even after duration of use was taken into account. Surprisingly, it was 
additionally found that former cannabis users with an abstinence period of less than 5 
years demonstrated better skills in the Temporal Organisation of Behaviour compared to 
former cannabis users with an abstinence period of equal to, or greater than, 5 years, 
although this result was shown for performance on the Zoo Map measure only. This is 
somewhat consistent with previous findings which showed that in addition to frequency, 
recency of cannabis use was also associated with better neurocognitive performance 
related to attention/processing speed and executive function in schizophrenia patients 
(Coulston et al., 2007). Stirling and colleagues (2005) also found that schizophrenia 
patients who had sustained their cannabis use at follow-up demonstrated better 
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neurocognitive performance on a variety of measures (i.e., design memory, verbal 
fluency, object assembly, block design, picture completion, picture arrangement, face 
recognition memory), than those individuals who did not continue their use until this 
time. An explanation for this finding may involve the possibility that those individuals 
with more recent use may still possess intact temporal organisational skills even after 
cannabis use cessation. It could also be considered that perhaps these abilities begin to 
reduce over time from the lack of exposure to drug-obtaining and drug use maintenance 
activities, as well as the lack of rehearsal of the behaviours necessary to achieve these 
objectives. This is a plausible explanation considering the temporal organisation of 
behaviour involves temporally organizing steps of a process which serve as a guide in 
selecting appropriate behaviors required to complete tasks (Fuster, 1989). It could be 
also speculated that such processes are considered to be involved in the perpetuation of 
drug use. Results of the current study suggest that these abilities also appear to be intact, 
irrespective of the presence or absence of the illness of schizophrenia. 
The Validity of West’s Theoretical Model of Executive Function 
While there was no specific hypothesis outlined regarding the construct validity 
of West’s (1996) theoretical model of executive functioning, findings indicated the 
presence of an underlying structure on a number of selected tests of executive function 
in the current study. The executive function measures which significantly loaded onto 
factor 1 (namely Mental Control and Self-Regulation) were those which were guided by 
West’s theoretical model. In addition, the executive function measures which were 
added for exploration due to not appearing to be accounted for in West’s model (i.e., 
Verbal Fluency and an Emotion-based Decision-making task) seemed to either load 
onto a separate component or failed to meet criterion for PCA. The overall results 
appear to not only in part, confirm the construct validity of West’s theoretical model of 
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executive function, but also provide support for the convergent validity, as well as 
divergent validity, of the model. Such results are also in part, supported by Num’s 
(2006) findings. It is possible that the additional executive function domains that 
weren’t accounted for in West’s model are not in fact, reflective of ‘pure’ executive 
function domains due to having loaded onto a different component or not being able to 
be included in PCA. This may be due to such measures tapping into other 
neurocognitive domains in addition to those falling under the executive function 
umbrella. While tests of verbal fluency (namely phonemic fluency) are one of the most 
frequently utilised measures in the assessment of executive function (Baddley, 1996; 
Baldo et al., 2001; Stuss & Levina, 2002), they also are known to activate non-frontal 
brain areas (Frith, Friston, Herold, Silbersweig, Fletcher, Cahill et al., 1995; Paulesu, 
Goldacre, Scifo, Cappa, Gilardi, Castiglioni et al., 1997). Interestingly, an additional 
factor was produced as an outcome of the analysis, namely ‘Maintenance of Intention 
for Future Action’. A possible explanation for why the event-based prospective memory 
task loaded onto a different factor to factor 1 in the PCA, may have been due to the 
specific measure that was selected in the current study not being sensitive enough to tap 
into the true prospective memory construct. Similar to Wang et al.’s (2009) conclusions, 
time-based prospective memory tasks have been thought to place a greater demand on 
self-initiation for successful performance due to the lack of external cues provided in 
such a measure and consequently more heavily relies on executive functioning 
processes (McDaniel & Einstein, 1993). In addition, the result of Kinch and 
McDonald’s (2001) study, suggest that successful performance in an event-based 
prospective memory task was primarily attributed to retrospective memory abilities. 
Therefore, it is possible that the abilities assessed by this particular type of prospective 
memory task may not just reflect a more crucial underlying executive function process 
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such as retrospective memory, but in addition may tap into abilities falling outside of 
the executive function domain alone. It is also reasonable to consider that Trial 3 of the 
Color-Word Interference subtest of the D-KEFS may not just reflect the inhibition of 
more dominant, habitual responses, but also measure the maintenance of information 
required to perform a future action.   
 It has been argued that while various neuropsychological measures may have 
good face validity, demonstrated high construct validity is imperative in order for such 
measures to represent a construct accurately (Salthouse et al., 2003). Therefore, results 
suggest that the majority of the executive function measures which loaded onto factor 1 
demonstrate an ability to be sensitive to the executive processes conceptualised by 
West’s model, but in addition they also demonstrate specificity in being able to tap into 
these specific neurocognitive processes as opposed to others.   
In order to conduct the PCA, the sub-samples were combined due to their small 
sizes. As it was considered in previous literature (e.g., Solowij & Michie, 2007) that 
cannabis users demonstrate deficits on cognitive measures similar to those shown in 
schizophrenia patients, there is a chance that the sub-samples in the current study are 
not all that dissimilar in cognition factor structure. Therefore, combining the samples 
would be appropriate. However, it is considered that if the sub-samples are indeed 
dissimilar to each other then this may help to explain why some executive function 
measures did not load onto factor 1. Considering the PCA was intended to be 
exploratory in nature, the results of this analysis were also not used in further analyses 
and therefore, the interpretation of results should only be considered on a theoretical 
basis. Prospective studies with larger samples should seek to further examine the factor 
structure of cognition in schizophrenia patients with cannabis use, and cannabis users 
with a similar cannabis use history, in order to clarify any similarities or dissimilarities. 
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It is also acknowledged that the current study did not aim to examine the actual 
hierarchy of functions from West’s (1996) hierarchical model of executive function. 
However, was considered that an analysis of this type would require much larger 
samples. Future studies should look to examine the hierarchy of functions in West’s 
model in patient populations in order to assist in further evaluating the validity of the 
hierarchical nature of the model. 
As the current study is the only study to date to have utilised this theoretical 
model of executive function to guide test selections in order to assess the executive 
functioning of individuals with schizophrenia, further studies are warranted to replicate 
the present findings. Taking into account the abovementioned results, future 
investigations should also consider the use of a time-based prospective memory 
measure in order to better clarify the role, as well as confirm or disconfirm the 
inclusion, of this particular cognitive domain in the executive function model. However, 
the assessment methodology of the current study may provide a more effective approach 
to future research, particularly when attempting to comprehensively assess and 
fractionate the executive function system.       
Part B 
The Relationship Between Executive Function and Functional Outcome 
Findings from the present study not only showed that different aspects of 
executive functioning were predictive of ‘real world’ functional outcome in 
schizophrenia patients with cannabis use, but that these aspects also moderated the level 
of functional outcome in different groups. From the variety of executive function 
measures administered in the current research, it was found that performance on the 
specific measures of Digit Span and Symbol Search significantly predicted performance 
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in particular areas of functional outcome for schizophrenia patients with cannabis use, 
in comparison to that for the matched-control group.  
Findings suggest that performance on Digit Span (a measure used to assess 
Retrospective Memory), was significantly related to those functional outcome skills 
associated with hygiene and grooming. It can be speculated why this aspect of executive 
functioning would be related to this particular functional outcome sub-domain. It is 
reasonable to consider that Retrospective Memory, which involves the maintenance of 
task-relevant information online and provides a reference by which a task sequence is 
formed (Fuster, 1989), has particular importance in maintaining adequate independent 
skills in hygiene and grooming. Schroots, Dijkum, and Assink (2004) define 
retrospective autobiographical memory as the ability to retrieve certain memories, 
experiences, or past events in the present time. Dritschel et al. (1998) argued that 
participants with traumatic brain injury would be able to plan further activities more 
easily if they first tried to retrieve specific autobiographical memories of where they 
have executed similar activities in the past and described step-by-step what they did. In 
addition, Burgess and Shallice (1997) argued that the application of retrospective 
memory processes, in particular those that are implicated in the recollection of previous 
experiences play a critical part in prospective memory (i.e., the set of abilities that 
enable an individual to carry out a future intention or plan-following behaviour). In 
support of this, Kinch and McDonald (2001) also considered that a crucial component 
of remembering the intention to commit a future action or task (i.e., prospective 
memory) is considered to be largely retrospective in nature. Therefore, it appears that 
retrospective memory processes in some form have the capacity to assist individuals to 
carry out planned future intentions and one could expect such processes to be in 
involved in the daily requirements of hygiene and grooming activities. 
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While in the current study retrospective memory has been considered a 
component of executive function in West’s (1996) theoretical model of executive 
function, it is acknowledged that the retrospective memory does include some more 
general cognitive abilities that are not necessarily specific to the frontal lobe system. 
However, Fuster (2000) refers to retrospective memory as short-term memory or 
sensory working memory and uses the term ‘active short-term memory’ to encompass 
the construct (p. 67). It has also been well documented that short-term active memory 
involves prefrontal neurons (e.g., Funahashi, 1989; Fuster, 1973; Niki, 1974). In 
addition, West (1996) conceptualises retrospective memory in his model as involving 
the retrieval and maintenance of information that is task-relevant from its storage in 
memory and is conceptualised to be similar to working memory. Much consistency 
between the types of memory deficits experienced by patients with lesions of the frontal 
lobe and by healthy older adults has been observed due to both types of subjects 
demonstrating deficits on measures of memory which are thought to heavily require 
processes that are strategic in nature and hence, executive functioning (Moscovitch & 
Winocur, 1992). Further, it is important to note there have been a number of measures 
utilised when assessing retrospective memory abilities in the literature. Some of these 
include span, working memory, recall and recognition type measures. In the current 
study, two measures were used in an attempt to assess retrospective memory abilities, 
namely Digit Span (forwards assessing span, and backwards assessing working 
memory) and Zoo Map recall (assessing free recall). While it is acknowledged that total 
Digit Span provides a combination of span, as well as working memory abilities, 
previous research has also utilised forward Digit Span as one approach to assessing 
retrospective memory abilities (Maylor, Smith, Della Salla, & Logie, 2002). The authors 
described retrospective memory being usually assessed by tasks that involve the 
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presentation of information that is subsequently required to be recalled or recognized 
following a cue. In addition, the results of Maylor and colleagues’ (2002) factor analytic 
study showed that more traditional Retrospective abilities (as measured by free recall 
and recognition) and working memory abilities (as measured by Digit Span and 
Sentence Span) loaded highly on one factor in a sample patients with Alzheimer’s 
Disease and healthy older adults.  
It is noted that the findings of Dickinson et al.’s (2008) study indicate that the 
neuropsychological impairments associated with the illness of schizophrenia relative to 
healthy control subjects is largely mediated through a common ability factor and that 
further analyses revealed direct diagnosis effects on verbal memory and processing 
speed. Therefore, it is reasonable to consider that processing speed and simple 
maintenance working memory may have a more direct impact on the everyday 
outcomes of schizophrenia patients based on such results. However, it may be erroneous 
to apply the same conclusions about the cognition of schizophrenia patients with 
cannabis use, particularly because the current study’s results related to impairment 
levels (in conjunction with previous findings) suggest that this subgroup of the 
schizophrenia patients may be dissimilar with regard to cognitive abilities.  
Findings also showed that performance on Symbol Search (used to assess 
Interference Control) is predictive of performance in the functional outcome areas of 
interpersonal skills, cooking, resource utilization, medication management, as well as 
overall functional outcome. These results are suggestive that the ability to deal with 
interference or conﬂict from recently presented information that was once relevant, but 
is now irrelevant, could be necessary to maintain independence in the abovementioned 
areas and that these specific areas may also be important to the overall functional 
outcome of this particular subgroup of individuals with schizophrenia. This could be 
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due to the possibility that poorer interference control abilities may limit the capacity of 
individuals with schizophrenia to filter out previously attained information (that is no 
longer relevant to the situation at hand) and adapt to new situations. It has been 
considered that interference control abilities help to clear inappropriate information to 
the task at hand from retrospective memory storage (West, 1996). It is possible that the 
abovementioned sub-domains of functional outcome (as opposed to the sub-domains of 
personal management, clothing, basic skills, home maintenance, money management, 
and general occupational skills) may be more related to interference control deficits in 
this particular schizophrenia sample. One could assume that such independent living 
skills are not entirely guided by routine, but instead may involve modified action 
sequences depending on the individual’s day-to-day circumstances (i.e., presenting the 
individual with new information or demands). For example, this could occur when an 
individual receives a phone call in the middle of following a recipe. Whereas the other 
sub-domains not predicted by interference control abilities could either possibly 
subscribe to more basic cognitive skill functions or even those cognitive abilities that 
were not assessed for in the current study. It is also considered that proactive 
interference is a major contributing factor to memory failure and in an attempt to 
resolve the effects of interference from prior learning or encoding, individuals will 
typically slow down and employ some type of cognitive control strategy (Persson & 
Reuter-Lorenz, 2008). For example, this may involve either efforts to make a mental 
note of where the individual left off before the interference/distraction, or even using a 
compensatory approach such as marking the recipe at the interrupted step. Gaining a 
better understanding of the nature of the neurocognitive domains which may serve to 
significantly contribute to performance in specific functional outcome areas has the 
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potential to more effectively guide cognitive rehabilitation efforts and ultimately 
increase their effectiveness and success.     
Interestingly, the predictors identified as being significantly related to outcome 
in the current study are in fact the variables that are not specific to executive functions 
alone. While Symbol Search involves a measurement of interference control, it is also a 
measure of processing speed. In this test, the participant is required to match a symbol 
to an identical target that is displayed among several distractor stimuli that share similar 
physical features. Interference control is assessed through the selection of correct 
matches identified from the variety of distractors and speed is assessed by the number of 
correct items the participant completes within the time limit. Definitions of interference 
control commonly involve reference to the selection of relevant information and the 
ignoring of irrelevant information (Dempster, 1993; Harnishfeger, 1995; Nigg, 2000). In 
a study examining the relationship between inhibition and interference control, the 
authors assessed ‘resistance to distractor interference’ with tasks in which participants 
were required to select targets that were presented with irrelevant distracters (Friedman 
& Miyake, 2004). For example, the authors utilised the Eriksen flanker task (Eriksen & 
Eriksen, 1974) to measure this construct in which participants were required to identify 
a target letter that was presented either alone or with response-incompatible letters 
beside it, as quickly as possible without sacrificing accuracy. It is considered that 
‘resistance to distractor interference’ is being assessed when distracting information is 
presented simultaneously with the target information and is irrelevant to the response 
required (Friedman et al., 2004). It would be reasonable to assume that the approach in 
which to quantify interference control abilities would inevitably involve not only 
determining one’s ability to control interference/distraction (i.e., by calculation of 
accuracy via a number of errors score), but also the efficiency of one’s ability to control 
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interference/distraction (i.e., by calculation of the speed in which one can complete the 
task). Therefore, the examination of one’s performance on such measures in the context 
of both accuracy and speed seems fitting to determine an individual’s success on these 
tasks. As the current findings also indicate that Trail Making Test performance (which 
was also used as measure of Interference Control) did not significantly predict 
functional outcome, this may suggest that interference from distraction could be more 
directly related to the functional outcome domains of interpersonal skills, cooking, 
resource utilization, medication management, as well as overall functional outcome, 
compared to abilities that involve more of an active suppression process. 
In addition, it is acknowledged that while there are some functional outcome 
domains assessed by the Independent Living Skills Inventory that apply more to a 
patient population, the current study required an inventory that was considered a valid 
instrument to utilise in the assessment of this specific clinical population. As mentioned 
previously the purpose of the regression analyses was to identify whether there is 
potential for improvements to specific cognitive abilities which in turn may affect 
associated functional outcome. Without a comprehensive assessment of a number of 
functional outcome domains, the clinical relevance of potentially targeting the specific 
functional outcome domains deemed to be involved in patient independent living skills 
would be lost. 
These results are not only in line with previous research suggesting a significant 
relationship between executive functioning and functional outcome, but also extend 
previous findings by being able to identify which specific aspects of executive function 
(according to a theoretical model of executive function) significantly predict particular 
sub-domains of functional outcome. By using a range of measures to assess the different 
theoretical components of executive function and identifying which of these have better 
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predictive ability in relation to ‘real world’ functional outcome, we were able to more 
comprehensively evaluate this relationship as well as potentially increase the ability to 
detect differences between groups on this multi-faceted and complex neurocognitive 
domain.       
The results demonstrating moderation effects indicate that the abovementioned 
measures in particular also have greater predictive power for schizophrenia patients 
with cannabis use than they have for healthy matched-controls with a similar cannabis 
use history. One explanation for this finding could be related to previous research 
suggesting that cannabis may have differential effects on individuals with 
schizophrenia, in comparison to healthy individuals (Jockers-Schrübl et al., 2007). Due 
to a potential higher cognitive reserve (as suggested by their cannabis use history), it 
would be expected that any preservation in cognitive performance would translate to 
relative preservations in functional outcome areas. Therefore, it is possible that those 
with more preserved outcome (across similar functional outcome sub-domains) in this 
subpopulation may possess more preserved retrospective memory and interference 
control abilities. Such findings suggest that the measures assessing these specific 
executive function domains could be considered as useful tools in predicting the 
functional outcome of this subgroup of individuals with schizophrenia, particularly in 
relation to identifying areas for improvement regarding the associated day-to-day 
independent living skills.    
Practical Applications of the Findings 
 Given the significant association between cognition and functional outcome in 
schizophrenia, over-and-above the effects of positive, negative and disorganisation 
symptoms (Green, 1996; Green et al., 2000), it is considered imperative that both 
researchers and clinicians look to develop specific and effective strategies in order to 
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improve cognitive function in this clinical population. The current study demonstrates 
that through comprehensive and more construct-targeted assessment approaches, it is 
possible to identify appropriate strategies that are both practical and customised to the 
individual’s specific deficits. The treatment of cognition in schizophrenia has been 
largely influenced and inspired by the field of neurological impairment rehabilitation 
(Medalia & Choi, 2009). The cognitive problems associated with the ‘dysexecutive 
syndrome’ are considered to represent a major challenge to the functional adaptation 
and recovery of individuals affected by such deficits and consequently, serve as crucial 
rehabilitation targets (Hewitt, Evans, & Dritschel, 2006). Therefore, clinical 
neurocognitively-based rehabilitation techniques, particularly those focused on the 
training of executive skills, are ideally suited to address the relationship between 
cognitive dysfunction and functional outcome.  
The present findings have value in that the current neurocognitive assessment 
methods utilised can help to possibly attribute performance in a number of functional 
outcome areas, specifically to difficulties in retrospective memory and interference 
control abilities in schizophrenia patients with cannabis use. The results also indicate 
that this relationship mainly exists between retrospective memory and interference 
control, and various functional outcome areas, in comparison to the other executive 
function domains assessed. Such findings suggest that targeting these specific executive 
function domains in rehabilitation efforts may not only facilitate improvements in 
performance on measures assessing these particular executive function domains, but 
may also translate to performance improvements in day-to-day real-world functional 
outcome areas in this subgroup. This notion is supported in the literature which 
proposes that cognitive enhancement in individuals with schizophrenia may not just 
generalise to neurocognitive task performance, but may also be observed in an 
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individual’s performance across everyday activities particularly if the skills required in 
such activities tap into similar neurocognitive domains (for discussion, see Medalia & 
Choi, 2009). 
There are a number of rehabilitation programs which have been developed in 
order to remediate cognitive impairments more specific to executive function, in 
schizophrenia patients. The intention of cognitive remediation approaches is to assist 
individuals to develop cognitive skills which are deemed fundamental in helping to 
improve their function in day-to-day activities (Medalia & Choi, 2009). Some cognitive 
rehabilitation interventions have been designed to target a number of neurocognitive 
domains which include those that involve executive function abilities (Bell, Bryson,  
Greig, Corcoran, & Wexler, 2001; Bellack, Dickinson, Morris, & Tenhula, 2005). Other 
intervention approaches are tailored in order to target more specific executive processes, 
such as working memory, cognitive flexibility, and planning abilities (Wykes, Reeder,  
Landau, Everitt, Knapp, Patel, & Romeo 2007), and problem-solving abilities (Medalia, 
Revheim, & Casey, 2002). A well-validated intervention aimed at the rehabilitation of 
those executive function abilities involved in the self-regulation of behaviour is Goal 
Management Training (GMT) (Levine, Robertson, Clare, Carter, Hong, Wilson et al., 
2000; Levine, Stuss, Winocur, Binns, Fahy, Mandic et al., 2007; Robertson, 1996; 
Robertson, Levine, & Manly, 2005). GMT is a theoretically derived cognitive training 
protocol based on Duncan’s theory of ‘goal neglect’ (Duncan, 1986; Duncan, Emslie, 
Williams, Johnson, & Freer 1996), which describes deficits in strategic self-regulation 
associated with the dysexecutive syndrome. The approach is a standardised, interactive 
manual-based cognitive rehabilitation program that aims at improving an individual’s 
attentional and organisation skills in order to improve the ability to achieve goal-
directed plans. The program provides a specific focus on goal-directed behaviours found 
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in everyday contexts. GMT procedures encompass training 5 steps, with each 
emphasizing and corresponding to an important aspect of goal-directed behaviour. The 
strategy involves training individuals as a first step to ‘stop and think’ by taking pauses 
during the task at hand and direct their awareness to pertinent goals. Once relevant goals 
are selected at step two, the individual is then required to subdivide the goal into smaller 
and more manageable subgoals at step three. The fourth step trains the individual to 
encode and maintain the goal, and more simple subgoals, in memory. At step five, the 
outcome is then compared with and checked against the intended goal. This approach is 
repeated in the event that the action outcome is mismatched with the original goal. 
GMT is considered to be a top-down approach that aims to train processes across 
several neurocognitive domains and incorporate different aspects involved in the stages 
of goal management such as attention and task orientation, goal definition, problem-
solving, encoding, retention and retrieval strategies, and monitoring (Levine et al., 2000, 
2007; Levaux, Larøi, Malmedier, Offerlin-Meyer, Danion, & Van der Linden, 2012). 
Such an approach aims to promote generalisation where different behaviours or 
activities that may not specifically be targeted in the actual GMT intervention may be 
also subject to improvements, or the skills trained can be applied to various other 
contexts that require the formulation of goal-directed plans (Levaux et al., 2012). 
Levaux and colleagues (2012), sought to apply this method to a patient with 
schizophrenia suffering from executive deficits in a case study. In their research they 
applied the GMT strategies across three steps: (1) psychoeducation and learning GM 
steps; (2) training GM principles on pencil-and-paper tasks; and (3) training in practical, 
real-life situations. Results of the study showed improvements in planning and 
dominant verbal response inhibition, as well as increased care and attention to tasks 
(with the patient taking more contextual information into account). Progress was found 
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to be maintained 2 years later and continued to evolve, and generalisation of the effect 
of GMT was observed on both non-trained laboratory and non-trained everyday tasks. A 
significant increase in the patient’s self-esteem score was also found. Overall, the results 
of the case study suggest that GMT is a promising technique for the rehabilitation of 
everyday executive difficulties in people with schizophrenia. However, it was important 
to note that there was no change in impaired flexibility, response inhibition and 
attentional functions following the GMT intervention. In addition, working memory and 
language flexibility remain preserved, and non-verbal process speed remained slowed. 
Beneficial effects on a number of executive function deficits have been 
demonstrated in patients with traumatic brain injury and older adults (Levine et al., 
2000, 2007; van Hooren, Valentijn, Bosma, Ponds, Van Boxtel, Levine et al., 2007), as 
well as potentially for schizophrenia patients (Levaux et al., 2012), as a result of GMT 
interventions. However, the approach has rarely been utilised in the context of substance 
abuse. Alfonso and colleagues (2011), developed a program which not only included 
methods derived from the GMT protocol, but in addition also incorporated aspects of 
mindfulness-based meditation. Mindfulness-based meditation was considered to serve 
as an effective compliment to traditional GMT training methods in order to improve 
attention scanning and ‘reading’ of emotional signals involved in adaptive decision-
making. Mindfulness-based mediation practices promote paying attention to the present 
moment, in a purposeful, non-judgemental, and emotionally aware manner (Kabat-Zinn, 
Massion, Kristeller, Peterson, Fletcher, Pbert, Lenderking, & Santorelli, 1992; Segal, 
Williams, & Teasdale, 2002). The use of mindfulness techniques has been considered a 
promising approach for the treatment of problematic substance-use related behaviours 
and supporting relapse prevention efforts (Bowen, Chawla, Collins, Witkiewitz, Hsu, 
Grow et al., 2009; Bowen & Marlatt, 2009; Witkiewitz, Bowen, Douglas, & Hsu, 2013). 
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Results of the study showed that the GMT and mindfulness meditation program 
significantly improved performance on working memory, selective attention/response 
inhibition and decision-making. The authors concluded from the findings of the study 
that improving competence in executive abilities may have the capacity to improve the 
clinical prognosis of substance abusers. However, it is important to note that there were 
no significant improvements in the neurocognitive domains of planning and flexibility 
following the GMT and mindfulness meditation program. It was considered by the 
authors that a possible explanation for this may perhaps involve the presence of 
impairments in other more basic, underlying skills. Shallice, Burgess and Robertson 
(1996) consider that an important process that serves to assist in appropriate strategy 
generation and planning is episodic memory retrieval. In other words, retrospective 
episodic memory processes. It is plausible that the recollection of previous similar 
experiences would be beneficial when attempting to formulate solutions to unfamiliar 
situations. It has been reported that retrieving more specific memories when devising 
strategies to low frequency activities (i.e., unfamiliar situations), is associated with more 
effective solutions as well as solutions containing more relevant steps (Dritschel et al., 
1998). This suggests that the recollection of previous similar experiences can be 
beneficial for planning and problem-solving contexts. Einstein and McDonald (1990) 
propose that the aspect of an activity that involves retrospective memory relates to one’s 
ability to maintain information regarding action and context. Burgess and Shallice 
(1997) also consider the view that the earlier stages of intention creation are not only 
facilitated by executive control systems, but that such systems mediate the development 
of intentions which involve complex retrieval. These findings are once again, consistent 
with the view that retrospective memory processes play an important role in strategy 
generation and planning future intentions.     
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The current study is believed to be an important first step in evaluating the 
applications of more comprehensive neuropsychological assessment which has been 
guided by a theoretical model of executive function (West, 1996). Considering the 
potential practical applications of the current findings, further research is required in 
order to demonstrate whether rehabilitation methods aimed at training specific executive 
function deficits can improve performance in more practical, everyday situations. It has 
been consistently found that cognitive remediation efforts aimed at specific cognitive 
abilities is an effective approach for cognitive enhancement (Green & Harvey, 2014). 
However, it is considered that such improvements may not necessarily translate to 
functional change. With the view to improve the functional outcomes of individuals 
with the illness, it is considered that the treatment of cognitive dysfunction as a sole 
approach may fall short in its effectiveness (Harvey, 2007). To enable a more effective 
translation of cognitive improvements into successful functional change, it is proposed 
that other forms of intensive support or assistance may be required which target those 
factors outside the illness that appear to also influence outcomes (e.g., demographics 
and psychosocial variables) (Harvey, 2007). Bell and colleagues (2008) conducted a 
study evaluating the effects of Neurocognitive Enhancement Therapy (NET) in 
conjunction with a supported employment program (VOC) on the enhancement of 
functional outcomes in patients with schizophrenia and schizoaffective disorder. The 
NET+VOC program consisted of computer-based cognitive training, work feedback and 
a social information information-processing group. Findings from the study suggested 
that the combination of cognitive retraining methods with additional skills training in 
other areas has the capacity to promote more beneficial functional gains. In a recent 
study conducted by Bowie, McGurk, Mausbach, Patterson, and Harvey (2012), 
individuals with schizophrenia living in community settings were randomly assigned to 
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either a cognitive remediation, functional skills training, or combined treatment group. 
It was reported that those patients who either received cognitive remediation, or the 
combined treatment, showed improved neurocognitive test performance from baseline 
to end of treatment. At a 12-week durability assessment, these effects were observed to 
be maintained. However, improvements in neurocognitive performance were not 
observed following the functional skills training alone intervention. Those individuals 
who either received functional skills training, or the combined treatment, demonstrated 
improved social competence (as measured by the Social Skills Performance 
Assessment) from baseline to end of treatment. In addition, patients who either received 
functional skills training, or the combined treatment, showed improvements in 
functional competence (as measured by a computed composite score from three 
measures of everyday functional skills) from baseline to end of treatment. However, the 
functional competence improvements demonstrated following functional skills training 
were no longer significant at the 12-week durability assessment when compared to 
baseline. It was noted that greater and more durable functional competence 
improvements were demonstrated in those patients who were assigned to the combined 
treatment group. Improvements in real-world community activities (as measured by the 
Specific Levels of Functioning Scale; Schneider & Struening, 1983) were found to be 
greater in patients who received the combined treatment, compared to the functional 
skills training group. Patients who were assigned to the either the functional skills 
training group, or the combined treatment group, showed improvements in real-world 
occupational skills (also measured by the Specific Levels of Functioning Scale) at 
baseline to end of treatment and these effects were maintained at the durability 
assessment. However, the treatment effects in the combined treatment group were found 
to be significantly larger than the functional skills group and the cognitive remediation 
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group. Overall findings from the study suggest that cognitive enhancement strategies in 
isolation do not result in functional improvements in real-world behaviour. The authors 
concluded that the transfer of cognitive improvements to everyday functioning is more 
likely to occur in the context of receiving supplementary functional skills training in 
addition to cognitive remediation intervention. While previous findings have indicated 
that the use of cognitive remediation strategies as a standalone treatment may be 
insufficient in translating to improvements in functional behaviour, it is considered that 
an ideal approach may involve treating professionals placing additional focus on the 
most appropriate avenues in supporting the efforts of schizophrenia patients and for 
empirical studies to aim to identify which of these support methods are most effective 
(Harvey, 2007). 
In order for cognitive rehabilitation efforts to be optimal in their effectiveness, 
there is also a need to better profile the patient samples of interest and the precise nature 
of the deficits needing to be addressed. Identifying different intervention factors that 
might serve to maximise the effectiveness of cognitive remediation efforts is also an 
area that has the potential to optimise the efficacy of future intervention efforts (e.g., 
different instructional techniques, learning and presentation formats, and materials 
used). There is also a need for the continued development of appropriate outcome 
measures to ensure that interventions translate into meaningful changes in real-world 
functioning. Further, future research should also not only aim to determine whether 
training in executive processes can be effectively translated into benefits in daily life, 
but to assess whether these benefits are maintained over time. 
Finally, as only a little more than half of the variance of a number of functional 
outcome areas were explained by performance on Digits Span or Symbol Search in the 
current research, this suggests that other variables which were not examined in this 
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study could also have a significant impact on functional outcome. Therefore, our results 
should be regarded as preliminary in nature. In addition, such results suggest that if only 
certain aspects of executive function are significantly related to various areas in the 
functional outcomes of schizophrenia patients with cannabis use, then other 
neurocognitive domains may serve to also be targeted or emphasized in a strength-based 
approach to cognitive training efforts. In other words, effective cognitive rehabilitation 
protocols involving this particular clinical population should not only involve cognitive 
training in identified deficits areas, but should also focus on making use of their intact 
neurocognitive abilities. The current findings have clinical importance in that they 
support the concept of developing interventions to treat neuropsychological deficits that 
may contribute to the more successful functional outcomes of such patients.  
Limitations and Future Directions 
The results reported in the present research need to be assessed and interpreted 
within the context of its limitations. Firstly, findings of the study should be considered 
to be exploratory in nature considering the small sample sizes. However, unlike some of 
the previous studies, the current research sought to collect more detailed information 
about potential confounding variables which have been found to have a relationship 
with cognitive impairment. These factors include cannabis use parameters such as 
frequency, severity/quantity, duration and time since cannabis use cessation (i.e., 
recency). Also, individuals with other neuropsychiatric or neuromedical illnesses were 
excluded from the study. Since the recruitment of participants also involved recruiting 
suitable matched-pairs (based on a strict matching criteria on a range of variables in 
order to restrict the possible impact of these potential confounds), the end result of 
smaller sample sizes was difficult to avoid but arguably, offset by the reduction in 
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extraneous variation in the sample. Prospective studies with larger sample sizes that 
maintain this strict matching process will help to extend the current findings.           
Another potential limitation in the current study involves combining both former 
users and current users in the primary ANCOVA analyses (due to small sub-sample 
sizes). However, as previously mentioned a carefully matched-controls design was used 
in an attempt to control for any confounding influence contributed to by variations in 
crucial cannabis-use indices (which have been considered to have an impact on 
cognitive performance) across individuals. Future studies could look to further examine 
the separate cannabis status groups across the executive function measures of interest. 
However, it is acknowledged that there would be difficulty in doing so reliably given 
that the time since cessation variable is largely self-report in nature. In addition, it is 
important to note the impact of small sample sizes on the validity of specific statistical 
approaches such as PCA and multiple regression analyses. However, the sample size was 
deemed sufficient for exploratory PCA. While findings from some of the multiple 
regression analyses failed to reach statistical significance, it is still considered important 
to particularly consider the effect sizes of all correlational analyses as indicated by the 
shared variance statistic. It is acknowledged that as p values are heavily influenced by 
small sample sizes and also do not provide an indication of the size or importance of the 
observed effect, future studies with larger samples may inevitably produce additional 
statistically significant results. As the shared variances found in the current study are 
notably similar to Green et al.’s (2000) meta-analytic findings regarding the range of 
detected effect sizes for the relationship between cognition and everyday outcomes in 
schizophrenia patients, the results of the present research are in support of previous findings. 
Therefore, future research with larger samples is also warranted for further evaluation of 
similar effect sizes. The small samples size of the current study also inevitably reduces 
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the statistical power of being able to detect what could possibly have been significant 
relationships. However, as mentioned the results of the present research are not all that 
dissimilar from previous findings. 
While the Holm-Bonferroni correction method is not considered as conservative 
in controlling for family-wise Type I error as the Bonferroni approach, as with all 
corrections the likelihood of Type II error is also increased. Therefore, truly important 
clinical differences may be deemed non-significant following correction. It is 
considered that the non-significant results emerging from the current study following 
Holm-Bonferroni adjustment are plausibly a consequence of the small sample size and 
reduced power, instead of reflective of the fact that none of these relationships 
exist. Given the similar effect sizes reported in previous research related to the amount 
of variance contributed to functional outcome by cognitive variables in the 
schizophrenia population (and thus, raising question against the likelihood that the null 
hypothesis is actually true), it is thought that it is entirely plausible for such 
relationships to not only exist, but also have statistical significance. Therefore, those 
results which had reached significance prior to Holm-Bonferroni correction have still 
been interpreted in the current study, with the precaution that at least some of these 
results may be truly reflective of Type I error. It is also considered that due to the small 
sample size, once again it is recommended that effect sizes be taken into account not 
just the overall significance level. Prospective studies should look to conduct similar 
comparisons with larger samples sizes in order to detect results of larger statistical 
significance and robustness. 
It is also acknowledged that as the current study included matched-control subjects 
with cannabis use as a comparison sample, it is difficult to differentiate between exceptional 
performance and cannabis use associated impairment. In other words, the minimal impairment 
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shown in the present study could indeed be a reflection of schizophrenia patients with cannabis 
use being more likely to be cognitively intact. However, it may also be that the matched-
control sample could be in some way cognitively impaired due to their cannabis use and that 
the patient sample was exceptional in their performance. In addition, it is possible that the 
cognitive signal for long-term cannabis use is relatively small in comparison to the signal for 
schizophrenia such that additional increments are difficult to detect. The latter would not be 
implausible as the cognitive deficits associated with chronic or heavy cannabis use are similar 
to those seem in schizophrenia, which could serve to narrow the gap between controls and 
patients. Although the similarities referred to here are related to deficits, the current 
study’s results indicate a significantly larger proportion of schizophrenia patients with 
cannabis use demonstrating performances in the clinically non-impaired range. While the 
current study did not aim to examine the cumulative effects of schizophrenia and cannabis use, 
future studies adopting a similar matched-control design, as well as including the addition of a 
cannabis-naive schizophrenia patient sample would help to further elucidate these 
relationships.  
While it is acknowledged above that the current study did not have a cannabis 
naive schizophrenia group or a cannabis-naive healthy control group for comparison, 
this is the first study to directly compare between schizophrenic and non-schizophrenic 
samples with carefully matched cannabis use histories. We also categorised our subjects 
according to their current cannabis use status (i.e., currently using schizophrenia 
patients with cannabis use, non-currently using schizophrenia patients with cannabis 
use, currently using healthy controls with a similar cannabis use history and non-
currently using healthy controls with a similar cannabis use history) in subsequent 
analyses. Rabin and colleagues (2013), also parsed their participants in terms of current 
cannabis use status, but in addition included a group of patients containing 8 subjects 
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with minimal/no lifetime use. The current study also recruited a similar group, but 
instead found individuals with no reported historical use at all (i.e., not even to a 
minimal extent). The general pattern of recruited schizophrenia subjects in the present 
research included either those patients who reported regular current or former use, or no 
lifetime use at all. However, only 4 cannabis-naive individuals with schizophrenia were 
recruited over a period of well over a 24-month timeframe. The small sample size of 
this similar type of subgroup in Rabin and colleagues’ study may be reflective of related 
difficulties faced when recruiting from this population. It is not entirely clear why such 
limited numbers in this particular subgroup sample were achieved. One possible 
explanation is that similarly to Rabin and colleagues’ (2013) study, recruitment was 
community-based with only outpatients being included in these studies. It is reasonable 
to consider that the cohort of individuals who are cannabis-naive may have much 
smaller numbers in the community due to differing illness presentation, than there are in 
the inpatient settings. The current study did not attempt to recruit individuals with 
schizophrenia from an inpatient setting in order to reduce the likelihood of the acute 
effects of the illness influencing results. The premise suggesting that schizophrenia 
patients with cannabis use have better premorbid adjustment, social skills and 
prognosis, supports this possibility. Future studies including all possible comparison 
groups (i.e., patients with cannabis use (both current and former users), cannabis-naive 
patients, healthy matched-controls with a similar cannabis use history (both current and 
former users), and cannabis-naive healthy normals), will not only allow for more 
informative between-subject comparisons, but will overall increase the generalisability 
of findings. In addition, prospective investigations ascertaining the population 
dispersion in both inpatient and outpatient settings in relation to patients with cannabis 
use versus patients with no reported historical use, may help to provide a better 
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understanding of the overall schizophrenia population characteristics, but may also 
serve to either additionally confirm or disconfirm the hypothesis related to better 
premorbid adjustment in the cohort with cannabis use. Due to the cognitive 
heterogeneity associated with this particular disorder (Joyce & Roiser, 2007), future 
research should also look to adopt longitudinal designs that use within-subjects 
approaches to statistical analyses so that not just cannabis use status, but the cumulative 
effects of cannabis use over time, can be further examined within each of these groups.  
A common limitation across many of the studies, including this one, when 
investigating the relationship between cannabis use and neurocognitive performance 
involves the ability to adequately measure the variability regarding different 
concentrations of Delta-9-tetrahydrocannabinol (∆9-THC). Over the years the ∆9-THC 
content in cannabis has been seen to progressively increase with the average level of ∆9-
THC content from the 1960’s to 1980’s reported to approximate 1.5-3.5%, with 
modern efforts to enhance its potency resulting in concentrations reaching up to 20% 
(for discussion, see Adams & Martin, 1996). In addition to this, through more frequent 
and deeper inhalation techniques experienced cannabis users are able to modify the dose 
if desired, thus further altering concentration levels (Iversen, 2000). This issue poses 
challenges regarding the range of variability in ∆9-THC concentration across users and 
the difficulty in controlling for this factor in empirical research. However, by 
controlling for differences in frequency, severity/quantity, duration of use and length of 
abstinence through the matching process in the current study, the present research aimed 
to address at least those measurable cannabis-use parameters which are associated with 
variability in cannabis use. The objective measurement of ∆9-THC concentration in 
future studies would help to address this issue and allow for more control when 
considering the variations in cannabis use as a potential confound.  
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In the current study, we also did not directly examine the effects of frequency of 
use and severity/quantity on neurocognitive performance. However, as mentioned 
above, the present research did allow for the assessment of these parameters and 
attempted to control for any possible differences via the matched-pairs design. While 
the importance of taking into account the possible effects of these particular parameters 
in cannabis use research is acknowledged, previous research has suggested that duration 
of use may place more of a significant contribution to the development of 
neurocognitive impairment when compared to the cannabis use parameters of frequency 
of use or quantity (Solowij et al., 2002). Future investigations should look to closely 
examine the possible effects of frequency, severity/quantity, duration of use, and time 
since last use across all of the abovementioned relevant comparison groups in order to 
determine whether these parameters have differential effects depending on group 
membership.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
As the current study only required the minimum of a 24-hour period of cannabis 
use abstinence, it is possible that for the individuals that were current users their results 
only represent the early stages of neurocognitive recovery, or quite possibly the 
remaining effects from intoxication. However, following ∆9-THC inhalation peak 
plasma concentrations and the associated psychotropic effects are thought to reach their 
maximum level within 15-30 minutes and that the intoxication effects of the drug begin 
to diminish within 2-3 hours (Grotenhermen, 2003). Previous studies have also adopted 
a 24-hour abstinence period in an attempt capture the narrow window which occurs 
between intoxication and drug withdrawal (Coulston et al., 2007; DeRosse et al., 2010). 
In a study conducted by Budney and colleagues (2003) the withdrawal symptoms and 
patterns following cannabis use abstinence were examined. Findings showed that the 
onset of withdrawal symptoms usually occurred during the first day following cannabis 
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use cessation and that the peak of withdrawal symptom effects occurred between 2 and 
6 days. It was also found that most effects lasted between 4 and 14 days. However, the 
current study did aim to investigate effects associated with different lifetime use 
categories (i.e., across current users and abstinent users) and therefore a much longer 
period of abstinence prior to testing would have inevitably ruled out the ability to 
compare performance with ‘current’ users.   
Another limitation of the current study is that the history of drug consumption 
was assessed using the self-report of subjects. Given the variability in cannabis use 
across individuals, it would be difficult to precisely calculate an individual’s history and 
pattern of substance use across their lifetime. Adherence to the 24-hour abstinence 
period was also assessed using self-report. However, it has been reported that 
information given by subjects about their drug use tends to be relatively reliable 
(Brown, Kranzler, & Del Boca, 1992; Harrison, Haaga, & Richards, 1993; Pope et al., 
2001). Self-reports of substance use have also been found to correspond with urine 
screen results (Fowler, Carr, Carter, & Lewin, 1998; Pope et al., 2001). In addition, the 
quantification of various cannabis use parameters was also based on self-report. While it 
has been identified that self-reporting bias is a potential limitation of the current study, 
reporting the different aspects of their use is the best proxy that was available (for 
example, reporting time since cessation in comparison to actual measurement of this 
variable via longitudinal design). It is also acknowledged that the determination of the 
validity and reliability of self-report measures of drug use in people with schizophrenia 
is currently lacking. This may be particularly problematic given their difficulties with 
memory and other cognitive abilities. Future studies aiming to replicate the current 
study’s findings should consider the utilisation of drug-usage screening processes in 
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order to supplement the information provided in user self-reports and help to provide an 
overall more accurate picture of actual use.  
Conclusions 
The main aims of the present study were to examine the patterns of executive 
functioning of schizophrenia patients with cannabis use in comparison to otherwise 
healthy matched-controls with a similar cannabis use history. An examination of these 
complex neurocognitive profiles has clinical significance due to the reported 
relationship between executive function and the functional outcome of individuals with 
the illness. An additional aim was to also investigate the relationship between level of 
executive functioning and ‘real world’ functional outcome. The identification of 
specific functional outcome predictors is also considered a research area with important 
clinical applications due to its potential in not only being able to more effectively guide 
rehabilitation plans, but ultimately increasing their efficacy by offering specific 
information regarding possible practical rehabilitation modifications. For example, in 
order to better assist and support individuals with retrospective memory deficits, 
strategies aimed at improving hygiene and grooming skills may not only involve more 
structured approaches, but that these approaches could be chunked into smaller parts in 
order to reduce the number of cognitive and behavioural units held online and 
ultimately facilitate the more effective recall and implementation of these learned 
strategies. In addition, for those with difficulties in interference control, strategies aimed 
at improving interpersonal, cooking, resource utilisation and medication management 
skills could involve once again more structured approaches, but also include the 
repeated practice and rehearsal of scenarios where there are changing or interfering 
circumstances, or even with distractors present. Such rehearsal could help to enhance 
more fluency in behavioural adaptation to differing/interfering environmental demands 
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and possibly reduce the tendency for responses to be based on task-inappropriate 
habitual behavioural patterns.       
The strengths of the current study lie in the comprehensive assessment of a 
multi-faceted neurocognitive construct thought to be related to functional outcome. 
While the results are encouraging, this study also highlights the difficulties and 
complexities associated in adequately assessing executive function. This is the first 
study to use this type of assessment methodology in a clinical population such as 
schizophrenia. The present findings also reinforce the importance of considering 
executive function as a complex cognitive construct that is not always adequately 
tapped into via the use of traditional executive functioning measures and this may help 
to explain the previous mixed findings. Despite the noted limitations in the present 
study, the comprehensive assessment of executive function has afforded an extension to 
the existing knowledge about the neurocognitive profiles of schizophrenia patients with 
cannabis use. This study also builds upon previous research by examining the relative 
contribution of different components of executive function in explaining performance in 
functional outcome. Specifically, the findings of this study suggest that schizophrenia 
patients with cannabis use reported to demonstrate inadequate functional outcome in the 
particular areas of hygiene and grooming, interpersonal skills, cooking, resource 
utilization, and medication management, as well as overall functional outcome related 
to independent living skills, may be partially due to less intact or poorer retrospective 
memory and interference control abilities.  
The neurocognitive measures used in the current study represented a theoretical 
hierarchical model of the construct of executive function, allowing us to tap into a wide 
range of executive processes. However, what remains unclear is which particular facets 
of executive function contribute to the most crucial areas of functional outcome. Given 
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this identified gap, future research is needed in order to determine which aspects of 
functional outcome are the most important to successful independent living.  
While further research is required to replicate the study’s findings, the current 
work suggests that neuropsychological evidence can be instrumental in identifying 
specific neurocognitive domains and their likely functional outcome correlates. The 
results of the present study and the applications of its findings, also suggest that 
tailoring rehabilitation plans utilising neurocognitive information specific to particular 
clinical subgroups has the potential to improve the functional outcomes of patients. 
Prospective studies should endeavour to build upon such approaches and while the 
future of research in the area may present its associated challenges, it also has the 
potential to offer considerable promise. ‘Schizophrenia in the past was a grim diagnosis 
with a poor prognosis. At the present time, it can probably be better described as a 
serious condition, with plenty of reasons to be hopeful’ (Green & Harvey, 2014, p. 7). 
The methodological approach of the current study is considered a first step in the 
development of neurocognitive process-specific training protocols for this particular 
subgroup of the schizophrenia population.  
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Appendices 
Appendix A: Structured Interview 
 
Demographic Information 
“I’d like to ask you a few questions regarding some personal information about yourself” 
 
(1) What is your age?_____ years _____ months (DOB:___________) 
 
(2) Gender       Male       Female  
 
(3) How many years of full-time education have you completed? ______ years 
What grades (on average) did you achieve? _______ 
 
(4) Have you experienced any of the following medical conditions/disabilities: 
 
Head/Brain injury      specify ______________________ 
Neurological conditions (e.g. epilepsy, MS)  specify ______________________ 
Mental Illness      specify ______________________ 
Intellectual disability/learning difficulties  specify ______________________ 
Stroke        
Cardiac Arrest       
 
(5) Are you currently using medication? Yes   No  
 
If yes, please specify___________________________ 
 
Approximately, how long have you been taking this medication? ____________ 
 
(6) Do you use drugs/alcohol (including cigarettes)? Yes   No  
 
If yes:  
 
Please specify and how often? ________________________(days per week) 
 
Approximately, how much of the drug do you use per using-day __________(e.g., cones, joints) 
 
Approximately, how long have you been using the drug ________(months/years) 
 
When was the last time you used the drug?______________ 
 
Has your use of drugs/alcohol ever:  
 
Had a negative effect on your interpersonal    specify ______________________ 
relationships       
 
Interfered with your ability to attend/persist    specify ______________________   
with work/school activities    
 
Put your physical safety (e.g. while driving a    specify ______________________ 
vehicle or operating machinery), at risk 
 
Resulted in legal issues (e.g. arrests for         specify ______________________ 
substance related disorderly conduct) 
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Appendix B(i): Advertisement for Clinical Participants – Cannabis Users 
 
RESEARCH STUDY 
Do you want to contribute to valuable new research??? 
 
This study is about schizophrenia, cannabis use and thinking processes. Your 
contribution would be most appreciated. 
 
We’re asking for adults, both male and female aged between 18 and 55 years 
with a diagnosis of schizophrenia (no other mental illness diagnoses included), and who 
are also regular cannabis users (but do not use any other illicit drug), to come and be a 
part of this research. Participation is voluntary and confidentiality will be strictly 
maintained!!! 
 
If you agree to volunteer, you will be asked some questions about you (e.g., age, 
gender, educational level, health status, symptoms, and cannabis use), as well as asked 
to fill out a questionnaire about your mood. In addition you will also be asked to 
complete a range of tasks involving solving puzzles, planning trips and card 
games. 
 
As a token of appreciation for your participation you will receive a $25 
voucher for Coles-Myer. 
 
The researcher Khristin Highet (Doctor of Psychology (Clinical) student), can be 
contacted on the following email address for more information: 
 
k.highet@murdoch.edu.au 
 
or on: 
 
0415 494 551 
 
OR 
 
Alternatively, you can leave your contact details on the form provided at the 
reception desk, in order for the researcher to contact you. 
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Appendix B(ii): Advertisement for Clinical Participants – Non-drug Users 
 
RESEARCH STUDY 
Do you want to contribute to valuable new research??? 
 
This study is about schizophrenia, cannabis use and thinking processes. Your 
contribution would be most appreciated. 
 
We’re asking for adults, both male and female aged between 18 and 55 years 
with a diagnosis of schizophrenia (no other mental illness diagnoses included), and who 
do not use any illicit drug, to come and be a part of this research. Participation is 
voluntary and confidentiality will be strictly maintained!!! 
 
If you agree to volunteer, you will be asked some questions about you (e.g., age, 
gender, educational level, health status, and symptoms), as well as asked to fill out a 
questionnaire about your mood. In addition you will also be asked to complete a range 
of tasks involving solving puzzles, planning trips and card games. 
 
As a token of appreciation for your participation you will receive a $25 
voucher for Coles-Myer. 
 
The researcher Khristin Highet (Doctor of Psychology (Clinical) student), can be 
contacted on the following email address for more information: 
 
k.highet@murdoch.edu.au 
 
or on: 
 
0415 494 551 
 
OR 
 
Alternatively, you can leave your contact details on the form provided at the 
reception desk, in order for the researcher to contact you. 
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Appendix C: Clinical Participant Information Form   
CENTRAL NORTHERN ADELAIDE HEALTH SERVICE 
(CNAHS) 
The Queen Elizabeth Hospital & Lyell McEwin Hospital 
 
PARTICIPANT INFORMATION SHEET 
Title: Relationships between schizophrenia and cannabis use on everyday adjustment 
Application Number: 2009010 
 
INVITATION TO PARTICIPATE 
We invite you to participate in a study which we believe is of potential importance to 
people with schizophrenia. But, before you decide whether you wish to participate, we 
need to be sure that you understand: 
 why we are doing it, and 
 what it would involve if you agreed. 
So, please read the following carefully and be sure to ask any questions you have. I will 
be happy to discuss it with you and answer your questions. You are also free to discuss 
it with others if you wish (i.e., family, friends, your local Doctor and / or your clinical 
treatment team).  
 
You do not have to make an immediate decision.  
 
PARTICIPATION IS VOLUNTARY 
This is a research project and you do not have to be involved. Your medical care or 
clinical treatment will not be affected in any way if you choose not to participate. Also, 
if you agree to participate, you are free to change your mind and withdraw at any stage. 
 
BACKGROUND TO THE STUDY 
What is the research about? 
My name is Khristin Highet. I am completing this research as part of my Doctor of 
Psychology (Clinical) degree through Murdoch University in Western Australia. I’m 
looking at the relationship between schizophrenia, cannabis use, thinking processes and 
everyday life skills. 
 
Who is sponsoring it, and are they paying the researcher or her department to do the 
research? 
I’m a post-graduate student of Murdoch University and the university is sponsoring this 
study. I will not be paid for conducting this research. 
 
Why is the research being done? 
I hope that the study will help treating professionals to make better informed decisions 
about treatment plans for people with schizophrenia. In addition, it may be of help when 
developing treatment plans for patients who may also use cannabis.  
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Who can participate? 
I’m inviting both male and female adults with schizophrenia, aged between 18 and 55 
years, and who do NOT have a history of serious head/brain injury, mental illness 
diagnoses other than schizophrenia, learning disability, chronic substance use (other than 
cannabis use), stroke and/or a neurological condition, to take part in the study. 
 
How many other people have been asked to consider participating?  
Around 60 participants will be included in the study. This will include people with 
schizophrenia who attend The Queen Elizabeth Hospital and the Lyell McEwin 
Hospital, or any other affiliated public mental health service under CNAHS.  
 
What is involved if I choose to participate? 
If you agree to participate, a testing session will be scheduled. During this session, I will 
then ask some questions about you (e.g., your age, gender, years of education, health 
status, cannabis use, symptoms) and your mood. This will take about 30-45 minutes. 
Afterwards, I will ask you to do some tasks looking at your reading abilities, memory, 
planning, attention and everyday skills, which will take about 60-90 minutes. Most 
people find these tasks enjoyable and you can have a break at any time. 
 
With your permission, I will also ask a member of your treatment team, or your 
community support worker (if applicable), to fill in a questionnaire outlining your 
everyday skills. If you do not want your treatment team or support person to be 
involved, this will not stop you from being involved in the study. A family member or 
significant other may answer the questions related to your everyday skills. 
 
DISCOMFORTS, RISKS AND SIDE EFFECTS 
Who should I contact if I am worried about any effects that I experience? 
No risks or side effects are anticipated as a result of the current research. But, if you 
should experience undue emotional distress, or I observe a significant change in your 
condition during the research process, you can stop the session, and I will encourage 
you to contact your clinical treatment team for consultation. You can recommence the 
study at a later stage if you wish to.  
 
WHAT WILL HAPPEN TO THE INFORMATION COLLECTED? 
All information you give is confidential. No names or other information that might 
identify you will be used in any publication arising from the study. The information 
collected from the research will be stored in locked cabinets located at Murdoch 
University. Only my research supervisors and I will have access to the data. 
 
WHAT ARE MY RIGHTS? 
If you become injured during this study, and your injury is a direct result of the effects 
of study procedures, The Queen Elizabeth Hospital will provide reasonable medical 
treatment. Your participation in this study shall not affect any other right to 
compensation you may have under common law. Should you wish to obtain more 
information about your rights as a participant, you can contact the Executive Officer of 
the Ethics Of Human Research committee, on (08) 8222 6841. 
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IS THERE ANY PAYMENT FOR PARTICIPATION? 
We understand that involvement in this study requires a time commitment and we are 
extremely appreciative of your participation and time given. As a token of appreciation 
for your participation you will receive a $25 voucher for Coles-Myer. 
 
BENEFITS OF THE RESEARCH 
I hope that this study will assist in helping people with schizophrenia to successfully 
transition out of hospital care and return to community living. However, these benefits 
may not directly affect you. 
 
WHAT IF I HAVE A QUESTION ABOUT THE STUDY? 
If you have any questions or concerns about your involvement in the study, you may 
contact the chief project supervisor, Dr Marjorie Collins via email: 
m.collins@murdoch.edu.au 
 
The Central Northern Adelaide Health Service Ethics of Human Research Committee 
(TQEH & LMH) has approved this study. 
 
Should you wish to speak to a person not directly involved in the study in relation to  
 matters concerning policies,  
 information about the conduct of the study  
 your rights as a participant, or 
should you wish to make a confidential complaint, you may contact The Executive 
Officer of this committee, on (08) 8222 6841. 
 
Thank you, 
 
 
Khristin Highet 
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Appendix D: Advertisement for Control Participants 
RESEARCH STUDY 
Do you want to contribute to valuable new research??? 
 
This study is about schizophrenia, cannabis use and thinking processes. Your 
contribution would be most appreciated. 
 
We’re asking for adults, both male and female aged between 18 and 55 years 
who do not have any mental illness diagnosis and are regular cannabis users (but do 
not use any other illicit drug), to come and be a part of this research. Participation is 
voluntary and confidentiality will be strictly maintained!!! 
 
If you agree to volunteer, you will be asked some questions about you (e.g., age, 
gender, educational level, health status, and cannabis use), as well as asked to fill out a 
questionnaire about your mood. In addition you will also be asked to complete a range 
of tasks involving solving puzzles, planning trips and card games. 
 
As a token of appreciation for your participation you will receive a $25 
voucher for Coles-Myer. 
 
The researcher Khristin Highet (Doctor of Psychology (Clinical) student), can be 
contacted on the following email address for more information: 
 
k.highet@murdoch.edu.au 
 
or on: 
 
0415 494 551 
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Appendix E: Control Participant Information Form 
   
MURDOCH UNIVERSITY 
School of Psychology 
 
 
PARTICIPANT INFORMATION SHEET 
Title: Relationships between schizophrenia and cannabis use on everyday adjustment 
Permit Number: 2008/168 
 
INVITATION TO PARTICIPATE 
We invite you to participate in a study which we believe is of potential importance to 
people with schizophrenia. But, before you decide whether you wish to participate, we 
need to be sure that you understand: 
 why we are doing it, and 
 what it would involve if you agreed. 
So, please read the following carefully and be sure to ask any questions you have. We 
will be happy to discuss it with you and answer your questions. You are also free to 
discuss it with others if you wish (i.e., family, friends, and/or your local Doctor).  
 
You do not have to make an immediate decision.  
 
PARTICIPATION IS VOLUNTARY 
This is a research project and you do not have to be involved. Participation is voluntary. 
Also, if you agree to participate, you are free to change your mind and withdraw at any 
stage. 
 
BACKGROUND TO THE STUDY 
What is the research about? 
My name is Khristin Highet. I am completing this research as part of my Doctor of 
Psychology (Clinical) degree through Murdoch University in Western Australia. I’m 
looking at the relationship between schizophrenia, cannabis use, thinking processes and 
everyday life skills. 
 
Who is sponsoring it, and are they paying the researcher or her department to do the 
research? 
I’m a post-graduate student of Murdoch University and the university is sponsoring this 
study. I will not be paid for conducting this research. 
 
Why is the research being done? 
I hope that the study will help treating professionals to make better informed decisions 
about treatment plans for people with schizophrenia. In addition, it may be of help when 
developing treatment plans for patients who may also use cannabis. Please note: The 
involvement of participants without a mental illness, such as yourself, will help me 
to better understand the effects of both cannabis use and schizophrenia, in 
comparison to the effects of cannabis use alone (i.e., your results will be used in a 
comparison group; comparing your results to those who have schizophrenia, but 
also use cannabis in addition).   
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Who can participate? 
I’m inviting both male and female current or past regular cannabis users, aged between 
18 and 55 years, who do NOT have a history of serious head/brain injury, mental illness 
diagnosis, learning disability, chronic substance use (other than cannabis use), stroke 
and/or a neurological condition, to take part in the study. 
 
How many other people have been asked to consider participating?  
Around 60 participants will be included in the study. This will include individuals with 
schizophrenia who use cannabis, as well as members of the community who do not have 
a mental illness diagnosis who are either current or past cannabis users.  
 
What is involved if I choose to participate? 
If you agree to participate, I will initially ask you some questions via telephone about 
you (e.g. your age, gender, years of education, health status, cannabis use) in order to 
determine your eligibility for the study. This will take about 10-15 minutes. If you are 
considered eligible for the study, you will be invited to a testing session where you will 
be asked some questions about your mood, as well as I will ask you to complete some 
tasks looking at your reading abilities, memory, planning, and attention, which will take 
about 45-60 minutes. Most people find these tasks enjoyable and you can have a break at 
any time. 
 
DISCOMFORTS, RISKS AND SIDE EFFECTS 
Who should I contact if I am worried about any effects that I experience? 
No risks or side effects are anticipated as a result of the current research. But, if you 
should experience undue emotional distress, you can stop the session, and I will 
encourage you to contact your local doctor for consultation. You can recommence the 
study at a later stage if you wish to.  
 
WHAT WILL HAPPEN TO THE INFORMATION COLLECTED? 
All information you give is confidential. No names or other information that might 
identify you will be used in any publication arising from the study. The information 
collected from the research will be stored in locked cabinets located at Murdoch 
University. Only my research supervisors and I will have access to the data. 
 
IS THERE ANY PAYMENT FOR PARTICIPATION? 
We understand that involvement in this study requires a time commitment and we are 
extremely appreciative of your participation and time given. As a token of appreciation 
for your participation you will receive a $25 voucher for Coles-Myer. 
 
BENEFITS OF THE RESEARCH 
I hope that this study will assist in helping people with schizophrenia who may use 
cannabis to successfully transition out of hospital care and return to community living. 
However, these benefits may not directly affect you. 
 
WHAT IF I HAVE A QUESTION ABOUT THE STUDY? 
If you have any questions or concerns about your involvement in the study, you may 
contact the chief project supervisor, Dr Marjorie Collins via email: 
m.collins@murdoch.edu.au 
 
CANNABIS USE, SCHIZOPHRENIA & EXECUTIVE FUNCTION 226 
 
If you have any ethical concerns about the project or questions about your rights as a 
participant, please contact The Murdoch University Human Research Ethics Committee 
on (08) 9360 6677 or e-mail: ethics@murdoch.edu.au 
 
 
Thank you, 
 
 
Khristin Highet 
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Appendix F: Consent Form for Clinical Participants 
 
CENTRAL NORTHERN ADELAIDE HEALTH SERVICE 
(CNAHS) 
The Queen Elizabeth Hospital & Lyell McEwin Hospital 
 
 
CONSENT FORM 
Title: Relationships between schizophrenia and cannabis use on everyday adjustment. 
 
Researcher’s name: Khristin Highet 
Supervisor’s name: Dr Marjorie Collins  
 
Protocol Number: 2009010 
 
I, the undersigned  ..................................................................................... hereby consent    
to my involvement in the research project explained above. 
 
 I have read the information sheet, and I understand the reasons for this study. The 
researcher has explained the ways in which it will affect me. My questions have 
been answered to my satisfaction. My consent is given voluntarily. I am also aware 
that I may change my mind and stop at any time without this affecting my treatment, 
either now or in the future.  
 I have been given the opportunity to have a family member, a friend or a member of 
my clinical treating team present while the project was explained to me. 
 I understand that I may not directly benefit from taking part in the study. 
 I understand the statement on the information sheet concerning payment for taking 
part in this study.  
 I understand that parts of the testing session will be audio-taped and that all records 
and responses (including those audio-taped) will be kept in a safe and secure place 
at Murdoch University where only the researcher and supervisors will have access. 
 I understand that all information provided is treated as confidential and will not be 
released by the researcher unless required to do so by law.  
 I agree that research data gathered for this study may be published provided my 
name or other information which might identify me is not used. 
 
PATIENT SIGNATURE.......................................................  DATE ……./……./……. 
 
WITNESS (optional)............................................................... DATE ……./……./……. 
______________________________________________________________________ 
 
I have provided information about the research to the research participant and believe 
that he/she understands what is involved. 
 
RESEARCHER........................................................................ DATE ……./……./…….
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Appendix G: Consent Form for Control Participants 
   
MURDOCH UNIVERSITY 
School of Psychology 
 
 
CONSENT FORM 
 
Title: Relationships between schizophrenia and cannabis use on everyday adjustment 
 
Researcher’s name: Khristin Highet 
Supervisor’s name: Dr Marjorie Collins  
 
Permit Number: 2008/168 
 
I, the undersigned  .................................................................................. hereby consent  
to my involvement in the research study explained above. 
 
 I have read the information sheet, and I understand the reasons for this study. The 
researcher has explained the ways in which it will affect me. My questions have 
been answered to my satisfaction. My consent is given voluntarily. I am also aware 
that I may change my mind and stop at any time without this resulting in prejudice, 
either now or in the future.  
 I understand that I may not directly benefit from taking part in the study. 
 I understand the statement on the information sheet concerning payment for taking 
part in this study.  
 I understand that parts of the testing session will be audio-taped and that all records 
and responses (including those audio-taped) will be kept in a safe and secure place 
at Murdoch University where only the researcher and supervisors will have access. 
 I understand that all information provided is treated as confidential and will not be 
released by the researcher unless required to do so by law.  
 I agree that research data gathered for this study may be published provided my 
name or other information which might identify me is not used. 
 
 
PARTICIPANT’S SIGNATURE..........................................  DATE ……./……./……. 
______________________________________________________________________ 
 
I have provided information about the research to the research participant and believe 
that he/she understands what is involved. 
 
RESEARCHER....................................................................... DATE ……./……./…….
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Appendix H: Debrief Information 
ABOUT THIS STUDY 
 
Thank you for participating in this study. Your time and efforts are much appreciated. 
 
The aim of the research is to examine the relationship between schizophrenia, cannabis 
use, and ‘executive functions’. Executive functions are a group of thinking processes 
that generally involve planning, problem solving, self-monitoring, and stopping a 
response that is not the best one for the task at hand. The tasks you have undertaken 
today are thought to assess such processes.  
 
Another aim of our research is to look at the relationship between these thinking 
abilities and everyday skills. We hope that the results of the research project will help to 
better inform treating professionals in developing more effective treatment plans for 
individuals with schizophrenia who may present with cannabis abuse issues.   
 
If any aspect of the research process has raised any concerns, we encourage you to 
consult with your clinical treatment team/doctor. You may also contact the following 
service for help if necessary: 
 
Assessment & Crisis Intervention Service (ACIS) - 24 hour Emergency Mental Health 
Service Ph. No: 13 14 65 
 
Thank you once again for your contribution and participation in our project.    
  
 
